BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bosch FX, Ribes J, Borràs J. Epidemiology of primary liver cancer. Semin Liver Dis. 1999;19:271-285. [PMID: 10518307 DOI: 10.1055/s-2007-1007117] [Cited by in Crossref: 644] [Cited by in F6Publishing: 618] [Article Influence: 28.0] [Reference Citation Analysis]
Number Citing Articles
1 Cheng CH, Lee CF, Wu TH, Chan KM, Chou HS, Wu TJ, Yu MC, Chen TC, Lee WC, Chen MF. Evaluation of the new AJCC staging system for resectable hepatocellular carcinoma. World J Surg Oncol. 2011;9:114. [PMID: 21958080 DOI: 10.1186/1477-7819-9-114] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 3.1] [Reference Citation Analysis]
2 Weis S, Franke A, Mössner J, Jakobsen JC, Schoppmeyer K. Radiofrequency (thermal) ablation versus no intervention or other interventions for hepatocellular carcinoma. Cochrane Database Syst Rev. 2013;12:CD003046. [PMID: 24357457 DOI: 10.1002/14651858.cd003046] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
3 Varotti G, Ramacciato G, Ercolani G, Grazi GL, Vetrone G, Cescon M, Del Gaudio M, Ravaioli M, Ziparo V, Lauro A, Pinna A. Comparison between the fifth and sixth editions of the AJCC/UICC TNM staging systems for hepatocellular carcinoma: multicentric study on 393 cirrhotic resected patients. Eur J Surg Oncol 2005;31:760-7. [PMID: 15975760 DOI: 10.1016/j.ejso.2005.04.008] [Cited by in Crossref: 55] [Cited by in F6Publishing: 46] [Article Influence: 3.2] [Reference Citation Analysis]
4 Chen J. The prognostic analysis of different metastatic patterns in advanced liver cancer patients: A population based analysis. PLoS One 2018;13:e0200909. [PMID: 30102707 DOI: 10.1371/journal.pone.0200909] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
5 Andrew Schumacher P, Powell JJ, Macneill AJ, Buczkowski AK, Erb SR, Ho SG, Scudamore CH, Stembrecher UP, Weiss A, Yoshida E, Chung SW. Multimodal therapy for hepatocellular carcinoma: A complementary approach to liver transplantation. Annals of Hepatology 2010;9:23-32. [DOI: 10.1016/s1665-2681(19)31675-8] [Cited by in Crossref: 8] [Article Influence: 0.7] [Reference Citation Analysis]
6 Llovet JM. Evidence-based medicine in the treatment of hepatocellular carcinoma: Evidence-based treatment of HCC. Journal of Gastroenterology and Hepatology 2002;17:S428-33. [DOI: 10.1046/j.1440-1746.17.s3.40.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
7 John U, Hanke M. Tobacco smoking- and alcohol drinking-attributable cancer mortality in Germany. Eur J Cancer Prev 2002;11:11-7. [PMID: 11917204 DOI: 10.1097/00008469-200202000-00003] [Cited by in Crossref: 30] [Cited by in F6Publishing: 21] [Article Influence: 1.5] [Reference Citation Analysis]
8 Hoofnagle JH. Hepatocellular carcinoma: summary and recommendations. Gastroenterology 2004;127:S319-23. [PMID: 15508100 DOI: 10.1053/j.gastro.2004.09.047] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 2.0] [Reference Citation Analysis]
9 Wible BC, Rilling WS, Drescher P, Hieb RA, Saeian K, Frangakis C, Chen Y, Eastwood D, Kim HS. Longitudinal quality of life assessment of patients with hepatocellular carcinoma after primary transarterial chemoembolization. J Vasc Interv Radiol. 2010;21:1024-1030. [PMID: 20621715 DOI: 10.1016/j.jvir.2010.03.005] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 2.7] [Reference Citation Analysis]
10 Montalto G, Cervello M, Giannitrapani L, Dantona F, Terranova A, Castagnetta LA. Epidemiology, risk factors, and natural history of hepatocellular carcinoma. Ann N Y Acad Sci. 2002;963:13-20. [PMID: 12095924 DOI: 10.1111/j.1749-6632.2002.tb04090.x] [Cited by in Crossref: 183] [Cited by in F6Publishing: 188] [Article Influence: 9.2] [Reference Citation Analysis]
11 Saad ZM, Fouad Y, Ali LH, Hassanin TM. Clinical Significance of Annexin A4 as a Biomarker in the Early Diagnosis of Hepatocellular Carcinoma. Asian Pac J Cancer Prev 2020;21:2661-5. [PMID: 32986366 DOI: 10.31557/APJCP.2020.21.9.2661] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
12 Wu LM, Zhang F, Xie HY, Xu X, Chen QX, Yin SY, Liu XC, Zhou L, Xu XB, Sun YL. MMP2 promoter polymorphism (C-1306T) and risk of recurrence in patients with hepatocellular carcinoma after transplantation. Clin Genet. 2008;73:273-278. [PMID: 18177474 DOI: 10.1111/j.1399-0004.2007.00955.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 1.6] [Reference Citation Analysis]
13 Branco F, Brú C, Vilana R, Bianchi L, Alves de Mattos A. Percutaneous ethanol injection before liver transplantation in the hepatocellular carcinoma. Annals of Hepatology 2009;8:220-7. [DOI: 10.1016/s1665-2681(19)31769-7] [Cited by in Crossref: 8] [Article Influence: 0.6] [Reference Citation Analysis]
14 Zhang YJ, Li H, Wu HC, Shen J, Wang L, Yu MW, Lee PH, Bernard Weinstein I, Santella RM. Silencing of Hint1, a novel tumor suppressor gene, by promoter hypermethylation in hepatocellular carcinoma. Cancer Lett. 2009;275:277-284. [PMID: 19081673 DOI: 10.1016/j.canlet.2008.10.042] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 2.4] [Reference Citation Analysis]
15 Ward SC, Thung SN, Lim KH, Tran TT, Hong TK, Hoang PL, Jang JJ, Park YN, Abe K. Hepatic progenitor cells in liver cancers from Asian children. Liver Int. 2010;30:102-111. [PMID: 19793197 DOI: 10.1111/j.1478-3231.2009.02126.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
16 Xu HX, Xie XY, Lu MD, Chen JW, Yin XY, Xu ZF, Liu GJ. Ultrasound-guided percutaneous thermal ablation of hepatocellular carcinoma using microwave and radiofrequency ablation. Clin Radiol. 2004;59:53-61. [PMID: 14697375 DOI: 10.1016/j.crad.2003.09.006] [Cited by in Crossref: 76] [Cited by in F6Publishing: 73] [Article Influence: 4.2] [Reference Citation Analysis]
17 Lin YH, Chiou YY, Chou YH, Chau GY, Wang HK, Chiang JH, Chang CY. Radiofrequency ablation for recurrent hepatocellular carcinoma in postresectional patients: prognostic factors analysis. Eur J Gastroenterol Hepatol 2011;23:1239-44. [PMID: 21941191 DOI: 10.1097/MEG.0b013e32834c5b13] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
18 Nishikawa H, Osaki Y, Inuzuka T, Takeda H, Nakajima J, Matsuda F, Henmi S, Sakamoto A, Ishikawa T, Saito S, Kita R, Kimura T. Branched-chain amino acid treatment before transcatheter arterial chemoembolization for hepatocellular carcinoma. World J Gastroenterol 2012; 18(12): 1379-1384 [PMID: 22493552 DOI: 10.3748/wjg.v18.i12.1379] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 24] [Article Influence: 2.0] [Reference Citation Analysis]
19 Liu XR, Zhou RL, Zhang QY, Zhang Y, Jin YY, Lin M, Rui JA, Ye DX. Structure analysis and expressions of a novel tetratransmembrane protein, lysosoma-associated protein transmembrane 4 β associated with hepatocellular carcinoma. World J Gastroenterol 2004; 10(11): 1555-1559 [PMID: 15162524 DOI: 10.3748/wjg.v10.i11.1555] [Cited by in CrossRef: 42] [Cited by in F6Publishing: 44] [Article Influence: 2.3] [Reference Citation Analysis]
20 Marrero JA. Screening tests for hepatocellular carcinoma. Clin Liver Dis. 2005;9:235-251, vi. [PMID: 15831271 DOI: 10.1016/j.cld.2004.12.006] [Cited by in Crossref: 48] [Cited by in F6Publishing: 48] [Article Influence: 2.8] [Reference Citation Analysis]
21 Tannus RK, Almeida-Carvalho SR, Loureiro-Matos CA, Miziara-Gonzalez A, Salzedas-Netto AA, Szejnfeld D, D'Ippolito G, Pereira-Lanzoni V, Souza-Silva I. Evaluation of survival of patients with hepatocellular carcinoma: A comparative analysis of prognostic systems. PLoS One 2018;13:e0194922. [PMID: 29617435 DOI: 10.1371/journal.pone.0194922] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
22 Soulakova JN, Huang H, Crockett LJ. Racial/Ethnic Disparities in Consistent Reporting of Smoking-Related Behaviors. J Addict Behav Ther Rehabil 2015;4. [PMID: 27088100 DOI: 10.4172/2324-9005.1000147] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
23 Omata M, Dan Y, Daniele B, Plentz R, Rudolph KL, Manns M, Piratvisuth T, Chen DS, Tateishi R, Chutaputti A. Clinical features, etiology, and survival of hepatocellular carcinoma among different countries: Comparison of HCC from different countries. Journal of Gastroenterology and Hepatology 2002;17:S40-9. [DOI: 10.1046/j.1440-1746.17.s1.14.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
24 Escarda A, Vaquer P, Bonet L, Miralbés S, Gómez C, Obrador A. [Clivus metastasis from hepatocarcinoma associated with transarterial hepatic chemoembolization]. Gastroenterol Hepatol 2006;29:401-4. [PMID: 16938255 DOI: 10.1157/13091453] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
25 Guglielmi A, Ruzzenente A, Sandri M, Pachera S, Pedrazzani C, Tasselli S, Iacono C. Radio frequency ablation for hepatocellular carcinoma in cirrhotic patients: prognostic factors for survival. J Gastrointest Surg. 2007;11:143-149. [PMID: 17390163 DOI: 10.1007/s11605-006-0082-y] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 1.7] [Reference Citation Analysis]
26 Ismail A, Fouad O, Abdelnasser A, Chowdhury A, Selim A. Stem cell therapy improves the outcome of liver resection in cirrhotics. J Gastrointest Cancer. 2010;41:17-23. [PMID: 20012230 DOI: 10.1007/s12029-009-9092-9] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 2.1] [Reference Citation Analysis]
27 Jiang CG, Chen Q, Wu L, Wang G, Ma J. The innovative regularity and role of p16 methylation in blood during HCC development. J Cancer 2018;9:1925-31. [PMID: 29896276 DOI: 10.7150/jca.23968] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
28 Tian F, Wu JX, Yu WB. Prognostic Factors and Clinical Characteristics for Hepatocellular Carcinoma Patients with Benign Enlarged Perihepatic Lymph Nodes: a Single-Center Experience from China. J Gastrointest Surg. 2015;19:1822-1832. [PMID: 26259664 DOI: 10.1007/s11605-015-2900-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
29 Colledge D, Soppe S, Yuen L, Selleck L, Walsh R, Locarnini S, Warner N. Stop codons in the hepatitis B surface proteins are enriched during antiviral therapy and are associated with host cell apoptosis. Virology 2017;501:70-8. [DOI: 10.1016/j.virol.2016.11.007] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
30 Wei BR, Edwards JB, Hoover SB, Tillman HS, Reed LT, Sills RC, Simpson RM. Altered {beta}-catenin accumulation in hepatocellular carcinomas of diethylnitrosamine-exposed rhesus macaques. Toxicol Pathol 2008;36:972-80. [PMID: 18978308 DOI: 10.1177/0192623308327120] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
31 Chen MS, Li JQ, Zheng Y, Guo RP, Liang HH, Zhang YQ, Lin XJ, Lau WY. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg 2006;243:321-8. [PMID: 16495695 DOI: 10.1097/01.sla.0000201480.65519.b8] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
32 Moreno Planas J, López Monclús J, Gómez Cruz A, Rubio González E, Pérez Arangüena R, Boullosa Graña E, Garcia Suárez A, Pérez-picouto J, Fernández Ruiz M, Lucena de la Poza J, Sánchez Turrión V, Cuervas-mons Martı́nez V. Efficacy of Hepatocellular Carcinoma Locoregional Therapies on Patients Waiting for Liver Transplantation. Transplantation Proceedings 2005;37:1484-5. [DOI: 10.1016/j.transproceed.2005.02.042] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
33 Pandya H, Shah C, Lakhani J, Patel M. Intra-atrial tumour thrombus secondary to hepatocellular carcinoma. Australas Med J 2013;6:321-4. [PMID: 23837079 DOI: 10.4066/AMJ.2013.1635] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
34 Jae HJ, Chung JW, Park HS, Lee MJ, Lee KC, Kim HC, Yoon JH, Chung H, Park JH. The antitumor effect and hepatotoxicity of a hexokinase II inhibitor 3-bromopyruvate: in vivo investigation of intraarterial administration in a rabbit VX2 hepatoma model. Korean J Radiol. 2009;10:596-603. [PMID: 19885316 DOI: 10.3348/kjr.2009.10.6.596] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 2.2] [Reference Citation Analysis]
35 Benson AB, Abrams TA, Ben-Josef E, Bloomston PM, Botha JF, Clary BM, Covey A, Curley SA, D'Angelica MI, Davila R, Ensminger WD, Gibbs JF, Laheru D, Malafa MP, Marrero J, Meranze SG, Mulvihill SJ, Park JO, Posey JA, Sachdev J, Salem R, Sigurdson ER, Sofocleous C, Vauthey JN, Venook AP, Goff LW, Yen Y, Zhu AX. NCCN clinical practice guidelines in oncology: hepatobiliary cancers. J Natl Compr Canc Netw. 2009;7:350-391. [PMID: 19406039 DOI: 10.6004/jnccn.2009.0027] [Cited by in Crossref: 299] [Cited by in F6Publishing: 324] [Article Influence: 23.0] [Reference Citation Analysis]
36 Jiang N, Chen W, Zhang JW, Li Y, Zeng XC, Zhang T, Fu BS, Yi HM, Zhang Q. Aberrantly regulated dysadherin and B-cell lymphoma 2/B-cell lymphoma 2-associated X enhances tumorigenesis and DNA targeting drug resistance of liver cancer stem cells. Mol Med Rep 2015;12:7239-46. [PMID: 26458963 DOI: 10.3892/mmr.2015.4363] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
37 Jiang SS, Weng DS, Wang QJ, Pan K, Zhang YJ, Li YQ, Li JJ, Zhao JJ, He J, Lv L. Galectin-3 is associated with a poor prognosis in primary hepatocellular carcinoma. J Transl Med. 2014;12:273. [PMID: 25260879 DOI: 10.1186/s12967-014-0273-3] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 3.9] [Reference Citation Analysis]
38 Giannelli G, Marinosci F, Trerotoli P, Volpe A, Quaranta M, Dentico P, Antonaci S. SCCA antigen combined with alpha-fetoprotein as serologic markers of HCC. Int J Cancer. 2005;117:506-509. [PMID: 15906357 DOI: 10.1002/ijc.21189] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 2.5] [Reference Citation Analysis]
39 Gómez-Rubio M, Moya-Valdés M, García J. Diagnostic laparoscopy and laparoscopic ultrasonography with local anesthesia in hepatocellular carcinoma. World J Gastroenterol 2005; 11(26): 4120-4123 [PMID: 15996044 DOI: 10.3748/wjg.v11.i26.4120] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
40 Kang JS, Wanibuchi H, Morimura K, Puatanachokchai R, Salim EI, Hagihara A, Seki S, Fukushima S. Enhancement by estradiol 3-benzoate in thioacetamide-induced liver cirrhosis of rats. Toxicol Sci. 2005;85:720-726. [PMID: 15716488 DOI: 10.1093/toxsci/kfi113] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]
41 Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology. 2004;127:S35-S50. [PMID: 15508101 DOI: 10.1053/j.gastro.2004.09.014] [Cited by in Crossref: 1497] [Cited by in F6Publishing: 1384] [Article Influence: 83.2] [Reference Citation Analysis]
42 Maddala YK, Stadheim L, Andrews JC, Burgart LJ, Rosen CB, Kremers WK, Gores G. Drop-out rates of patients with hepatocellular cancer listed for liver transplantation: Outcome with chemoembolization: Drop-Out Rates for HCC. Liver Transpl 2004;10:449-55. [DOI: 10.1002/lt.20099] [Cited by in Crossref: 168] [Cited by in F6Publishing: 152] [Article Influence: 9.3] [Reference Citation Analysis]
43 Kalinina OA, Kalinin SA, Polack EW, Mikaelian I, Panda S, Costa RH, Adami GR. Sustained hepatic expression of FoxM1B in transgenic mice has minimal effects on hepatocellular carcinoma development but increases cell proliferation rates in preneoplastic and early neoplastic lesions. Oncogene 2003;22:6266-76. [DOI: 10.1038/sj.onc.1206640] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 1.8] [Reference Citation Analysis]
44 Llovet JM, Real MI, Montaña X, Planas R, Coll S, Aponte J, Ayuso C, Sala M, Muchart J, Solà R, Rodés J, Bruix J. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. The Lancet 2002;359:1734-9. [DOI: 10.1016/s0140-6736(02)08649-x] [Cited by in Crossref: 2274] [Cited by in F6Publishing: 844] [Article Influence: 113.7] [Reference Citation Analysis]
45 Cantarini MC, Trevisani F, Morselli-Labate AM, Rapaccini G, Farinati F, Del Poggio P, Di Nolfo MA, Benvegnù L, Zoli M, Borzio F. Effect of the etiology of viral cirrhosis on the survival of patients with hepatocellular carcinoma. Am J Gastroenterol. 2006;101:91-98. [PMID: 16405539 DOI: 10.1111/j.1572-0241.2006.00364.x] [Cited by in Crossref: 62] [Cited by in F6Publishing: 60] [Article Influence: 3.9] [Reference Citation Analysis]
46 Zhuang L, Wen T, Xu M, Yang J, Wang W, Wu H, Zeng Y, Yan L, Wei Y, Li B. Sorafenib combined with hepatectomy in patients with intermediate-stage and advanced hepatocellular carcinoma. Arch Med Sci 2017;13:1383-93. [PMID: 29181069 DOI: 10.5114/aoms.2017.71066] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
47 Chen Ban K, Singh H, Krishnan R, Fong Seow H. Comparison of the expression of beta-catenin in hepatocellular carcinoma in areas with high and low levels of exposure to aflatoxin B1. J Surg Oncol. 2004;86:157-163. [PMID: 15170655 DOI: 10.1002/jso.20051] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
48 Long J, Ouyang Y, Duan H, Xiang Z, Ma H, Ju M, Sun D. Multiple Factor Analysis of Depression and/or Anxiety in Patients with Acute Exacerbation Chronic Obstructive Pulmonary Disease. Int J Chron Obstruct Pulmon Dis 2020;15:1449-64. [PMID: 32606653 DOI: 10.2147/COPD.S245842] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
49 Zekri AR, Bahnassy AA, Abdel-Wahab SA, Khafagy MM, Loutfy SA, Radwan H, Shaarawy SM. Expression of pro- and anti-inflammatory cytokines in relation to apoptotic genes in Egyptian liver disease patients associated with HCV-genotype-4. J Gastroenterol Hepatol. 2009;24:416-428. [PMID: 19054267 DOI: 10.1111/j.1440-1746.2008.05699.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
50 Qi LN, Bai T, Chen ZS, Wu FX, Chen YY, De Xiang B, Peng T, Han ZG, Li LQ. The p53 mutation spectrum in hepatocellular carcinoma from Guangxi, China: role of chronic hepatitis B virus infection and aflatoxin B1 exposure. Liver Int. 2015;35:999-1009. [PMID: 24461059 DOI: 10.1111/liv.12460] [Cited by in Crossref: 46] [Cited by in F6Publishing: 37] [Article Influence: 5.8] [Reference Citation Analysis]
51 Vilana R, Llovet JM, Bianchi L, Sanchez M, Pagés M, Sala M, Gilabert R, Nicolau C, Garcia A, Ayuso C. Contrast-enhanced power Doppler sonography and helical computed tomography for assessment of vascularity of small hepatocellular carcinomas before and after percutaneous ablation. J Clin Ultrasound. 2003;31:119-128. [PMID: 12594796 DOI: 10.1002/jcu.10151] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 1.3] [Reference Citation Analysis]
52 Köhle C, Schwarz M, Bock KW. Promotion of hepatocarcinogenesis in humans and animal models. Arch Toxicol 2008;82:623-31. [DOI: 10.1007/s00204-007-0273-7] [Cited by in Crossref: 38] [Cited by in F6Publishing: 28] [Article Influence: 2.7] [Reference Citation Analysis]
53 Fecht WJ Jr, Befeler AS. Hepatocellular carcinoma: updates in primary prevention. Curr Gastroenterol Rep 2004;6:37-43. [PMID: 14720452 DOI: 10.1007/s11894-004-0024-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
54 Bosch F, Ribes J, Díaz M, Cléries R. Primary liver cancer: Worldwide incidence and trends. Gastroenterology 2004;127:S5-S16. [DOI: 10.1053/j.gastro.2004.09.011] [Cited by in Crossref: 1676] [Cited by in F6Publishing: 1575] [Article Influence: 93.1] [Reference Citation Analysis]
55 Liu YI, Kamaya A, Jeffrey RB, Shin LK. Multidetector Computed Tomography Triphasic Evaluation of the Liver Before Transplantation: Importance of Equilibrium Phase Washout and Morphology for Characterizing Hypervascular Lesions. Journal of Computer Assisted Tomography 2012;36:213-9. [DOI: 10.1097/rct.0b013e318247c8f0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 2] [Article Influence: 1.2] [Reference Citation Analysis]
56 Wang Y, Jiang J, Ma H, Han J, Sun Z, Liu Z, Xu Z. Role of ZIC1 methylation in hepatocellular carcinoma and its clinical significance. Tumor Biol 2014;35:7429-33. [DOI: 10.1007/s13277-014-1971-4] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
57 Ng KK, Lam CM, Poon RT, Ai V, Tso WK, Fan ST. Thermal ablative therapy for malignant liver tumors: a critical appraisal. J Gastroenterol Hepatol. 2003;18:616-629. [PMID: 12753142 DOI: 10.1046/j.1440-1746.2003.02991.x] [Cited by in Crossref: 44] [Cited by in F6Publishing: 44] [Article Influence: 2.4] [Reference Citation Analysis]
58 Othman AM, El-houseini ME, El-sofy MS, Aboul-enein HY. Potentiometric determination of α-l-fucosidase enzyme by using 2-chloro-4-nitrophenol-rhodamine B ion pair chemical recognition in PVC membrane sensor. Anal Bioanal Chem 2011;400:787-95. [DOI: 10.1007/s00216-011-4774-0] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
59 Broelsch CE, Frilling A, Malago M. Hepatoma—resection or transplantation. Surgical Clinics of North America 2004;84:495-511. [DOI: 10.1016/j.suc.2003.11.001] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
60 Bosch F, Ribes J. The epidemiology of primary liver cancer: global epidemiology. Viruses and Liver Cancer. Elsevier; 2002. pp. 1-16. [DOI: 10.1016/s0168-7069(02)06062-7] [Cited by in Crossref: 7] [Article Influence: 0.4] [Reference Citation Analysis]
61 Santoyo J, Suárez M, Fernández J, Jiménez M, Ramírez C, Pérez Daga A, Bondia J, de la Fuente A. Tratamiento quirúrgico del hepatocarcinoma en el paciente cirrótico: ¿resección o trasplante? Cirugía Española 2001;70:42-8. [DOI: 10.1016/s0009-739x(01)71839-8] [Cited by in Crossref: 5] [Article Influence: 0.2] [Reference Citation Analysis]
62 Marrero JA. Hepatocellular carcinoma: . Current Opinion in Gastroenterology 2006;22:248-53. [DOI: 10.1097/01.mog.0000218961.86182.8c] [Cited by in Crossref: 76] [Cited by in F6Publishing: 71] [Article Influence: 4.8] [Reference Citation Analysis]
63 McKillop IH, Moran DM, Jin X, Koniaris LG. Molecular pathogenesis of hepatocellular carcinoma. J Surg Res. 2006;136:125-135. [PMID: 17023002 DOI: 10.1016/j.jss.2006.04.013] [Cited by in Crossref: 76] [Cited by in F6Publishing: 67] [Article Influence: 4.8] [Reference Citation Analysis]
64 Jeng KS, Sheen IS, Jeng WJ, Yu MC, Tsai HH, Chang FY, Su JC. Blockade of the sonic hedgehog pathway effectively inhibits the growth of hepatoma in mice: An in vivo study. Oncol Lett. 2012;4:1158-1162. [PMID: 23205113 DOI: 10.3892/ol.2012.935] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
65 Di Bisceglie AM. Epidemiology and clinical presentation of hepatocellular carcinoma. J Vasc Interv Radiol 2002;13:S169-71. [PMID: 12354833 DOI: 10.1016/s1051-0443(07)61783-7] [Cited by in Crossref: 61] [Cited by in F6Publishing: 27] [Article Influence: 3.2] [Reference Citation Analysis]
66 Lee IJ, Kim YI, Kim KW, Kim DH, Ryoo I, Lee MW, Chung JW. Radiofrequency ablation combined with transcatheter arterial embolisation in rabbit liver: investigation of the ablation zone according to the time interval between the two therapies. Br J Radiol 2012;85:e987-94. [PMID: 22674711 DOI: 10.1259/bjr/90024696] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
67 Liu FY, Yu XL, Liang P, Wang Y, Zhou P, Yu J. Comparison of percutaneous 915 MHz microwave ablation and 2450 MHz microwave ablation in large hepatocellular carcinoma. Int J Hyperthermia. 2010;26:448-455. [PMID: 20433313 DOI: 10.3109/02656731003717574] [Cited by in Crossref: 44] [Cited by in F6Publishing: 42] [Article Influence: 3.7] [Reference Citation Analysis]
68 Wang M, Scapaticci R, Cavagnaro M, Crocco L. Towards a Microwave Imaging System for Continuous Monitoring of Liver Tumor Ablation: Design and In Silico Validation of an Experimental Setup. Diagnostics (Basel) 2021;11:866. [PMID: 34065015 DOI: 10.3390/diagnostics11050866] [Reference Citation Analysis]
69 Huang MA, Marrero JA. Hepatocellular carcinoma: . Current Opinion in Gastroenterology 2002;18:345-50. [DOI: 10.1097/00001574-200205000-00008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
70 Wong Ch, Goh K. Chronic hepatitis B infection and liver cancer. Biomed Imaging Interv J 2006;2:e7. [PMID: 21614253 DOI: 10.2349/biij.2.3.e7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
71 Csepregi A, Röcken C, Hoffmann J, Gu P, Saliger S, Müller O, Schneider-Stock R, Kutzner N, Roessner A, Malfertheiner P. APC promoter methylation and protein expression in hepatocellular carcinoma. J Cancer Res Clin Oncol. 2008;134:579-589. [PMID: 17973119 DOI: 10.1007/s00432-007-0321-y] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 2.1] [Reference Citation Analysis]
72 Yu HC, Cheng JS, Lai KH, Lin CP, Lo GH, Lin CK, Hsu PI, Chan HH, Lo CC, Tsai WL, Chen WC. Factors for early tumor recurrence of single small hepatocellular carcinoma after percutaneous radiofrequency ablation therapy. World J Gastroenterol 2005; 11(10): 1439-1444 [PMID: 15770718 DOI: 10.3748/wjg.v11.i10.1439] [Cited by in CrossRef: 52] [Cited by in F6Publishing: 52] [Article Influence: 3.1] [Reference Citation Analysis]
73 Chang MS, Nguyen MH. Epidemiology of hepatitis B and the role of vaccination. Best Pract Res Clin Gastroenterol 2017;31:239-47. [PMID: 28774405 DOI: 10.1016/j.bpg.2017.05.008] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
74 Young AP, Sigman DS. Conformational effects of volatile anesthetics on the membrane-bound acetylcholine receptor protein: facilitation of the agonist-induced affinity conversion. Biochemistry. 1983;22:2155-2162. [PMID: 6860656 DOI: 10.1016/s0065-230x(06)95003-9] [Cited by in Crossref: 20] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
75 Yoshida K, Murata M, Yamaguchi T, Matsuzaki K. TGF-β/Smad signaling during hepatic fibro-carcinogenesis (review). Int J Oncol 2014;45:1363-71. [PMID: 25050845 DOI: 10.3892/ijo.2014.2552] [Cited by in Crossref: 76] [Cited by in F6Publishing: 69] [Article Influence: 9.5] [Reference Citation Analysis]
76 Anzola M, Cuevas N, Lopez-Martinez M, Martinez de Pancorbo M, Burgos JJ. p16INK4A gene alterations are not a prognostic indicator for survival in patients with hepatocellular carcinoma undergoing curative hepatectomy. J Gastroenterol Hepatol. 2004;19:397-405. [PMID: 15012776 DOI: 10.1111/j.1440-1746.2003.03305.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 0.7] [Reference Citation Analysis]
77 Bush DA, Hillebrand DJ, Slater JM, Slater JD. High-dose proton beam radiotherapy of hepatocellular carcinoma: Preliminary results of a phase II trial. Gastroenterology. 2004;127:S189-S193. [PMID: 15508084 DOI: 10.1053/j.gastro.2004.09.033] [Cited by in Crossref: 109] [Cited by in F6Publishing: 79] [Article Influence: 6.1] [Reference Citation Analysis]
78 Shun SC, Lai YH, Jing TT, Jeng C, Lee FY, Hu LS, Cheng SY. Fatigue patterns and correlates in male liver cancer patients receiving transcatheter hepatic arterial chemoembolization. Support Care Cancer 2005;13:311-7. [PMID: 15611851 DOI: 10.1007/s00520-004-0740-0] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 1.3] [Reference Citation Analysis]
79 Chen X, Liu HP, Li M, Qiao L. Advances in non-surgical management of primary liver cancer. World J Gastroenterol 2014; 20(44): 16630-16638 [PMID: 25469032 DOI: 10.3748/wjg.v20.i44.16630] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 29] [Article Influence: 3.3] [Reference Citation Analysis]
80 Huppert P. Current concepts in transarterial chemoembolization of hepatocellular carcinoma. Abdom Imaging. 2011;36:677-683. [PMID: 21674193 DOI: 10.1007/s00261-011-9755-4] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
81 Kiyosawa K, Umemura T, Ichijo T, Matsumoto A, Yoshizawa K, Gad A, Tanaka E. Hepatocellular carcinoma: recent trends in Japan. Gastroenterology. 2004;127:S17-S26. [PMID: 15508082 DOI: 10.1053/j.gastro.2004.09.012] [Cited by in Crossref: 221] [Cited by in F6Publishing: 217] [Article Influence: 12.3] [Reference Citation Analysis]
82 Di Carlo I, Mannino M, Toro A, Ardiri A, Galia A, Cappello G, Bertino G. Persistent increase in alpha-fetoprotein level in a patient without underlying liver disease who underwent curative resection of hepatocellular carcinoma. A case report and review of the literature. World J Surg Oncol 2012;10:79. [PMID: 22559879 DOI: 10.1186/1477-7819-10-79] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
83 Ritter M, Ali MY, Grimm CF, Weth R, Mohr L, Bocher WO, Endrulat K, Wedemeyer H, Blum HE, Geissler M. Immunoregulation of dendritic and T cells by alpha-fetoprotein in patients with hepatocellular carcinoma. J Hepatol. 2004;41:999-1007. [PMID: 15582134 DOI: 10.1016/j.jhep.2004.08.013] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 1.5] [Reference Citation Analysis]
84 Kang JS, Park KD, Ahn B, Han BS. Decreased Diethylnitrosamine-induced Liver Preneoplastic Lesions by Estradiol-3-benzoate Treatment. Toxicol Res 2011;27:247-51. [PMID: 24278579 DOI: 10.5487/TR.2011.27.4.247] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
85 Hsing AW, Gao Y, Mcglynn KA, Niwa S, Zhang M, Han T, Wang B, Chen J, Sakoda LC, Shen M, Zhang B, Deng J, Rashid A. Biliary tract cancer and stones in relation to chronic liver conditions: A population-based study in Shanghai, China. Int J Cancer 2007;120:1981-5. [DOI: 10.1002/ijc.22375] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 1.7] [Reference Citation Analysis]
86 Nagahara T, Okano J, Fujise Y, Abe R, Murawaki Y. Preventive effect of JTE-522, a selective cyclooxygenase-2 inhibitor, on DEN-induced hepatocarcinogenesis in rats. Biomed Pharmacother 2010;64:319-26. [PMID: 20434301 DOI: 10.1016/j.biopha.2009.09.023] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
87 Chien MH, Ying TH, Yang SF, Yu JK, Hsu CW, Hsieh SC, Hsieh YH. Lipocalin-2 induces apoptosis in human hepatocellular carcinoma cells through activation of mitochondria pathways. Cell Biochem Biophys 2012;64:177-86. [PMID: 22707293 DOI: 10.1007/s12013-012-9370-1] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
88 Moore SW, Davidson A, Hadley GP, Kruger M, Poole J, Stones D, Wainwright L, Wessels G. Malignant Liver Tumors in South African Children: A National Audit. World J Surg 2008;32:1389-95. [DOI: 10.1007/s00268-008-9526-8] [Cited by in Crossref: 40] [Cited by in F6Publishing: 23] [Article Influence: 2.9] [Reference Citation Analysis]
89 Hayashi S, Khan A, Simons BC, Homan C, Matsui T, Ogawa K, Kawashima K, Murakami S, Takahashi S, Isogawa M, Ikeo K, Mizokami M, McMahon BJ, Tanaka Y. An Association Between Core Mutations in Hepatitis B Virus Genotype F1b and Hepatocellular Carcinoma in Alaskan Native People. Hepatology 2019;69:19-33. [PMID: 29893492 DOI: 10.1002/hep.30111] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
90 Nishikawa H, Inuzuka T, Takeda H, Nakajima J, Matsuda F, Sakamoto A, Henmi S, Hatamaru K, Ishikawa T, Saito S, Nasu A, Kita R, Kimura T, Arimoto A, Osaki Y. Comparison of percutaneous radiofrequency thermal ablation and surgical resection for small hepatocellular carcinoma. BMC Gastroenterol 2011;11:143. [PMID: 22204311 DOI: 10.1186/1471-230X-11-143] [Cited by in Crossref: 49] [Cited by in F6Publishing: 23] [Article Influence: 4.5] [Reference Citation Analysis]
91 Kew M. Epidemiology of chronic hepatitis B virus infection, hepatocellular carcinoma, and hepatitis B virus-induced hepatocellular carcinoma. Pathologie Biologie 2010;58:273-7. [DOI: 10.1016/j.patbio.2010.01.005] [Cited by in Crossref: 168] [Cited by in F6Publishing: 167] [Article Influence: 14.0] [Reference Citation Analysis]
92 Breuker C, Planque C, Rajabi F, Nault JC, Couchy G, Zucman-Rossi J, Evrard A, Kantar J, Chevet E, Bioulac-Sage P, Ramos J, Assenat E, Joubert D, Pannequin J, Hollande F, Pascussi JM. Characterization of a novel PXR isoform with potential dominant-negative properties. J Hepatol 2014;61:609-16. [PMID: 24798619 DOI: 10.1016/j.jhep.2014.04.030] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
93 Van Deusen MA, Abdalla EK, Vauthey JN, Roh MS. Staging classifications for hepatocellular carcinoma. Expert Rev Mol Diagn 2005;5:377-83. [PMID: 15934814 DOI: 10.1586/14737159.5.3.377] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
94 Jiang SS, Tang Y, Zhang YJ, Weng DS, Zhou ZG, Pan K, Pan QZ, Wang QJ, Liu Q, He J, Zhao JJ, Li J, Chen MS, Chang AE, Li Q, Xia JC. A phase I clinical trial utilizing autologous tumor-infiltrating lymphocytes in patients with primary hepatocellular carcinoma. Oncotarget. 2015;6:41339-41349. [PMID: 26515587 DOI: 10.18632/oncotarget.5463] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 6.3] [Reference Citation Analysis]
95 Zheng Q, Yang H, Wei J, Tong J, Shu Y. The role and mechanisms of nanoparticles to enhance radiosensitivity in hepatocellular cell. Biomedicine & Pharmacotherapy 2013;67:569-75. [DOI: 10.1016/j.biopha.2013.04.003] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 3.0] [Reference Citation Analysis]
96 Graveel CR, Harkins-Perry SR, Acevedo LG, Farnham PJ. Identification and characterization of CRG-L2, a new marker for liver tumor development. Oncogene 2003;22:1730-6. [PMID: 12642876 DOI: 10.1038/sj.onc.1206309] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 0.7] [Reference Citation Analysis]
97 Dupont-Bierre E, Compagnon P, Raoul JL, Fayet G, de Lajarte-Thirouard AS, Boudjema K. Resection of hepatocellular carcinoma in noncirrhotic liver: analysis of risk factors for survival. J Am Coll Surg 2005;201:663-70. [PMID: 16256907 DOI: 10.1016/j.jamcollsurg.2005.06.265] [Cited by in Crossref: 65] [Cited by in F6Publishing: 59] [Article Influence: 3.8] [Reference Citation Analysis]
98 Fan Z, Yang G, Zhang W, Liu Q, Liu G, Liu P, Xu L, Wang J, Yan Z, Han H, Liu R, Shu M. Hypoxia blocks ferroptosis of hepatocellular carcinoma via suppression of METTL14 triggered YTHDF2-dependent silencing of SLC7A11. J Cell Mol Med 2021;25:10197-212. [PMID: 34609072 DOI: 10.1111/jcmm.16957] [Reference Citation Analysis]
99 Sukowati CH, Rosso N, Crocè LS, Tiribelli C. Hepatic cancer stem cells and drug resistance: Relevance in targeted therapies for hepatocellular carcinoma. World J Hepatol 2010; 2(3): 114-126 [PMID: 21160982 DOI: 10.4254/wjh.v2.i3.114] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 2.3] [Reference Citation Analysis]
100 Bugianesi E, Leone N, Vanni E, Marchesini G, Brunello F, Carucci P, Musso A, De Paolis P, Capussotti L, Salizzoni M, Rizzetto M. Expanding the natural history of nonalcoholic steatohepatitis: From cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002;123:134-40. [DOI: 10.1053/gast.2002.34168] [Cited by in Crossref: 998] [Cited by in F6Publishing: 934] [Article Influence: 49.9] [Reference Citation Analysis]
101 Nishikawa H, Osaki Y, Iguchi E, Takeda H, Matsuda F, Nakajima J, Sakamoto A, Hatamaru K, Saito S, Nasu A, Kita R, Kimura T. Radiofrequency ablation for hepatocellular carcinoma: the relationship between a new grading system for the ablative margin and clinical outcomes. J Gastroenterol 2013;48:951-65. [PMID: 23065022 DOI: 10.1007/s00535-012-0690-0] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 2.7] [Reference Citation Analysis]
102 Maruyama H, Yoshikawa M, Yokosuka O. Current role of ultrasound for the management of hepatocellular carcinoma. World J Gastroenterol 2008; 14(11): 1710-1719 [PMID: 18350602 DOI: 10.3748/wjg.14.1710] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 26] [Article Influence: 2.4] [Reference Citation Analysis]
103 Singal AK, Singh A, Jaganmohan S, Guturu P, Mummadi R, Kuo YF, Sood GK. Antiviral therapy reduces risk of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis. Clin Gastroenterol Hepatol. 2010;8:192-199. [PMID: 19879972 DOI: 10.1016/j.cgh.2009.10.026] [Cited by in Crossref: 147] [Cited by in F6Publishing: 140] [Article Influence: 11.3] [Reference Citation Analysis]
104 Lin TL, Yap AQ, Wang JH, Chen CL, Iyer SG, Low JK, Lin CC, Li WF, Chen TY, Bora D, Lin CY, Wang CC. Long term survival in patients with hepatocellular carcinoma directly invading the gastrointestinal tract: case reports and literature review. Surg Oncol 2011;20:e207-14. [PMID: 21824763 DOI: 10.1016/j.suronc.2011.06.008] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
105 Abdo AA, Hassanain M, AlJumah A, Al Olayan A, Sanai FM, Alsuhaibani HA, Abdulkareem H, Abdallah K, AlMuaikeel M, Al Saghier M, Babatin M, Kabbani M, Bazarbashi S, Metrakos P, Bruix J; Saudi Association for the Study of Liver Diseases and Transplantation., Saudi Oncology Society. Saudi guidelines for the diagnosis and management of hepatocellular carcinoma: technical review and practice guidelines. Ann Saudi Med 2012;32:174-99. [PMID: 22366832 DOI: 10.5144/0256-4947.2012.174] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
106 Voigt MD. Alcohol in hepatocellular cancer. Clin Liver Dis. 2005;9:151-169. [PMID: 15763234 DOI: 10.1016/j.cld.2004.10.003] [Cited by in Crossref: 52] [Cited by in F6Publishing: 46] [Article Influence: 3.1] [Reference Citation Analysis]
107 Nishikawa H, Osaki Y, Iguchi E, Koshikawa Y, Ako S, Inuzuka T, Takeda H, Nakajima J, Matsuda F, Sakamoto A. The effect of long-term supplementation with branched-chain amino acid granules in patients with hepatitis C virus-related hepatocellular carcinoma after radiofrequency thermal ablation. J Clin Gastroenterol. 2013;47:359-366. [PMID: 23090049 DOI: 10.1097/mcg.0b013e31826be9ad] [Cited by in Crossref: 25] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
108 Graveel CR, Jatkoe T, Madore SJ, Holt AL, Farnham PJ. Expression profiling and identification of novel genes in hepatocellular carcinomas. Oncogene. 2001;20:2704-2712. [PMID: 11420682 DOI: 10.1038/sj.onc.1204391] [Cited by in Crossref: 53] [Cited by in F6Publishing: 50] [Article Influence: 2.5] [Reference Citation Analysis]
109 Jiang K, Centeno BA. Primary Liver Cancers, Part 2: Progression Pathways and Carcinogenesis. Cancer Control 2018;25:1073274817744658. [PMID: 29353494 DOI: 10.1177/1073274817744658] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
110 Shen L, Zhang Y, Shen H, Zeng S, Wang X, Wang C, Le Y, Shen H. Liver targeting and the delayed drug release of the nanoparticles of adriamycin polybutylcyanoacrylate in mice: . Chinese Medical Journal 2006;119:1287-93. [DOI: 10.1097/00029330-200608010-00009] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
111 Masuzaki R, Yoshida H, Tateishi R, Shiina S, Omata M. Hepatocellular carcinoma in viral hepatitis: improving standard therapy. Best Pract Res Clin Gastroenterol. 2008;22:1137-1151. [PMID: 19187872 DOI: 10.1016/j.bpg.2008.11.005] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
112 Abdel-Hamid NM. Recent insights on risk factors of hepatocellular carcinoma. World J Hepatol 2009; 1(1): 3-7 [PMID: 21160959 DOI: 10.4254/wjh.v1.i1.3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
113 Sturgeon CM, Duffy MJ, Hofmann BR, Lamerz R, Fritsche HA, Gaarenstroom K, Bonfrer J, Ecke TH, Grossman HB, Hayes P, Hoffmann RT, Lerner SP, Löhe F, Louhimo J, Sawczuk I, Taketa K, Diamandis EP; National Academy of Clinical Biochemistry. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in liver, bladder, cervical, and gastric cancers. Clin Chem 2010;56:e1-48. [PMID: 20207771 DOI: 10.1373/clinchem.2009.133124] [Cited by in Crossref: 146] [Cited by in F6Publishing: 119] [Article Influence: 12.2] [Reference Citation Analysis]
114 Shiraha H, Yamamoto K, Namba M. Human hepatocyte carcinogenesis (review). Int J Oncol. 2013;42:1133-1138. [PMID: 23426905 DOI: 10.3892/ijo.2013.1829] [Cited by in Crossref: 75] [Cited by in F6Publishing: 80] [Article Influence: 8.3] [Reference Citation Analysis]
115 Park EK, Kim HJ, Kim CY, Hur YH, Koh YS, Kim JC, Kim HJ, Kim JW, Cho CK. A comparison between surgical resection and radiofrequency ablation in the treatment of hepatocellular carcinoma. Ann Surg Treat Res 2014;87:72-80. [PMID: 25114886 DOI: 10.4174/astr.2014.87.2.72] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 3.5] [Reference Citation Analysis]
116 Jacob JR, Sterczer A, Toshkov IA, Yeager AE, Korba BE, Cote PJ, Buendia MA, Gerin JL, Tennant BC. Integration of woodchuck hepatitis and N-myc rearrangement determine size and histologic grade of hepatic tumors. Hepatology. 2004;39:1008-1016. [PMID: 15057905 DOI: 10.1002/hep.20106] [Cited by in Crossref: 36] [Cited by in F6Publishing: 39] [Article Influence: 2.0] [Reference Citation Analysis]
117 Nakamura J, Toyabe S, Aoyagi Y, Akazawa K. Economic impact of extended treatment with peginterferon α-2a and ribavirin for slow hepatitis C virologic responders. J Viral Hepat 2008;15:293-9. [DOI: 10.1111/j.1365-2893.2007.00943.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
118 Chang J, Lan T, Li C, Ji X, Zheng L, Gou H, Ou Y, Wu T, Qi C, Zhang Q, Li J, Gu Q, Wen D, Cao L, Qiao L, Ding Y, Wang L. Activation of Slit2-Robo1 signaling promotes liver fibrosis. Journal of Hepatology 2015;63:1413-20. [DOI: 10.1016/j.jhep.2015.07.033] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 3.6] [Reference Citation Analysis]
119 Feldman ED, Wu PC, Beresneva T, Helsabeck C, Rodriguez M, Bartlett DL, Libutti SK, Pingpank JF, Alexander HR. Treatment of patients with unresectable primary hepatic malignancies using hyperthermic isolated hepatic perfusion. J Gastrointest Surg. 2004;8:200-207. [PMID: 15036196 DOI: 10.1016/j.gassur.2003.11.005] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 1.5] [Reference Citation Analysis]
120 Minami K, Hiwatashi K, Ueno S, Sakoda M, Iino S, Okumura H, Hashiguchi M, Kawasaki Y, Kurahara H, Mataki Y, Maemura K, Shinchi H, Natsugoe S. Prognostic significance of CD68, CD163 and Folate receptor-β positive macrophages in hepatocellular carcinoma. Exp Ther Med 2018;15:4465-76. [PMID: 29731831 DOI: 10.3892/etm.2018.5959] [Cited by in Crossref: 11] [Cited by in F6Publishing: 20] [Article Influence: 2.8] [Reference Citation Analysis]
121 Tsou AP, Chuang YC, Su JY, Yang CW, Liao YL, Liu WK, Chiu JH, Chou CK. Overexpression of a novel imprinted gene, PEG10, in human hepatocellular carcinoma and in regenerating mouse livers. J Biomed Sci. 2003;10:625-635. [PMID: 14576465 DOI: 10.1007/bf02256313] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
122 Kim JY, Chung SM, Choi BO, Kay CS. Hepatocellular carcinoma with portal vein tumor thrombosis: Improved treatment outcomes with external beam radiation therapy. Hepatol Res 2011;41:813-24. [PMID: 21696524 DOI: 10.1111/j.1872-034X.2011.00826.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
123 Ghouri YA, Mian I, Rowe JH. Review of hepatocellular carcinoma: Epidemiology, etiology, and carcinogenesis. J Carcinog 2017;16:1. [PMID: 28694740 DOI: 10.4103/jcar.JCar_9_16] [Cited by in Crossref: 313] [Cited by in F6Publishing: 221] [Article Influence: 62.6] [Reference Citation Analysis]
124 Naboulsi W, Bracht T, Megger DA, Reis H, Ahrens M, Turewicz M, Eisenacher M, Tautges S, Canbay AE, Meyer HE, Weber F, Baba HA, Sitek B. Quantitative proteome analysis reveals the correlation between endocytosis-associated proteins and hepatocellular carcinoma dedifferentiation. Biochim Biophys Acta 2016;1864:1579-85. [PMID: 27519163 DOI: 10.1016/j.bbapap.2016.08.005] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
125 Yerian LM, Anders RA, Tretiakova M, Hart J. Caveolin and Thrombospondin Expression During Hepatocellular Carcinogenesis: . The American Journal of Surgical Pathology 2004;28:357-64. [DOI: 10.1097/00000478-200403000-00008] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 1.4] [Reference Citation Analysis]
126 Xu H, Li X, Xie JX, Yang ZH, Wang B. Diffusion-weighted magnetic resonance imaging of focal hepatic nodules in an experimental hepatocellular carcinoma rat model. Acad Radiol 2007;14:279-86. [PMID: 17307660 DOI: 10.1016/j.acra.2006.12.005] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 1.9] [Reference Citation Analysis]
127 Mattos AA, Gomes EB, Tovo CV, Alexandre CO, Remião JO. Hepatitis B vaccine efficacy in patients with chronic liver disease by hepatitis C virus. Arq Gastroenterol 2004;41:180-4. [PMID: 15678203 DOI: 10.1590/s0004-28032004000300008] [Cited by in Crossref: 25] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
128 Ovejero C, Cavard C, Périanin A, Hakvoort T, Vermeulen J, Godard C, Fabre M, Chafey P, Suzuki K, Romagnolo B, Yamagoe S, Perret C. Identification of the leukocyte cell-derived chemotaxin 2 as a direct target gene of β-catenin in the liver. Hepatology 2004;40:167-76. [DOI: 10.1002/hep.20286] [Cited by in Crossref: 77] [Cited by in F6Publishing: 81] [Article Influence: 4.3] [Reference Citation Analysis]
129 Maruyama H, Takahashi M, Ishibashi H, Okugawa H, Okabe S, Yoshikawa M, Yokosuka O. Ultrasound-guided treatments under low acoustic power contrast harmonic imaging for hepatocellular carcinomas undetected by B-mode ultrasonography. Liver Int 2009;29:708-14. [PMID: 18803588 DOI: 10.1111/j.1478-3231.2008.01875.x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 38] [Article Influence: 3.1] [Reference Citation Analysis]
130 Lai R, Peng Z, Chen D, Wang X, Xing W, Zeng W, Chen M. The effects of anesthetic technique on cancer recurrence in percutaneous radiofrequency ablation of small hepatocellular carcinoma. Anesth Analg. 2012;114:290-296. [PMID: 22104077 DOI: 10.1213/ane.0b013e318239c2e3] [Cited by in Crossref: 54] [Cited by in F6Publishing: 20] [Article Influence: 4.9] [Reference Citation Analysis]
131 Ramalingam R, Vaiyapuri M. Effects of umbelliferone on lipid peroxidation and antioxidant status in diethylnitrosamine-induced hepatocellular carcinoma. Journal of Acute Medicine 2013;3:73-82. [DOI: 10.1016/j.jacme.2013.05.001] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
132 Weber S, Jarnagin W, Duffy A, O'reilly EM, Abou-alfa GK, Blumgart L. Liver and Bile Duct Cancer. Abeloff's Clinical Oncology. Elsevier; 2008. pp. 1569-94. [DOI: 10.1016/b978-0-443-06694-8.50088-9] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
133 Liu J, Ding X, Tang J, Cao Y, Hu P, Zhou F, Shan X, Cai X, Chen Q, Ling N. Enhancement of canonical Wnt/β-catenin signaling activity by HCV core protein promotes cell growth of hepatocellular carcinoma cells. PLoS One. 2011;6:e27496. [PMID: 22110662 DOI: 10.1371/journal.pone.0027496] [Cited by in Crossref: 80] [Cited by in F6Publishing: 76] [Article Influence: 7.3] [Reference Citation Analysis]
134 Hussein YM, Morad FE, Gameel MA, Emam WA, El Sawy WH, El Tarhouny SA, Bayomy ES, Raafat N. MAGE-4 gene m-RNA and TGF in blood as potential biochemical markers for HCC in HCV-infected patients.Med Oncol. 2012;29:3055-3062. [PMID: 22653756 DOI: 10.1007/s12032-012-0257-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
135 Libbrecht L, Craninx M, Nevens F, Desmet V, Roskams T. Predictive value of liver cell dysplasia for development of hepatocellular carcinoma in patients with non-cirrhotic and cirrhotic chronic viral hepatitis. Histopathology 2001;39:66-73. [PMID: 11454046 DOI: 10.1046/j.1365-2559.2001.01172.x] [Cited by in Crossref: 83] [Cited by in F6Publishing: 60] [Article Influence: 4.0] [Reference Citation Analysis]
136 Poon RT, Fan ST, Wong J. Does diabetes mellitus influence the perioperative outcome or long term prognosis after resection of hepatocellular carcinoma? Am J Gastroenterol 2002;97:1480-8. [PMID: 12094870 DOI: 10.1111/j.1572-0241.2002.05792.x] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 1.9] [Reference Citation Analysis]
137 Imada H, Kato H, Yasuda S, Yamada S, Yanagi T, Kishimoto R, Kandatsu S, Mizoe JE, Kamada T, Yokosuka O. Comparison of efficacy and toxicity of short-course carbon ion radiotherapy for hepatocellular carcinoma depending on their proximity to the porta hepatis. Radiother Oncol. 2010;96:231-235. [PMID: 20579756 DOI: 10.1016/j.radonc.2010.05.019] [Cited by in Crossref: 55] [Cited by in F6Publishing: 44] [Article Influence: 4.6] [Reference Citation Analysis]
138 Pang RWC, Joh JW, Johnson PJ, Monden M, Pawlik TM, Poon RTP. Biology of Hepatocellular Carcinoma. Ann Surg Oncol 2008;15:962-71. [DOI: 10.1245/s10434-007-9730-z] [Cited by in Crossref: 122] [Cited by in F6Publishing: 118] [Article Influence: 8.7] [Reference Citation Analysis]
139 Zhang GX, Zhao ZQ, Wang HD, Hao B. Enhancement of osteopontin expression in HepG2 cells by epidermal growth factor via phosphatidylinositol 3-kinase signaling pathway. World J Gastroenterol 2004; 10(2): 205-208 [PMID: 14716823 DOI: 10.3748/wjg.v10.i2.205] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 15] [Article Influence: 0.8] [Reference Citation Analysis]
140 Maruyama H, Takahashi M, Ishibashi H, Okabe S, Yoshikawa M, Yokosuka O. Changes in tumor vascularity precede microbubble contrast accumulation deficit in the process of dedifferentiation of hepatocellular carcinoma. Eur J Radiol 2010;75:e102-6. [PMID: 19783392 DOI: 10.1016/j.ejrad.2009.08.017] [Cited by in Crossref: 8] [Cited by in F6Publishing: 13] [Article Influence: 0.6] [Reference Citation Analysis]
141 Anzola M, Cuevas N, López-Martínez M, Saiz A, Burgos JJ, Martínez de Pancorboa M. P14ARF gene alterations in human hepatocellular carcinoma. Eur J Gastroenterol Hepatol. 2004;16:19-26. [PMID: 15095848 DOI: 10.1097/00042737-200401000-00004] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 1.0] [Reference Citation Analysis]
142 Branda M, Wands JR. Signal transduction cascades and hepatitis B and C related hepatocellular carcinoma. Hepatology. 2006;43:891-902. [PMID: 16628664 DOI: 10.1002/hep.21196] [Cited by in Crossref: 77] [Cited by in F6Publishing: 74] [Article Influence: 4.8] [Reference Citation Analysis]
143 Lee DW, Jang MJ, Lee KH, Cho EJ, Lee JH, Yu SJ, Kim YJ, Yoon JH, Kim TY, Han SW, Oh DY, Im SA, Kim TY. TTP as a surrogate endpoint in advanced hepatocellular carcinoma treated with molecular targeted therapy: meta-analysis of randomised controlled trials. Br J Cancer 2016;115:1201-5. [PMID: 27736843 DOI: 10.1038/bjc.2016.322] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
144 Kaibori M, Ishizaki M, Matsui K, Kwon AH. Clinicopathologic characteristics of patients with non-B non-C hepatitis virus hepatocellular carcinoma after hepatectomy. Am J Surg. 2012;204:300-307. [PMID: 22591698 DOI: 10.1016/j.amjsurg.2011.11.014] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.2] [Reference Citation Analysis]
145 Bharadwaj M, Roy G, Dutta K, Misbah M, Husain M, Hussain S. Tackling hepatitis B virus-associated hepatocellular carcinoma--the future is now. Cancer Metastasis Rev. 2013;32:229-268. [PMID: 23114844 DOI: 10.1007/s10555-012-9412-6] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
146 Schwartz JD, Llovet JM. Molecular Targeting in Hepatocellular Carcinoma. In: Kaufman HL, Wadler S, Antman K, editors. Molecular Targeting in Oncology. Totowa: Humana Press; 2008. pp. 165-210. [DOI: 10.1007/978-1-59745-337-0_8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
147 Enninga EA, Nevala WK, Holtan SG, Markovic SN. Immune Reactivation by Cell-Free Fetal DNA in Healthy Pregnancies Re-Purposed to Target Tumors: Novel Checkpoint Inhibition in Cancer Therapeutics. Front Immunol 2015;6:424. [PMID: 26379664 DOI: 10.3389/fimmu.2015.00424] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
148 Chen MS, Li JQ, Zheng Y, Guo RP, Liang HH, Zhang YQ, Lin XJ, Lau WY. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg. 2006;243:321-328. [PMID: 16495695 DOI: 10.1097/01.sla.0000201480.65519.b8] [Cited by in Crossref: 919] [Cited by in F6Publishing: 833] [Article Influence: 57.4] [Reference Citation Analysis]
149 Tsai FC, Liu CJ, Chen CL, Chen PJ, Lai MY, Kao JH, Chen DS. Lower serum viral loads in young patients with hepatitis-B-virus-related hepatocellular carcinoma. J Viral Hepat 2007;14:153-60. [PMID: 17305880 DOI: 10.1111/j.1365-2893.2006.00780.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]
150 Hoffe SE, Finkelstein SE, Russell MS, Shridhar R. Nonsurgical options for hepatocellular carcinoma: evolving role of external beam radiotherapy. Cancer Control 2010;17:100-10. [PMID: 20404793 DOI: 10.1177/107327481001700205] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
151 Wang S, Chai P, Jia R, Jia R. Novel insights on m6A RNA methylation in tumorigenesis: a double-edged sword. Mol Cancer 2018;17:101. [PMID: 30031372 DOI: 10.1186/s12943-018-0847-4] [Cited by in Crossref: 72] [Cited by in F6Publishing: 75] [Article Influence: 18.0] [Reference Citation Analysis]
152 Kawamura Y, Ikeda K, Arase Y, Yatsuji H, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Saitoh S, Suzuki F. Diabetes mellitus worsens the recurrence rate after potentially curative therapy in patients with hepatocellular carcinoma associated with nonviral hepatitis. J Gastroenterol Hepatol. 2008;23:1739-1746. [PMID: 18713301 DOI: 10.1111/j.1440-1746.2008.05436.x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 2.1] [Reference Citation Analysis]
153 Chen XQ, He JR, Wang HY. Decreased expression of ALDH1L1 is associated with a poor prognosis in hepatocellular carcinoma. Med Oncol 2012;29:1843-9. [PMID: 21987076 DOI: 10.1007/s12032-011-0075-x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 22] [Article Influence: 1.5] [Reference Citation Analysis]
154 Garin E, Noiret N, Malbert C, Lepareur N, Roucoux A, Caulet-Maugendre S, Moisan A, Lecloirec J, Herry JY, Bourguet P. Development and biodistribution of 188Re-SSS lipiodol following injection into the hepatic artery of healthy pigs. Eur J Nucl Med Mol Imaging 2004;31:542-6. [PMID: 14691613 DOI: 10.1007/s00259-003-1402-z] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 1.4] [Reference Citation Analysis]
155 Lertpipopmetha K, Tubtawee T, Piratvisuth T, Chamroonkul N. Comparison between Computer Tomography and Magnetic Resonance Imaging in the Diagnosis of Small Hepatocellular Carcinoma. Asian Pac J Cancer Prev 2016;17:4805-11. [PMID: 28030903 DOI: 10.22034/APJCP.2016.17.11.4805] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
156 Di Maso V, Avellini C, Crocè LS, Rosso N, Quadrifoglio F, Cesaratto L, Codarin E, Bedogni G, Beltrami CA, Tell G, Tiribelli C. Subcellular localization of APE1/Ref-1 in human hepatocellular carcinoma: possible prognostic significance. Mol Med 2007;13:89-96. [PMID: 17515960 DOI: 10.2119/2006-00084.dimaso] [Cited by in Crossref: 66] [Cited by in F6Publishing: 43] [Article Influence: 4.4] [Reference Citation Analysis]
157 Schröder PC, Fernández-Irigoyen J, Bigaud E, Serna A, Renández-Alcoceba R, Lu SC, Mato JM, Prieto J, Corrales FJ. Proteomic analysis of human hepatoma cells expressing methionine adenosyltransferase I/III: Characterization of DDX3X as a target of S-adenosylmethionine. J Proteomics 2012;75:2855-68. [PMID: 22270009 DOI: 10.1016/j.jprot.2012.01.009] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
158 Gao H, Lu Q, Liu X, Cong H, Zhao L, Wang H, Lin D. Application of 1H NMR-based metabonomics in the study of metabolic profiling of human hepatocellular carcinoma and liver cirrhosis. Cancer Sci. 2009;100:782-785. [PMID: 19469021 DOI: 10.1111/j.1349-7006.2009.01086.x] [Cited by in Crossref: 138] [Cited by in F6Publishing: 136] [Article Influence: 10.6] [Reference Citation Analysis]
159 Zhang YJ, Chen MS. Role of radiofrequency ablation in the treatment of small hepatocellular carcinoma. World J Hepatol 2010; 2(4): 146-150 [PMID: 21160987 DOI: 10.4254/wjh.v2.i4.146] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
160 Wu L, Xu X, Shen J, Xie H, Yu S, Liang T, Wang W, Shen Y, Zhang M, Zheng S. MDR1 gene polymorphisms and risk of recurrence in patients With hepatocellular carcinoma after liver transplantation. J Surg Oncol 2007;96:62-8. [DOI: 10.1002/jso.20774] [Cited by in Crossref: 42] [Cited by in F6Publishing: 42] [Article Influence: 2.8] [Reference Citation Analysis]
161 Marcellin P, Boyer N. Transition of care between paediatric and adult gastroenterology. Chronic viral hepatitis. Best Pract Res Clin Gastroenterol. 2003;17:259-275. [PMID: 12676118 DOI: 10.1016/S1521-6918(03)00014-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
162 Kavoosi F, Dastjerdi MN, Valiani A, Esfandiari E, Sanaei M, Hakemi MG. Genistein potentiates the effect of 17-beta estradiol on human hepatocellular carcinoma cell line. Adv Biomed Res 2016;5:133. [PMID: 27656602 DOI: 10.4103/2277-9175.187395] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
163 Zeeneldin AA, Salem SE, Darwish AD, El-Gammal MM, Hussein MM, Saadeldin M. Untreated hepatocellular carcinoma in Egypt: outcome and prognostic factors. J Hepatocell Carcinoma 2015;2:3-9. [PMID: 27508189 DOI: 10.2147/JHC.S73828] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
164 Li J, Ling W, Lu Q, Lu C, He D, Luo Y. Liver Stiffness and Serum Alpha-Fetoprotein in Discriminating Small Hepatocellular Carcinoma from Cirrhotic Nodule. Ultrasound Quarterly 2016;32:319-26. [DOI: 10.1097/ruq.0000000000000244] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
165 Herold C, Reck T, Fischler P, Ott R, Radespiel-troeger M, Ganslmayer M, Hohenberger W, Hahn EG, Schuppan D. Prognosis of a large cohort of patients with hepatocellular carcinoma in a single European centre: Prognosis of hepatocellular carcinoma. Liver 2002;22:23-8. [DOI: 10.1046/j.0106-9543.2001.01571.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 1.6] [Reference Citation Analysis]
166 Lam VW, Ng KK, Chok KS, Cheung TT, Wat J, Fan ST, Poon RT. Safety and efficacy of radiofrequency ablation for periductal hepatocellular carcinoma with intraductal cooling of the central bile duct. J Am Coll Surg 2008;207:e1-5. [PMID: 18656036 DOI: 10.1016/j.jamcollsurg.2008.03.028] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
167 Lee EW, Thakor AS, Tafti BA, Liu DM. Y90 Selective Internal Radiation Therapy. Surgical Oncology Clinics of North America 2015;24:167-85. [DOI: 10.1016/j.soc.2014.09.011] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
168 Kim SJ, Choi MS, Kang JY, Choi DI, Park CK, Gwak GY, Lee JH, Koh KC, Paik SW, Yoo BC. Prediction of complete necrosis of hepatocellular carcinoma treated with transarterial chemoembolization prior to liver transplantation. Gut Liver 2009;3:285-91. [PMID: 20431762 DOI: 10.5009/gnl.2009.3.4.285] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
169 Lu JW, Liao CY, Yang WY, Lin YM, Jin SL, Wang HD, Yuh CH. Overexpression of endothelin 1 triggers hepatocarcinogenesis in zebrafish and promotes cell proliferation and migration through the AKT pathway. PLoS One. 2014;9:e85318. [PMID: 24416389 DOI: 10.1371/journal.pone.0085318] [Cited by in Crossref: 47] [Cited by in F6Publishing: 49] [Article Influence: 5.9] [Reference Citation Analysis]
170 Li Z, Li F, Peng Y, Fang J, Zhou J. Identification of three m6A-related mRNAs signature and risk score for the prognostication of hepatocellular carcinoma. Cancer Med 2020;9:1877-89. [PMID: 31943856 DOI: 10.1002/cam4.2833] [Cited by in Crossref: 18] [Cited by in F6Publishing: 24] [Article Influence: 9.0] [Reference Citation Analysis]
171 Zhang G, Wang Q, Xu R. Therapeutics Based on microRNA: A New Approach for Liver Cancer. Curr Genomics 2010;11:311-25. [PMID: 21286309 DOI: 10.2174/138920210791616671] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 2.3] [Reference Citation Analysis]
172 Nicolau C, Bianchi L, Vilana R. Gray-scale ultrasound in hepatic cirrhosis and chronic hepatitis: diagnosis, screening, and intervention. Semin Ultrasound CT MR. 2002;23:3-18. [PMID: 11866221 DOI: 10.1016/s0887-2171(02)90026-0] [Cited by in Crossref: 35] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
173 Lin YP, Cheng TJ. Why can't Chinese Han drink alcohol? Hepatitis B virus infection and the evolution of acetaldehyde dehydrogenase deficiency. Med Hypotheses 2002;59:204-7. [PMID: 12208210 DOI: 10.1016/s0306-9877(02)00253-0] [Cited by in Crossref: 20] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
174 Garin E, Noiret N, Malbert CH, Lepareur N, Roucoux A, Dazord L, Caulet-Maugendre S, Turlin B, Moisan A, Lecloirec J, Herry JY, Boucher E, Raoul JL, Bourguet P. Development of 99mTc labelled Lipiodol: biodistribution following injection into the hepatic artery of the healthy pig. Nucl Med Commun 2004;25:291-7. [PMID: 15094449 DOI: 10.1097/00006231-200403000-00013] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 0.6] [Reference Citation Analysis]
175 Abdalla MA, Haj-Ahmad Y. Promising Urinary Protein Biomarkers for the Early Detection of Hepatocellular Carcinoma among High-Risk Hepatitis C Virus Egyptian Patients. J Cancer. 2012;3:390-403. [PMID: 23074380 DOI: 10.7150/jca.4280] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
176 Kumar M, Zhao X, Wang XW. Molecular carcinogenesis of hepatocellular carcinoma and intrahepatic cholangiocarcinoma: one step closer to personalized medicine? Cell Biosci. 2011;1:5. [PMID: 21711594 DOI: 10.1186/2045-3701-1-5] [Cited by in Crossref: 58] [Cited by in F6Publishing: 52] [Article Influence: 5.3] [Reference Citation Analysis]
177 Hwang J, Kao S, Hsieh Y, Li K, Wang P, Hsu L, Liu J. Reduction of anion exchanger 2 expression induces apoptosis of human hepatocellular carcinoma cells. Mol Cell Biochem 2009;327:135-44. [DOI: 10.1007/s11010-009-0051-3] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
178 Ruff P. Therapeutic Options in Hepatocellular Carcinoma: . American Journal of Cancer 2004;3:119-31. [DOI: 10.2165/00024669-200403020-00004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
179 Hoda M, Pajaniradje S, Shakya G, Mohankumar K, Rajagopalan R. Anti-proliferative and apoptosis-triggering potential of disulfiram and disulfiram-loaded polysorbate 80-stabilized PLGA nanoparticles on hepatocellular carcinoma Hep3B cell line. Nanomedicine 2016;12:1641-50. [PMID: 27013133 DOI: 10.1016/j.nano.2016.02.013] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
180 Wang X, Zhang QY, Li ZJ, Ying XT, Lin JM. Development of high-performance magnetic chemiluminescence enzyme immunoassay for alpha-fetoprotein (AFP) in human serum. Clin Chim Acta 2008;393:90-4. [PMID: 18402780 DOI: 10.1016/j.cca.2008.03.010] [Cited by in Crossref: 60] [Cited by in F6Publishing: 52] [Article Influence: 4.3] [Reference Citation Analysis]
181 Bruix J. HCC surveillance: Who is the target population? Hepatology 2003;37:507-9. [DOI: 10.1053/jhep.2003.50142] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 2.1] [Reference Citation Analysis]
182 Kaibori M, Ishizaki M, Matsui K, Kwon AH. Predictors of microvascular invasion before hepatectomy for hepatocellular carcinoma. J Surg Oncol. 2010;102:462-468. [PMID: 20872949 DOI: 10.1002/jso.21631] [Cited by in Crossref: 91] [Cited by in F6Publishing: 89] [Article Influence: 7.6] [Reference Citation Analysis]
183 Sugarman J, Revill P, Zoulim F, Yazdanpanah Y, Janssen HLA, Lim SG, Lewin SR. Ethics and hepatitis B cure research. Gut 2017;66:389-92. [DOI: 10.1136/gutjnl-2016-313009] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
184 Becker S, Laffont S, Vitry F, Rolland Y, Lecloirec J, Boucher E, Raoul J, Herry J, Bourguet P, Garin E. Dosimetric evaluation and therapeutic response to internal radiation therapy of hepatocarcinomas using iodine-131-labelled lipiodol. Nuclear Medicine Communications 2008;29:815-25. [DOI: 10.1097/mnm.0b013e32830439c6] [Cited by in Crossref: 19] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
185 Mergental H, Porte RJ. Liver transplantation for unresectable hepatocellular carcinoma in patients without liver cirrhosis. Transpl Int 2010;23:662-7. [PMID: 20345561 DOI: 10.1111/j.1432-2277.2010.01076.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 1.6] [Reference Citation Analysis]
186 Li W, Cagle PT, Botero RC, Liang JJ, Zhang Z, Tan D. Significance of overexpression of alpha methylacyl-coenzyme A racemase in hepatocellular carcinoma. J Exp Clin Cancer Res 2008;27:2. [PMID: 18577240 DOI: 10.1186/1756-9966-27-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
187 Shah B, Bhowmick S. Evaluation of important treatment parameters in supraphysiological thermal therapy of human liver cancer HepG2 cells. Ann Biomed Eng 2006;34:1745-57. [PMID: 17031593 DOI: 10.1007/s10439-006-9185-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
188 Huang MT, Wei PL, Liu JJ, Liu DZ, Huey-Chun H, An J, Wu CC, Wu CH, Ho YS, Yang YY, Chang YJ. Knockdown of thrombomodulin enhances HCC cell migration through increase of ZEB1 and decrease of E-cadherin gene expression. Ann Surg Oncol 2010;17:3379-85. [PMID: 20625840 DOI: 10.1245/s10434-010-1163-4] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 1.9] [Reference Citation Analysis]
189 Testa R, Testa E, Giannini E, Botta F, Malfatti F, Chiarbonello B, Fumagalli A, Polegato S, Podesta E, Romagnoli P. Trans-catheter arterial chemoembolisation for hepatocellular carcinoma in patients with viral cirrhosis: role of combined staging systems, Cancer Liver Italian Program (CLIP) and Model for End-stage Liver Disease (MELD), in predicting outcome after treatment. Aliment Pharmacol Ther. 2003;17:1563-1569. [PMID: 12823161 DOI: 10.1046/j.1365-2036.2003.01647.x] [Cited by in Crossref: 42] [Cited by in F6Publishing: 40] [Article Influence: 2.2] [Reference Citation Analysis]
190 Guido M, Roskams T, Pontisso P, Fassan M, Thung SN, Giacomelli L, Sergio A, Farinati F, Cillo U, Rugge M. Squamous cell carcinoma antigen in human liver carcinogenesis. J Clin Pathol 2008;61:445-7. [DOI: 10.1136/jcp.2007.051383] [Cited by in Crossref: 54] [Cited by in F6Publishing: 50] [Article Influence: 3.6] [Reference Citation Analysis]
191 Chen M, Wong CM. The emerging roles of N6-methyladenosine (m6A) deregulation in liver carcinogenesis. Mol Cancer 2020;19:44. [PMID: 32111216 DOI: 10.1186/s12943-020-01172-y] [Cited by in Crossref: 48] [Cited by in F6Publishing: 47] [Article Influence: 24.0] [Reference Citation Analysis]
192 Afum C, Cudjoe L, Hills J, Hunt R, Padilla LA, Elmore S, Afriyie A, Opare-Sem O, Phillips T, Jolly PE. Association between Aflatoxin M₁ and Liver Disease in HBV/HCV Infected Persons in Ghana. Int J Environ Res Public Health 2016;13:377. [PMID: 27043586 DOI: 10.3390/ijerph13040377] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 3.5] [Reference Citation Analysis]
193 Moety HAA, Moety AAE, sayed PE. Evaluation of serum nitric oxide before and after local radiofrequency thermal ablation for hepatocellular carcinoma. Alexandria Journal of Medicine 2013;49:67-73. [DOI: 10.1016/j.ajme.2012.08.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
194 Wang H, Jiang W, Wang H, Wei Z, Li H, Yan H, Han P. Identification of Mutation Landscape and Immune Cell Component for Liver Hepatocellular Carcinoma Highlights Potential Therapeutic Targets and Prognostic Markers. Front Genet 2021;12:737965. [PMID: 34603396 DOI: 10.3389/fgene.2021.737965] [Reference Citation Analysis]
195 Wang H, Wang XY, Jiang XX, Ye ZX. Comparison of diffusion-weighted with T2-weighted Imaging for detection of small hepatocellular carcinoma in cirrhosis: preliminary quantitative study at 3-T. Acad Radiol 2010;17:239-43. [PMID: 19962912 DOI: 10.1016/j.acra.2009.09.012] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
196 Kaibori M, Kubo S, Nagano H, Hayashi M, Haji S, Nakai T, Ishizaki M, Matsui K, Uenishi T, Takemura S, Wada H, Marubashi S, Komeda K, Hirokawa F, Nakata Y, Uchiyama K, Kwon A. Clinicopathological Features of Recurrence in Patients After 10-year Disease-free Survival Following Curative Hepatic Resection of Hepatocellular Carcinoma. World J Surg 2013;37:820-8. [DOI: 10.1007/s00268-013-1902-3] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
197 Chen J, Huang K, Wu J, Zhu H, Shi Y, Wang Y, Zhao G. Survival after anatomic resection versus nonanatomic resection for hepatocellular carcinoma: a meta-analysis. Dig Dis Sci. 2011;56:1626-1633. [PMID: 21082347 DOI: 10.1007/s10620-010-1482-0] [Cited by in Crossref: 40] [Cited by in F6Publishing: 45] [Article Influence: 3.3] [Reference Citation Analysis]
198 Liu Y, Piao XJ, Xu WT, Zhang Y, Zhang T, Xue H, Li YN, Zuo WB, Sun G, Fu ZR, Luo YH, Jin CH. Calycosin induces mitochondrial-dependent apoptosis and cell cycle arrest, and inhibits cell migration through a ROS-mediated signaling pathway in HepG2 hepatocellular carcinoma cells. Toxicol In Vitro 2021;70:105052. [PMID: 33188878 DOI: 10.1016/j.tiv.2020.105052] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
199 Stagos D, Amoutzias GD, Matakos A, Spyrou A, Tsatsakis AM, Kouretas D. Chemoprevention of liver cancer by plant polyphenols. Food and Chemical Toxicology 2012;50:2155-70. [DOI: 10.1016/j.fct.2012.04.002] [Cited by in Crossref: 100] [Cited by in F6Publishing: 85] [Article Influence: 10.0] [Reference Citation Analysis]
200 Lee MJ, Xu DY, Li H, Yu GR, Leem SH, Chu IS, Kim IH, Kim DG. Pro-oncogenic potential of NM23-H2 in hepatocellular carcinoma. Exp Mol Med 2012;44:214-24. [PMID: 22192927 DOI: 10.3858/emm.2012.44.3.016] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.0] [Reference Citation Analysis]
201 Byrne TJ, Rakela J. Loco-regional therapies for patients with hepatocellular carcinoma awaiting liver transplantation: Selecting an optimal therapy. World J Transplant 2016; 6(2): 306-313 [PMID: 27358775 DOI: 10.5500/wjt.v6.i2.306] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
202 Liu Y, Huang L, Sun Q, Zhang M, Li T, Liang G, Pan W. Syntheses and anti-cancer activities of derivatives of tetrandrine and fangchinoline. Chem Res Chin Univ 2014;30:937-40. [DOI: 10.1007/s40242-014-4240-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
203 Zhao YN, Zhang YQ, Ye JZ, Liu X, Yang HZ, Cong FY, Xiang BD, Wu FX, Ma L, Li LQ, Ye HH. Hepatic resection versus transarterial chemoembolization for patients with Barcelona Clinic Liver Cancer intermediate stage Child-Pugh A hepatocellular carcinoma. Exp Ther Med 2016;12:3813-9. [PMID: 28105115 DOI: 10.3892/etm.2016.3810] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
204 Li W, Wang Y, Kellner DB, Zhao L, Xu L, Gao Q. Efficacy of RetroNectin-activated cytokine-induced killer cell therapy in the treatment of advanced hepatocelluar carcinoma. Oncol Lett. 2016;12:707-714. [PMID: 27347204 DOI: 10.3892/ol.2016.4629] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
205 Poon RT, Fan ST. Hepatectomy for hepatocellular carcinoma: patient selection and postoperative outcome. Liver Transpl. 2004;10:S39-S45. [PMID: 14762838 DOI: 10.1002/lt.20040] [Cited by in Crossref: 146] [Cited by in F6Publishing: 148] [Article Influence: 8.1] [Reference Citation Analysis]
206 Cucchetti A, Siniscalchi A, Ercolani G, Vivarelli M, Cescon M, Grazi GL, Faenza S, Pinna AD. Modification of acid-base balance in cirrhotic patients undergoing liver resection for hepatocellular carcinoma. Ann Surg 2007;245:902-8. [PMID: 17522516 DOI: 10.1097/01.sla.0000256356.23026.9f] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
207 Sugahara S, Nakayama H, Fukuda K, Mizumoto M, Tokita M, Abei M, Shoda J, Matsuzaki Y, Thono E, Tsuboi K, Tokuuye K. Proton-beam therapy for hepatocellular carcinoma associated with portal vein tumor thrombosis. Strahlenther Onkol. 2009;185:782-788. [PMID: 20013087 DOI: 10.1007/s00066-009-2020-x] [Cited by in Crossref: 79] [Cited by in F6Publishing: 67] [Article Influence: 6.1] [Reference Citation Analysis]
208 Kwon JH, Ahn KS, Moon YH, Park JY, Wang HJ, Choi KY, Kim G, Joh JW, Lee KG, Kang KJ. AROS Is a Significant Biomarker for Tumor Aggressiveness in Non-cirrhotic Hepatocellular Carcinoma. J Korean Med Sci 2015;30:1253-9. [PMID: 26339164 DOI: 10.3346/jkms.2015.30.9.1253] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
209 Dong F, Jiang S, Li J, Wang Y, Zhu L, Huang Y, Jiang X, Hu X, Zhou Q, Zhang Z, Bao Z. The histone demethylase KDM4D promotes hepatic fibrogenesis by modulating Toll-like receptor 4 signaling pathway. EBioMedicine 2019;39:472-83. [PMID: 30527625 DOI: 10.1016/j.ebiom.2018.11.055] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
210 Farker K, Schotte U, Scheele J, Hoffmann A. Impact of N-acetyltransferase polymorphism (NAT2) in hepatocellular carcinoma (HCC) – an investigation in a department of surgical medicine. Experimental and Toxicologic Pathology 2003;54:387-91. [DOI: 10.1078/0940-2993-00275] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
211 Chen MS, Li JQ, Zheng Y, Guo RP, Liang HH, Zhang YQ, Lin XJ, Lau WY. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg. 2006;243:321-328. [PMID: 16495695 DOI: 10.1097/01.sla.0000201480.65519.b8.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
212 Shin J, Yu JH, Jin YJ, Chae MH, Yoon CH, Lee JW. Comparison of survival outcomes of alcohol-related hepatocellular carcinoma with or without liver cirrhosis; a ten-year experience. Medicine (Baltimore) 2019;98:e18020. [PMID: 31764818 DOI: 10.1097/MD.0000000000018020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
213 Horner SM, Gale M. Intracellular innate immune cascades and interferon defenses that control hepatitis C virus. J Interferon Cytokine Res. 2009;29:489-498. [PMID: 19708811 DOI: 10.1089/jir.2009.0063] [Cited by in Crossref: 77] [Cited by in F6Publishing: 71] [Article Influence: 6.4] [Reference Citation Analysis]
214 Kaibori M, Tanigawa N, Kariya S, Ikeda H, Nakahashi Y, Hirohara J, Koreeda C, Seki T, Sawada S, Okazaki K, Kwon AH. A prospective randomized controlled trial of preoperative whole-liver chemolipiodolization for hepatocellular carcinoma. Dig Dis Sci 2012;57:1404-12. [PMID: 22271410 DOI: 10.1007/s10620-012-2029-3] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.0] [Reference Citation Analysis]
215 Fukuhara T, Sharp GB, Mizuno T, Itakura H, Yamamoto M, Tokunaga M, Tokuoka S, Cologne JB, Fujita Y, Soda M, Mabuchi K. Liver cancer in atomic-bomb survivors: histological characteristics and relationships to radiation and hepatitis B and C viruses. J Radiat Res 2001;42:117-30. [PMID: 11599879 DOI: 10.1269/jrr.42.117] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 0.8] [Reference Citation Analysis]
216 Libbrecht L, Bielen D, Verslype C, Vanbeckevoort D, Pirenne J, Nevens F, Desmet V, Roskams T. Focal lesions in cirrhotic explant livers: pathological evaluation and accuracy of pretransplantation imaging examinations. Liver Transpl. 2002;8:749-761. [PMID: 12200773 DOI: 10.1053/jlts.2002.34922] [Cited by in Crossref: 173] [Cited by in F6Publishing: 152] [Article Influence: 9.1] [Reference Citation Analysis]
217 Jaitovitch-Groisman I, Fotouhi-Ardakani N, Schecter RL, Woo A, Alaoui-Jamali MA, Batist G. Modulation of glutathione S-transferase alpha by hepatitis B virus and the chemopreventive drug oltipraz. J Biol Chem. 2000;275:33395-33403. [PMID: 10934196 DOI: 10.1074/jbc.M003754200] [Cited by in Crossref: 23] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
218 Shen L, Lei S, Zhang B, Li S, Huang L, Czachor A, Breitzig M, Gao Y, Huang M, Mo X, Zheng Q, Sun H, Wang F. Skipping of exon 10 in Axl pre-mRNA regulated by PTBP1 mediates invasion and metastasis process of liver cancer cells. Theranostics 2020;10:5719-35. [PMID: 32483414 DOI: 10.7150/thno.42010] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
219 Hata M, Tokuuye K, Sugahara S, Kagei K, Igaki H, Hashimoto T, Ohara K, Matsuzaki Y, Tanaka N, Akine Y. Proton beam therapy for hepatocellular carcinoma with portal vein tumor thrombus. Cancer. 2005;104:794-801. [PMID: 15981284 DOI: 10.1002/cncr.21237] [Cited by in Crossref: 81] [Cited by in F6Publishing: 66] [Article Influence: 4.8] [Reference Citation Analysis]
220 De Miglio MR, Pascale RM, Simile MM, Muroni MR, Virdis P, Kwong KM, Wong LK, Bosinco GM, Pulina FR, Calvisi DF, Frau M, Wood GA, Archer MC, Feo F. Polygenic control of hepatocarcinogenesis in Copenhagen x F344 rats. Int J Cancer 2004;111:9-16. [PMID: 15185337 DOI: 10.1002/ijc.20225] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 1.3] [Reference Citation Analysis]
221 Ho WH, Lee KT, Chen HY, Ho TW, Chiu HC. Disease-free survival after hepatic resection in hepatocellular carcinoma patients: a prediction approach using artificial neural network. PLoS One. 2012;7:e29179. [PMID: 22235270 DOI: 10.1371/journal.pone.0029179] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 4.1] [Reference Citation Analysis]
222 Masuzaki R, Omata M. HCC Screening and Surveillance. In: Al Knawy B, Reddy K, Bolondi L, editors. Hepatocellular Carcinoma. CRC Press; 2009. pp. 26-35. [DOI: 10.3109/9780203092880-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
223 Tan PC, Hou MC, Lin HC, Liu TT, Lee FY, Chang FY, Lee SD. A randomized trial of endoscopic treatment of acute gastric variceal hemorrhage: N-butyl-2-cyanoacrylate injection versus band ligation. Hepatology. 2006;43:690-697. [PMID: 16557539 DOI: 10.1002/hep.21145] [Cited by in Crossref: 214] [Cited by in F6Publishing: 174] [Article Influence: 13.4] [Reference Citation Analysis]
224 Vivekanandan P, Singh OV. High-dimensional biology to comprehend hepatocellular carcinoma. Expert Rev Proteomics. 2008;5:45-60. [PMID: 18282123 DOI: 10.1586/14789450.5.1.45] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.4] [Reference Citation Analysis]
225 Bruix J, Raoul JL, Sherman M, Mazzaferro V, Bolondi L, Craxi A, Galle PR, Santoro A, Beaugrand M, Sangiovanni A, Porta C, Gerken G, Marrero JA, Nadel A, Shan M, Moscovici M, Voliotis D, Llovet JM. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. J Hepatol. 2012;57:821-829. [PMID: 22727733 DOI: 10.1016/j.jhep.2012.06.014] [Cited by in Crossref: 473] [Cited by in F6Publishing: 467] [Article Influence: 47.3] [Reference Citation Analysis]
226 Iguchi T, Aishima S, Umeda K, Sanefuji K, Fujita N, Sugimachi K, Gion T, Taketomi A, Maehara Y, Tsuneyoshi M. Fascin expression in progression and prognosis of hepatocellular carcinoma. J Surg Oncol. 2009;100:575-579. [PMID: 19697358 DOI: 10.1002/jso.21377] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 2.5] [Reference Citation Analysis]
227 Cao H, Huang H, Xu W, Chen D, Yu J, Li J, Li L. Fecal metabolome profiling of liver cirrhosis and hepatocellular carcinoma patients by ultra performance liquid chromatography-mass spectrometry. Anal Chim Acta. 2011;691:68-75. [PMID: 21458633 DOI: 10.1016/j.aca.2011.02.038] [Cited by in Crossref: 74] [Cited by in F6Publishing: 70] [Article Influence: 6.7] [Reference Citation Analysis]
228 Kaibori M, Matsushima H, Ishizaki M, Kosaka H, Matsui K, Kariya S, Yoshii K, Sekimoto M. The Impact of Sorafenib in Combination with Transarterial Chemoembolization on the Outcomes of Intermediate-Stage Hepatocellular Carcinoma. Asian Pac J Cancer Prev 2021;22:1217-24. [PMID: 33906315 DOI: 10.31557/APJCP.2021.22.4.1217] [Reference Citation Analysis]
229 Hassoun Z, Gores GJ. What surgeons should know about viral hepatitis and hepatocellular carcinoma. Surg Oncol Clin N Am. 2003;12:1-11. [PMID: 12735125 DOI: 10.1016/S1055-3207(02)00081-9] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
230 Fan R, Miao Y, Shan X, Qian H, Song C, Wu G, Chen Y, Zha W. Bif-1 is overexpressed in hepatocellular carcinoma and correlates with shortened patient survival. Oncol Lett 2012;3:851-4. [PMID: 22741005 DOI: 10.3892/ol.2012.562] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
231 Cha J, Seong J, Lee IJ, Kim JW, Han KH. Feasibility of sorafenib combined with local radiotherapy in advanced hepatocellular carcinoma. Yonsei Med J. 2013;54:1178-1185. [PMID: 23918567 DOI: 10.3349/ymj.2013.54.5.1178] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 2.1] [Reference Citation Analysis]
232 Müller C. Hepatocellular carcinoma – Rising incidence, changing therapeutic strategies. Wien Med Wochenschr 2006;156:404-9. [DOI: 10.1007/s10354-006-0316-3] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
233 Lee S, Lee HJ, Kim JH, Lee HS, Jang JJ, Kang GH. Aberrant CpG island hypermethylation along multistep hepatocarcinogenesis. Am J Pathol. 2003;163:1371-1378. [PMID: 14507645 DOI: 10.1016/s0002-9440(10)63495-5] [Cited by in Crossref: 233] [Cited by in F6Publishing: 106] [Article Influence: 12.3] [Reference Citation Analysis]
234 Yu X, Zhao H, Liu L, Cao S, Ren B, Zhang N, An X, Yu J, Li H, Ren X. A randomized phase II study of autologous cytokine-induced killer cells in treatment of hepatocellular carcinoma. J Clin Immunol. 2014;34:194-203. [PMID: 24337625 DOI: 10.1007/s10875-013-9976-0] [Cited by in Crossref: 52] [Cited by in F6Publishing: 54] [Article Influence: 5.8] [Reference Citation Analysis]
235 Fukumitsu N, Sugahara S, Nakayama H, Fukuda K, Mizumoto M, Abei M, Shoda J, Thono E, Tsuboi K, Tokuuye K. A prospective study of hypofractionated proton beam therapy for patients with hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2009;74:831-836. [PMID: 19304408 DOI: 10.1016/j.ijrobp.2008.10.073] [Cited by in Crossref: 147] [Cited by in F6Publishing: 121] [Article Influence: 11.3] [Reference Citation Analysis]
236 Ahn J, Flamm SL. Hepatocellular carcinoma. Dis Mon 2004;50:556-73. [PMID: 15616490 DOI: 10.1016/j.disamonth.2004.10.001] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 1.3] [Reference Citation Analysis]
237 Brodsky EK, Bultman EM, Johnson KM, Horng DE, Schelman WR, Block WF, Reeder SB. High-spatial and high-temporal resolution dynamic contrast-enhanced perfusion imaging of the liver with time-resolved three-dimensional radial MRI. Magn Reson Med 2014;71:934-41. [PMID: 23519837 DOI: 10.1002/mrm.24727] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 2.9] [Reference Citation Analysis]
238 Li SH, Wei W, Guo RP, Shi M, Guo ZX, Chen ZY, Xiao CZ, Cai MY, Zheng L. Long-term outcomes after curative resection for patients with macroscopically solitary hepatocellular carcinoma without macrovascular invasion and an analysis of prognostic factors. Med Oncol 2013;30:696. [PMID: 23975633 DOI: 10.1007/s12032-013-0696-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
239 Dufey F, Walsh L, Sogl M, Tschense A, Schnelzer M, Kreuzer M. Radiation dose dependent risk of liver cancer mortality in the German uranium miners cohort 1946–2003. J Radiol Prot 2013;33:175-85. [DOI: 10.1088/0952-4746/33/1/175] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
240 Yang Y, Jiang H, Gao H, Kong J, Zhang P, Hu S, Shi B, Zhang P, Yao M, Li Z. The monoclonal antibody CH12 enhances the sorafenib-mediated growth inhibition of hepatocellular carcinoma xenografts expressing epidermal growth factor receptor variant III. Neoplasia 2012;14:509-18. [PMID: 22787432 DOI: 10.1593/neo.12328] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
241 Dufour DR, Lott JA, Nolte FS, Gretch DR, Koff RS, Seeff LB. Diagnosis and monitoring of hepatic injury. II. Recommendations for use of laboratory tests in screening, diagnosis, and monitoring. Clin Chem 2000;46:2050-68. [PMID: 11106350 [PMID: 11106350 DOI: 10.1093/clinchem/46.12.2050] [Cited by in Crossref: 213] [Cited by in F6Publishing: 105] [Article Influence: 10.1] [Reference Citation Analysis]
242 Alberti A, Fattovich G. Natural history of chronic hepatitis B. Curr hepatitis rep 2004;3:54-60. [DOI: 10.1007/s11901-004-0010-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
243 Yoshida H, Yoshida H, Shiina S, Omata M. Early liver cancer: concepts, diagnosis, and management. Int J Clin Oncol 2005;10:384-90. [DOI: 10.1007/s10147-005-0537-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
244 Lereau M, Gouas D, Villar S, Besaratinia A, Hautefeuille A, Berthillon P, Martel-planche G, Nogueira da Costa A, Ortiz-cuaran S, Hantz O, Pfeifer GP, Hainaut P, Chemin I. Interactions between hepatitis B virus and aflatoxin B1: effects on p53 induction in HepaRG cells. Journal of General Virology 2012;93:640-50. [DOI: 10.1099/vir.0.032482-0] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
245 Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Colombo M, Rodes J, EASL Panel of Experts on HCC. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol. 2001;35:421-430. [PMID: 11592607 DOI: 10.1016/s0168-8278(01)00130-1] [Cited by in Crossref: 3112] [Cited by in F6Publishing: 1064] [Article Influence: 155.6] [Reference Citation Analysis]
246 Zakhary NI, Mohamed MS, Khorshid O, Azer RS, Zayed N. Role of glypican-3 in the early diagnosis of hepatocellular carcinoma among Egyptian patients. Journal of Genetic Engineering and Biotechnology 2012;10:73-9. [DOI: 10.1016/j.jgeb.2012.04.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
247 Kim JH, Choi MS, Lee H, Kim do Y, Lee JH, Koh KC, Yoo BC, Paik SW, Rhee JC. Clinical features and prognosis of hepatocellular carcinoma in young patients from a hepatitis B-endemic area. J Gastroenterol Hepatol. 2006;21:588-594. [PMID: 16638104 DOI: 10.1111/j.1440-1746.2005.04127.x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 2.3] [Reference Citation Analysis]
248 Hu T, Du Q, Ren F, Liang S, Lin D, Li J, Chen Y. Spatial analysis of the home addresses of hospital patients with hepatitis B infection or hepatoma in Shenzhen, China from 2010 to 2012. Int J Environ Res Public Health. 2014;11:3143-3155. [PMID: 24637909 DOI: 10.3390/ijerph110303143] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
249 Zhao S, Xu C, Qian H, Lv L, Ji C, Chen C, Zhao X, Zheng D, Gu S, Xie Y, Mao Y. Cellular retinaldehyde-binding protein-like (CRALBPL), a novel human Sec14p-like gene that is upregulated in human hepatocellular carcinomas, may be used as a marker for human hepatocellular carcinomas. DNA Cell Biol 2008;27:159-63. [PMID: 18271718 DOI: 10.1089/dna.2007.0634] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
250 Matsuo N, Shiraha H, Fujikawa T, Takaoka N, Ueda N, Tanaka S, Nishina S, Nakanishi Y, Uemura M, Takaki A, Nakamura S, Kobayashi Y, Nouso K, Yagi T, Yamamoto K. Twist expression promotes migration and invasion in hepatocellular carcinoma. BMC Cancer 2009;9:240. [PMID: 19615090 DOI: 10.1186/1471-2407-9-240] [Cited by in Crossref: 85] [Cited by in F6Publishing: 76] [Article Influence: 6.5] [Reference Citation Analysis]
251 Van Damme P, Ward JW, Shouval D, Zanetti A. Hepatitis B Vaccines. Plotkin's Vaccines. Elsevier; 2018. pp. 342-374.e17. [DOI: 10.1016/b978-0-323-35761-6.00025-0] [Cited by in Crossref: 6] [Article Influence: 1.5] [Reference Citation Analysis]
252 Ariff B, Lloyd CR, Khan S, Shariff M, Thillainayagam AV, Bansi DS, Khan SA, Taylor-Robinson SD, Lim AK. Imaging of liver cancer. World J Gastroenterol 2009; 15(11): 1289-1300 [PMID: 19294758 DOI: 10.3748/wjg.15.1289] [Cited by in CrossRef: 71] [Cited by in F6Publishing: 50] [Article Influence: 5.5] [Reference Citation Analysis]
253 Li JK, Liu XH, Cui H, Xie XH. Radiofrequency ablation vs. surgical resection for resectable hepatocellular carcinoma: A systematic review and meta-analysis. Mol Clin Oncol 2020;12:15-22. [PMID: 31814972 DOI: 10.3892/mco.2019.1941] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
254 Cengiz C, Akarca US, Goker E, Yuce G. Detection of mutant p53 in hepatocellular cancer from Turkey and its correlation with clinicopathologic parameters. Dig Dis Sci 2003;48:865-9. [PMID: 12772781 DOI: 10.1023/a:1023031008757] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
255 Imada H, Kato H, Yasuda S, Yamada S, Yanagi T, Hara R, Kishimoto R, Kandatsu S, Minohara S, Mizoe JE. Compensatory enlargement of the liver after treatment of hepatocellular carcinoma with carbon ion radiotherapy - relation to prognosis and liver function. Radiother Oncol. 2010;96:236-242. [PMID: 20416964 DOI: 10.1016/j.radonc.2010.03.025] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
256 Ni JS, Lau WY, Yang Y, Pan ZY, Wang ZG, Liu H, Wu MC, Zhou WP. A prospective randomized controlled trial to compare pringle manoeuvre with hemi-hepatic vascular inflow occlusion in liver resection for hepatocellular carcinoma with cirrhosis. J Gastrointest Surg 2013;17:1414-21. [PMID: 23715650 DOI: 10.1007/s11605-013-2236-z] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
257 Iguchi T, Aishima S, Taketomi A, Nishihara Y, Fujita N, Sanefuji K, Maehara Y, Tsuneyoshi M. Extracapsular penetration is a new prognostic factor in human hepatocellular carcinoma. Am J Surg Pathol 2008;32:1675-82. [PMID: 18769333 DOI: 10.1097/PAS.0b013e31817a8ed5] [Cited by in Crossref: 20] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
258 Zou Y, Xiong H, Xiong H, Lu T, Zhu F, Luo Z, Yuan X, Wang Y. A polysaccharide from mushroom Huaier retards human hepatocellular carcinoma growth, angiogenesis, and metastasis in nude mice. Tumour Biol 2015;36:2929-36. [PMID: 25492485 DOI: 10.1007/s13277-014-2923-8] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 3.0] [Reference Citation Analysis]
259 Liu C, Liang P, Liu F, Wang Y, Li X, Han Z, Liu C. MWA combined with TACE as a combined therapy for unresectable large-sized hepotocellular carcinoma. Int J Hyperthermia. 2011;27:654-662. [PMID: 21966941 DOI: 10.3109/02656736.2011.605099] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 3.4] [Reference Citation Analysis]
260 Naowaratwattana W, De-eknamkul W, De Mejia EG. Phenolic-Containing Organic Extracts of Mulberry ( Morus alba L.) Leaves Inhibit HepG2 Hepatoma Cells Through G2/M Phase Arrest, Induction of Apoptosis, and Inhibition of Topoisomerase IIα Activity. Journal of Medicinal Food 2010;13:1045-56. [DOI: 10.1089/jmf.2010.1021] [Cited by in Crossref: 55] [Cited by in F6Publishing: 49] [Article Influence: 4.6] [Reference Citation Analysis]
261 Grazi GL, Cescon M, Ravaioli M, Ercolani G, Gardini A, Del Gaudio M, Vetrone G, Cavallari A. Liver resection for hepatocellular carcinoma in cirrhotics and noncirrhotics. Evaluation of clinicopathologic features and comparison of risk factors for long-term survival and tumour recurrence in a single centre. Aliment Pharmacol Ther. 2003;17 Suppl 2:119-129. [PMID: 12786623 DOI: 10.1046/j.1365-2036.17.s2.9.x] [Cited by in Crossref: 86] [Cited by in F6Publishing: 82] [Article Influence: 4.5] [Reference Citation Analysis]
262 Thorgeirsson SS, Grisham JW. Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet. 2002;31:339-346. [PMID: 12149612 DOI: 10.1038/ng0802-339] [Cited by in Crossref: 1034] [Cited by in F6Publishing: 964] [Article Influence: 51.7] [Reference Citation Analysis]
263 Pazienza V, Panebianco C, Andriulli A. Hepatitis viruses exploitation of host DNA methyltransferases functions. Clin Exp Med 2016;16:265-72. [PMID: 26148656 DOI: 10.1007/s10238-015-0372-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
264 Lin Y, Lin G, Fang W, Zhu H, Chu K. Increased expression of annexin A1 predicts poor prognosis in human hepatocellular carcinoma and enhances cell malignant phenotype. Med Oncol 2014;31:327. [PMID: 25412936 DOI: 10.1007/s12032-014-0327-7] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 3.3] [Reference Citation Analysis]
265 Fernández-Irigoyen J, Santamaría E, Sesma L, Muñoz J, Riezu JI, Caballería J, Lu SC, Prieto J, Mato JM, Avila MA, Corrales FJ. Oxidation of specific methionine and tryptophan residues of apolipoprotein A-I in hepatocarcinogenesis. Proteomics 2005;5:4964-72. [PMID: 16252306 DOI: 10.1002/pmic.200500070] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 1.8] [Reference Citation Analysis]
266 Brown KT. Fatal pulmonary complications after arterial Embolisation with 40-120- micro m tris-acryl gelatin microspheres. J Vasc Interv Radiol. 2004;15:197-200. [PMID: 14963189 DOI: 10.1097/01.rvi.0000109400.52762.1f] [Cited by in Crossref: 75] [Cited by in F6Publishing: 23] [Article Influence: 4.2] [Reference Citation Analysis]
267 Levrero M. Viral hepatitis and liver cancer: the case of hepatitis C. Oncogene 2006;25:3834-47. [DOI: 10.1038/sj.onc.1209562] [Cited by in Crossref: 278] [Cited by in F6Publishing: 265] [Article Influence: 17.4] [Reference Citation Analysis]
268 Imai N, Ikeda K, Seko Y, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Saitoh S, Suzuki F. Previous chemoembolization response after transcatheter arterial chemoembolization (TACE) can predict the anti-tumor effect of subsequent TACE with miriplatin in patients with recurrent hepatocellular carcinoma. Oncology. 2011;80:188-194. [PMID: 21709428 DOI: 10.1159/000328749] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
269 Cucchetti A, Ercolani G, Cescon M, Ravaioli M, Zanello M, Del Gaudio M, Lauro A, Vivarelli M, Grazi GL, Pinna AD. Recovery from liver failure after hepatectomy for hepatocellular carcinoma in cirrhosis: Meaning of the model for end-stage liver disease. J Am Coll Surg. 2006;203:670-676. [PMID: 17084328 DOI: 10.1016/j.jamcollsurg.2006.06.018] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 2.5] [Reference Citation Analysis]
270 Zhang Q, Zhou J, Ku X, Chen X, Zhang L, Xu J, Chen G, Li Q, Qian F, Tian R, Wen N, Chen Z. Expression of CD147 as a significantly unfavorable prognostic factor in hepatocellular carcinoma. European Journal of Cancer Prevention 2007;16:196-202. [DOI: 10.1097/01.cej.0000236245.40619.c3] [Cited by in Crossref: 40] [Cited by in F6Publishing: 34] [Article Influence: 2.7] [Reference Citation Analysis]
271 Kornberg A. Liver transplantation for hepatocellular carcinoma beyond Milan criteria: multidisciplinary approach to improve outcome. ISRN Hepatol. 2014;25:154-159. [PMID: 27335840 DOI: 10.1155/2014/706945] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
272 Dhifallah I, Khedhiri M, Chouikha A, Kharroubi G, Hammami W, Sadraoui A, Azzouz MM, Maamouri N, Khalfallah T, Triki H, Pineau P, Bahri O. Hepatitis viruses take advantage of traditional practices to increase the burden of hepatocellular carcinoma in Tunisia. Arch Virol 2020;165:33-42. [PMID: 31630275 DOI: 10.1007/s00705-019-04440-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
273 Frakes JM, Abuodeh YA, Naghavi AO, Echevarria MI, Shridhar R, Friedman M, Kim R, El-Haddad G, Kis B, Biebel B, Sweeney J, Choi J, Anaya D, Giuliano AR, Hoffe SE. Viral hepatitis associated hepatocellular carcinoma outcomes with yttrium-90 radioembolization. J Gastrointest Oncol 2018;9:546-52. [PMID: 29998020 DOI: 10.21037/jgo.2018.03.04] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
274 Santamaría E, Muñoz J, Fernández-irigoyen J, Prìeto J, Corrales FJ. Toward the discovery of new biomarkers of hepatocellular carcinoma by proteomics. Liver Int 2007;27:163-73. [DOI: 10.1111/j.1478-3231.2007.01447.x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 2.3] [Reference Citation Analysis]
275 Slupski MW, Szczylik C, Jasinski MK. Unexpected response to systemic chemotherapy in case of primarily nonresectable advanced disseminated intrahepatic cholangiocarcinoma. World J Surg Oncol. 2007;5:36. [PMID: 17376238 DOI: 10.1186/1477-7819-5-36] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
276 Zhang RK, Liu JL. Screening the genome for HCC-specific CpG methylation signatures as biomarkers for diagnosis and prognosis evaluation. BMC Med Genomics 2021;14:163. [PMID: 34147096 DOI: 10.1186/s12920-021-01015-9] [Reference Citation Analysis]
277 Tsai M, Wang J, Hung C, Kee K, Yen Y, Lee C, Hu T, Chen C, Lu S. Favorable α-fetoprotein decrease as a prognostic surrogate in patients with hepatocellular carcinoma after radiofrequency ablation: α-Fetoprotein after radiofrequency ablation. Journal of Gastroenterology and Hepatology 2010;25:605-12. [DOI: 10.1111/j.1440-1746.2009.06115.x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 2.3] [Reference Citation Analysis]
278 Ramirez-Tagle R, Escobar CA, Romero V, Montorfano I, Armisén R, Borgna V, Jeldes E, Pizarro L, Simon F, Echeverria C. Chalcone-Induced Apoptosis through Caspase-Dependent Intrinsic Pathways in Human Hepatocellular Carcinoma Cells. Int J Mol Sci 2016;17:260. [PMID: 26907262 DOI: 10.3390/ijms17020260] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
279 Yamamoto A, Sato T. Locoregional treatment of malignant hepatic tumors with biologic response modifiers. Surg Oncol Clin N Am 2008;17:935-55, xii. [PMID: 18722927 DOI: 10.1016/j.soc.2008.04.001] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
280 Ercolani G, Grazi GL, Ravaioli M, Del Gaudio M, Gardini A, Cescon M, Varotti G, Cetta F, Cavallari A. Liver resection for hepatocellular carcinoma on cirrhosis: univariate and multivariate analysis of risk factors for intrahepatic recurrence. Ann Surg. 2003;237:536-543. [PMID: 12677151 DOI: 10.1097/00000658-200304000-00016] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
281 Tashiro H, Aikata H, Waki K, Amano H, Oshita A, Kobayashi T, Tanimoto Y, Kuroda S, Tazawa H, Chayama K, Asahara T, Ohdan H. Treatment strategy for early hepatocellular carcinomas: Comparison of radiofrequency ablation with or without transcatheter arterial chemoembolization and surgical resection. J Surg Oncol 2011;104:3-9. [DOI: 10.1002/jso.21745] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
282 Ngoka LC. Dramatic down-regulation of oxidoreductases in human hepatocellular carcinoma hepG2 cells: proteomics and gene ontology unveiling new frontiers in cancer enzymology. Proteome Sci 2008;6:29. [PMID: 18950483 DOI: 10.1186/1477-5956-6-29] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
283 Rao A, Rao G, Ahmed I. Laparoscopic vs. open liver resection for malignant liver disease. A systematic review. Surgeon. 2012;10:194-201. [PMID: 22818276 DOI: 10.1016/j.surge.2011.06.007] [Cited by in Crossref: 38] [Cited by in F6Publishing: 30] [Article Influence: 3.5] [Reference Citation Analysis]
284 Yin L, Li H, Li AJ, Lau WY, Pan ZY, Lai EC, Wu MC, Zhou WP. Partial hepatectomy vs. transcatheter arterial chemoembolization for resectable multiple hepatocellular carcinoma beyond Milan Criteria: a RCT. J Hepatol. 2014;61:82-88. [PMID: 24650695 DOI: 10.1016/j.jhep.2014.03.012] [Cited by in Crossref: 145] [Cited by in F6Publishing: 150] [Article Influence: 18.1] [Reference Citation Analysis]
285 Feili X, Wu S, Ye W, Tu J, Lou L. MicroRNA-34a-5p inhibits liver fibrosis by regulating TGF-β1/Smad3 pathway in hepatic stellate cells. Cell Biol Int 2018;42:1370-6. [PMID: 29957876 DOI: 10.1002/cbin.11022] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 5.0] [Reference Citation Analysis]
286 Shen W, Chen C, Guan Y, Song X, Jin Y, Wang J, Hu Y, Xin T, Jiang Q, Zhong L. A pumpkin polysaccharide induces apoptosis by inhibiting the JAK2/STAT3 pathway in human hepatoma HepG2 cells. International Journal of Biological Macromolecules 2017;104:681-6. [DOI: 10.1016/j.ijbiomac.2017.06.078] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 4.2] [Reference Citation Analysis]
287 Wen Y, Han G, Anh VV. Laplacian normalization and bi-random walks on heterogeneous networks for predicting lncRNA-disease associations. BMC Syst Biol 2018;12:122. [PMID: 30598088 DOI: 10.1186/s12918-018-0660-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
288 Zuchowska A, Kwapiszewska K, Chudy M, Dybko A, Brzozka Z. Studies of anticancer drug cytotoxicity based on long-term HepG2 spheroid culture in a microfluidic system: Microfluidics & Miniaturization. ELECTROPHORESIS 2017;38:1206-16. [DOI: 10.1002/elps.201600417] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
289 Okano J, Nagahara T, Matsumoto K, Murawaki Y. Caffeine inhibits the proliferation of liver cancer cells and activates the MEK/ERK/EGFR signalling pathway. Basic Clin Pharmacol Toxicol. 2008;102:543-551. [PMID: 18346049 DOI: 10.1111/j.1742-7843.2008.00231.x] [Cited by in Crossref: 54] [Cited by in F6Publishing: 55] [Article Influence: 3.9] [Reference Citation Analysis]
290 Saito S, Ojima H, Ichikawa H, Hirohashi S, Kondo T. Molecular background of alpha-fetoprotein in liver cancer cells as revealed by global RNA expression analysis. Cancer Sci 2008;99:2402-9. [PMID: 19038010 DOI: 10.1111/j.1349-7006.2008.00973.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 1.7] [Reference Citation Analysis]
291 Lee JY, Kim Y, Rhim H, Lim HK, Choi D, Lee WJ. Pattern and Chronological Change of Iodized Oil Retention in Radiofrequency Ablation-Induced Vascular Injury Area: Differentiation From Iodized Oil Retention in Recurrent Hepatocellular Carcinoma on Computed Tomography. Journal of Computer Assisted Tomography 2010;34:354-61. [DOI: 10.1097/rct.0b013e3181cbf43a] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
292 Fan J, Li R, Zhang R, Liu HL, Zhang N, Zhang FQ, Dou KF. Effect of Bcl-2 and Bax on survival of side population cells from hepatocellular carcinoma cells. World J Gastroenterol 2007;13:6053-9. [PMID: 18023099 DOI: 10.3748/wjg.v13.45.6053] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
293 Zhang C, Guo X, Zhang L, Lu Z, Ma N, Cheng Y, Shen F, Zhang B, Wu M, Wei L. Methylation-Related silencing of p14ARF gene correlates with telomerase activity and mRNA expression of human telomerase reverse transcriptase in hepatocellular carcinoma. J Surg Oncol 2008;98:462-8. [DOI: 10.1002/jso.21131] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
294 Poon RT, Fan ST, Tsang FH, Wong J. Locoregional therapies for hepatocellular carcinoma: a critical review from the surgeon's perspective. Ann Surg 2002;235:466-86. [PMID: 11923602 DOI: 10.1097/00000658-200204000-00004] [Cited by in Crossref: 300] [Cited by in F6Publishing: 283] [Article Influence: 15.0] [Reference Citation Analysis]
295 Hao K, Luk JM, Lee NP, Mao M, Zhang C, Ferguson MD, Lamb J, Dai H, Ng IO, Sham PC. Predicting prognosis in hepatocellular carcinoma after curative surgery with common clinicopathologic parameters. BMC Cancer. 2009;9:389. [PMID: 19886989 DOI: 10.1186/1471-2407-9-389] [Cited by in Crossref: 84] [Cited by in F6Publishing: 91] [Article Influence: 6.5] [Reference Citation Analysis]
296 Jiang L, Yan Q, Fang S, Liu M, Li Y, Yuan YF, Li Y, Zhu Y, Qi J, Yang X, Kwong DLW, Guan XY. Calcium-binding protein 39 promotes hepatocellular carcinoma growth and metastasis by activating extracellular signal-regulated kinase signaling pathway. Hepatology 2017;66:1529-45. [PMID: 28605041 DOI: 10.1002/hep.29312] [Cited by in Crossref: 24] [Cited by in F6Publishing: 31] [Article Influence: 4.8] [Reference Citation Analysis]
297 Lazarevich NL, Fleishman DI. Tissue-specific transcription factors in progression of epithelial tumors. Biochemistry (Mosc). 2008;73:573-591. [PMID: 18605982 DOI: 10.1134/s0006297908050106] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
298 Zakhary NI, Khodeer SM, Shafik HE, Abdel Malak CA. Impact of PIVKA-II in diagnosis of hepatocellular carcinoma. J Adv Res. 2013;4:539-546. [PMID: 25685463 DOI: 10.1016/j.jare.2012.10.004] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
299 Marrero JA. Hepatocellular carcinoma: . Current Opinion in Gastroenterology 2005;21:308-12. [DOI: 10.1097/01.mog.0000159817.55661.ca] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 1.5] [Reference Citation Analysis]
300 Kaibori M, Ishizaki M, Matsui K, Nakatake R, Yoshiuchi S, Kimura Y, Kwon AH. Perioperative exercise for chronic liver injury patients with hepatocellular carcinoma undergoing hepatectomy. Am J Surg. 2013;206:202-209. [PMID: 23374372 DOI: 10.1016/j.amjsurg.2012.07.035] [Cited by in Crossref: 53] [Cited by in F6Publishing: 42] [Article Influence: 5.9] [Reference Citation Analysis]
301 Ladero JM, Martínez C, García-Martín E, Ropero P, Briceño O, Villegas A, Díaz-Rubio M, Agúndez JA. Glutathione S-transferase M1 and T1 genetic polymorphisms are not related to the risk of hepatocellular carcinoma: a study in the Spanish population. Eur J Cancer 2006;42:73-7. [PMID: 16314088 DOI: 10.1016/j.ejca.2005.08.033] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
302 He S, Tang J, Diao N, Liao Y, Shi J, Xu X, Xie F, Bai L. Parathyroid hormone-related protein activates HSCs via hedgehog signalling during liver fibrosis development. Artificial Cells, Nanomedicine, and Biotechnology 2019;47:1984-94. [DOI: 10.1080/21691401.2019.1615931] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
303 Wu CX, Wang D, Cai Y, Luo AR, Sun H. Effect of Autologous Bone Marrow Stem Cell Therapy in Patients with Liver Cirrhosis: A Meta-analysis. J Clin Transl Hepatol 2019;7:238-48. [PMID: 31608216 DOI: 10.14218/JCTH.2019.00008] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
304 Tien Kuo M, Savaraj N. Roles of reactive oxygen species in hepatocarcinogenesis and drug resistance gene expression in liver cancers. Mol Carcinog. 2006;45:701-709. [PMID: 16652372 DOI: 10.1002/mc.20240] [Cited by in Crossref: 59] [Cited by in F6Publishing: 54] [Article Influence: 3.7] [Reference Citation Analysis]
305 Damdinsuren B, Nagano H, Sakon M, Kondo M, Yamamoto T, Umeshita K, Dono K, Nakamori S, Monden M. Interferon-? Is More Potent Than Interferon-? in Inhibition of Human Hepatocellular Carcinoma Cell Growth When Used Alone and in Combination With Anticancer Drugs. Ann Surg Oncol 2003;10:1184-90. [DOI: 10.1245/aso.2003.03.010] [Cited by in Crossref: 44] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
306 Liang YX, Zhang W, Li DD, Liu HT, Gao P, Sun YN, Shao RG. Mitotic cell death in BEL-7402 cells induced by enediyne antibiotic lidamycin is associated with centrosome overduplication. World J Gastroenterol 2004; 10(18): 2632-2636 [PMID: 15309709 DOI: 10.3748/wjg.v10.i18.2632] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
307 Wu LM, Yang Z, Zhou L, Zhang F, Xie HY, Feng XW, Wu J, Zheng SS. Identification of histone deacetylase 3 as a biomarker for tumor recurrence following liver transplantation in HBV-associated hepatocellular carcinoma. PLoS One. 2010;5:e14460. [PMID: 21206745 DOI: 10.1371/journal.pone.0014460] [Cited by in Crossref: 74] [Cited by in F6Publishing: 75] [Article Influence: 6.2] [Reference Citation Analysis]
308 Kuznetsov V, Lee HK, Maurer-Stroh S, Molnár MJ, Pongor S, Eisenhaber B, Eisenhaber F. How bioinformatics influences health informatics: usage of biomolecular sequences, expression profiles and automated microscopic image analyses for clinical needs and public health. Health Inf Sci Syst 2013;1:2. [PMID: 25825654 DOI: 10.1186/2047-2501-1-2] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
309 Dhamija E, Paul SB, Kedia S. Non-alcoholic fatty liver disease associated with hepatocellular carcinoma: An increasing concern. Indian J Med Res. 2019;149:9-17. [PMID: 31115369 DOI: 10.4103/ijmr.ijmr_1456_17] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
310 Singh M, Kumar V. Transgenic mouse models of hepatitis B virus-associated hepatocellular carcinoma. Rev Med Virol. 2003;13:243-253. [PMID: 12820186 DOI: 10.1002/rmv.392] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 1.6] [Reference Citation Analysis]
311 Parolin MB, Coelho JCU, Matias JEF, Baretta GAP, Ioshii SO, Nardo H. Resultados do transplante hepático em pacientes com diagnóstico pré-operatório de hepatocarcinoma. Arq Gastroenterol 2006;43:259-64. [DOI: 10.1590/s0004-28032006000400003] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
312 Zhang SH, Cong WM, Shi JQ, Wei H. Genomic instability of murine hepatocellular carcinomas with low and high metastatic capacities. World J Gastroenterol 2004; 10(4): 521-524 [PMID: 14966909 DOI: 10.3748/wjg.v10.i4.521] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
313 Harder J, Opitz OG, Brabender J, Olschewski M, Blum HE, Nomoto S, Usadel H. Quantitative promoter methylation analysis of hepatocellular carcinoma, cirrhotic and normal liver. Int J Cancer. 2008;122:2800-2804. [PMID: 18351580 DOI: 10.1002/ijc.23433] [Cited by in Crossref: 37] [Cited by in F6Publishing: 39] [Article Influence: 2.6] [Reference Citation Analysis]
314 Zheng L, Liang P, Li J, Huang XB, Liu SC, Zhao HZ, Han KQ, Wang Z. ShRNA-targeted COMMD7 suppresses hepatocellular carcinoma growth. PLoS One 2012;7:e45412. [PMID: 23049798 DOI: 10.1371/journal.pone.0045412] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
315 Yuan Y, Liu J, Liu Z, He Y, Zhang Z, Jiang C, Qian Q. Chemokine CCL3 facilitates the migration of hepatoma cells by changing the concentration intracellular Ca. Hepatol Res. 2010;40:424-431. [PMID: 20236357 DOI: 10.1111/j.1872-034x.2009.00619.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
316 Abe R, Okano JI, Imamoto R, Fujise Y, Murawaki Y. Sequential analysis of diethylnitrosamine-induced hepatocarcinogenesis in rats. Exp Ther Med 2012;3:371-8. [PMID: 22969898 DOI: 10.3892/etm.2011.419] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
317 Kew MC. Epidemiology of hepatocellular carcinoma. Toxicology. 2002;181-182:35-38. [PMID: 12505281 DOI: 10.1016/s0300-483x(02)00251-2] [Cited by in Crossref: 65] [Cited by in F6Publishing: 31] [Article Influence: 3.4] [Reference Citation Analysis]
318 Imai N, Ikeda K, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Saitoh S, Suzuki F, Suzuki Y. Transcatheter arterial chemotherapy using miriplatin-lipiodol suspension with or without embolization for unresectable hepatocellular carcinoma. Jpn J Clin Oncol. 2012;42:175-182. [PMID: 22210921 DOI: 10.1093/jjco/hyr189] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
319 Bialecki ES, Ezenekwe AM, Brunt EM, Collins BT, Ponder TB, Bieneman BK, Di Bisceglie AM. Comparison of liver biopsy and noninvasive methods for diagnosis of hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2006;4:361-368. [PMID: 16527701 DOI: 10.1016/s1542-3565(05)00977-8] [Cited by in Crossref: 43] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
320 Chan AC, Fan ST, Poon RT, Cheung TT, Chok KS, Chan SC, Lo CM. Evaluation of the seventh edition of the American Joint Committee on Cancer tumour-node-metastasis (TNM) staging system for patients undergoing curative resection of hepatocellular carcinoma: implications for the development of a refined staging system. HPB (Oxford). 2013;15:439-448. [PMID: 23659567 DOI: 10.1111/j.1477-2574.2012.00617.x] [Cited by in Crossref: 46] [Cited by in F6Publishing: 46] [Article Influence: 4.6] [Reference Citation Analysis]
321 Roxburgh P, Evans TR. Systemic therapy of hepatocellular carcinoma: are we making progress? Adv Ther. 2008;25:1089-1104. [PMID: 18972075 DOI: 10.1007/s12325-008-0113-z] [Cited by in Crossref: 47] [Cited by in F6Publishing: 44] [Article Influence: 3.9] [Reference Citation Analysis]
322 Chen X, Xu J, Wang P, Shang L, Guo J, Huang L, Jiang YA, Chen J, Chen H, Shang Y, Zhang Q. Metallophosphoesterase 1, a novel candidate gene in hepatocellular carcinoma malignancy and recurrence. Cancer Biol Ther 2020;21:1005-13. [PMID: 33054568 DOI: 10.1080/15384047.2020.1824480] [Reference Citation Analysis]
323 Liu X, Liao W, Yuan Q, Ou Y, Huang J. TTK activates Akt and promotes proliferation and migration of hepatocellular carcinoma cells. Oncotarget. 2015;6:34309-34320. [PMID: 26418879 DOI: 10.18632/oncotarget.5295] [Cited by in Crossref: 43] [Cited by in F6Publishing: 44] [Article Influence: 7.2] [Reference Citation Analysis]
324 Ho YJ, Chang J, Yeh KT, Gong Z, Lin YM, Lu JW. Prognostic and Clinical Implications of WNK Lysine Deficient Protein Kinase 1 Expression in Patients With Hepatocellular Carcinoma. In Vivo 2020;34:2631-40. [PMID: 32871793 DOI: 10.21873/invivo.12081] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
325 Kim SH, Park YN, Lim JH, Choi GH, Choi JS, Kim KS. Characteristics of combined hepatocelluar-cholangiocarcinoma and comparison with intrahepatic cholangiocarcinoma. Eur J Surg Oncol. 2014;40:976-981. [PMID: 24909336 DOI: 10.1016/j.ejso.2014.04.016] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 4.0] [Reference Citation Analysis]
326 Harrison LE, Koneru B, Baramipour P, Fisher A, Barone A, Wilson D, Dela Torre A, Cho KC, Contractor D, Korogodsky M. Locoregional recurrences are frequent after radiofrequency ablation for hepatocellular carcinoma. Journal of the American College of Surgeons 2003;197:759-64. [DOI: 10.1016/s1072-7515(03)00750-6] [Cited by in Crossref: 95] [Cited by in F6Publishing: 32] [Article Influence: 5.0] [Reference Citation Analysis]
327 Chang Z, Yang L, Wang W, Peng J, Huang G, Tao Y, Ding X. Determination of High Mobility Group A1 (HMGA1) Expression in Hepatocellular Carcinoma: A Potential Prognostic Marker. Dig Dis Sci 2005;50:1764-70. [DOI: 10.1007/s10620-005-2934-9] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 2.0] [Reference Citation Analysis]
328 Kawakami T, Hoshida Y, Kanai F, Tanaka Y, Tateishi K, Ikenoue T, Obi S, Sato S, Teratani T, Shiina S. Proteomic analysis of sera from hepatocellular carcinoma patients after radiofrequency ablation treatment. Proteomics. 2005;5:4287-4295. [PMID: 16254924 DOI: 10.1002/pmic.200401287] [Cited by in Crossref: 40] [Cited by in F6Publishing: 44] [Article Influence: 2.5] [Reference Citation Analysis]
329 Hao XS, Chen KX, Wang PP, Rohan T. Changes in survival patterns in urban Chinese patients with liver cancer. World J Gastroenterol 2003; 9(6): 1212-1215 [PMID: 12800226 DOI: 10.3748/wjg.v9.i6.1212] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.3] [Reference Citation Analysis]
330 Wood GA, Sarma DS, Archer MC. Inheritance of resistance to promotion of preneoplastic liver lesions in Copenhagen rats. Exp Biol Med (Maywood) 2001;226:831-5. [PMID: 11568305 DOI: 10.1177/153537020122600904] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
331 Vogl TJ, Schwarz W, Eichler K, Hochmuth K, Hammerstingl R, Jacob U, Scheller A, Zangos S, Heller M. Hepatic intraarterial chemotherapy with gemcitabine in patients with unresectable cholangiocarcinomas and liver metastases of pancreatic cancer: a clinical study on maximum tolerable dose and treatment efficacy. J Cancer Res Clin Oncol. 2006;132:745-755. [PMID: 16858591 DOI: 10.1007/s00432-006-0138-0] [Cited by in Crossref: 41] [Cited by in F6Publishing: 30] [Article Influence: 2.6] [Reference Citation Analysis]
332 Boubertakh B, Liu X, Cheng X, Li P. A Spotlight on Chemical Constituents and Pharmacological Activities of Nigella glandulifera Freyn et Sint Seeds. Journal of Chemistry 2013;2013:1-12. [DOI: 10.1155/2013/820183] [Cited by in Crossref: 22] [Cited by in F6Publishing: 7] [Article Influence: 2.4] [Reference Citation Analysis]
333 Woo HY, Heo J. Sorafenib in liver cancer. Expert Opin Pharmacother. 2012;13:1059-1067. [PMID: 22519770 DOI: 10.1517/14656566.2012.679930] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 3.2] [Reference Citation Analysis]
334 Orejuela D, Jorquera R, Bergeron A, Finegold MJ, Tanguay RM. Hepatic stress in hereditary tyrosinemia type 1 (HT1) activates the AKT survival pathway in the fah-/- knockout mice model. J Hepatol 2008;48:308-17. [PMID: 18093685 DOI: 10.1016/j.jhep.2007.09.014] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 1.5] [Reference Citation Analysis]
335 Llovet JM, Beaugrand M. Hepatocellular carcinoma: present status and future prospects. Journal of Hepatology 2003;38:136-49. [DOI: 10.1016/s0168-8278(02)00432-4] [Cited by in Crossref: 156] [Cited by in F6Publishing: 56] [Article Influence: 8.2] [Reference Citation Analysis]
336 Haemmerich D, Webster JG. Automatic control of finite element models for temperature-controlled radiofrequency ablation. Biomed Eng Online 2005;4:42. [PMID: 16018811 DOI: 10.1186/1475-925X-4-42] [Cited by in Crossref: 34] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
337 Komura T, Mizukoshi E, Kita Y, Sakurai M, Takata Y, Arai K, Yamashita T, Ohta T, Shimizu K, Nakamoto Y. Impact of diabetes on recurrence of hepatocellular carcinoma after surgical treatment in patients with viral hepatitis. Am J Gastroenterol. 2007;102:1939-1946. [PMID: 17573788 DOI: 10.1111/j.1572-0241.2007.01354.x] [Cited by in Crossref: 53] [Cited by in F6Publishing: 45] [Article Influence: 3.5] [Reference Citation Analysis]
338 Miao X, Liu G, Xu X, Xie C, Sun F, Yang Y, Zhang T, Hua S, Fan W, Li Q, Huang S, Wang Q, Liu G, Zhong D. High expression of vanilloid receptor-1 is associated with better prognosis of patients with hepatocellular carcinoma. Cancer Genet Cytogenet 2008;186:25-32. [PMID: 18786439 DOI: 10.1016/j.cancergencyto.2008.05.011] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 2.4] [Reference Citation Analysis]
339 Rosenthal P. Hepatocarcinoma in Viral and Metabolic Liver Disease. Journal of Pediatric Gastroenterology & Nutrition 2008;46:370-5. [DOI: 10.1097/mpg.0b013e318158799b] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
340 Galandi D, Antes G, Galandi D. Radiofrequency thermal ablation versus other interventions for hepatocellular carcinoma. Cochrane Database of Systematic Reviews. Chichester: John Wiley & Sons, Ltd; 1996. [DOI: 10.1002/14651858.cd003046.pub2] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
341 Xuan SY, Xin YN, Chen H, Shi GJ, Guan HS, Li Y. Significance of hepatitis B virus surface antigen, hepatitis C virus expression in hepatocellular carcinoma and pericarcinomatous tissues. World J Gastroenterol 2007; 13(12): 1870-1874 [PMID: 17465484 DOI: 10.3748/wjg.v13.i12.1870] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
342 Alvite Canosa M, Pita Fernández S, Quintela Fandiño J, Aguirrezabalaga J, Otero A, Suárez F, Corbal G, Fernández C, Gutiérrez MG. [Surgical treatment of liver cancer: experience of the A Coruña UHC (Spain)]. Cir Esp 2011;89:223-9. [PMID: 21353668 DOI: 10.1016/j.ciresp.2010.12.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
343 Kaibori M, Ishizaki M, Saito T, Matsui K, Kwon AH, Kamiyama Y. Risk factors and outcome of early recurrence after resection of small hepatocellular carcinomas. Am J Surg. 2009;198:39-45. [PMID: 19178896 DOI: 10.1016/j.amjsurg.2008.07.051] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 2.8] [Reference Citation Analysis]
344 Llovet JM, Vilana R, Bianchi L, Brú C. [Radiofrequency in the treatment of hepatocellular carcinoma]. Gastroenterol Hepatol 2001;24:303-11. [PMID: 11459568 DOI: 10.1016/s0210-5705(01)70180-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
345 Huang JS, Chao CC, Su TL, Yeh SH, Chen DS, Chen CT, Chen PJ, Jou YS. Diverse cellular transformation capability of overexpressed genes in human hepatocellular carcinoma. Biochem Biophys Res Commun. 2004;315:950-958. [PMID: 14985104 DOI: 10.1016/j.bbrc.2004.01.151] [Cited by in Crossref: 105] [Cited by in F6Publishing: 105] [Article Influence: 5.8] [Reference Citation Analysis]
346 Luz JH, Luz PM, Martin HS, Gouveia HR, Levigard RB, Nogueira FD, Rodrigues BC, de Miranda TN, Mamede MH. DEB TACE for Intermediate and advanced HCC - Initial Experience in a Brazilian Cancer Center. Cancer Imaging 2017;17:5. [PMID: 28166821 DOI: 10.1186/s40644-017-0108-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
347 Serper M, Taddei TH, Mehta R, D'Addeo K, Dai F, Aytaman A, Baytarian M, Fox R, Hunt K, Goldberg DS, Valderrama A, Kaplan DE; VOCAL Study Group. Association of Provider Specialty and Multidisciplinary Care With Hepatocellular Carcinoma Treatment and Mortality. Gastroenterology. 2017;152:1954-1964. [PMID: 28283421 DOI: 10.1053/j.gastro.2017.02.040] [Cited by in Crossref: 94] [Cited by in F6Publishing: 84] [Article Influence: 18.8] [Reference Citation Analysis]
348 Nogueira JA, Ono-Nita SK, Nita ME, de Souza MM, do Carmo EP, Mello ES, Scapulatempo C, Paranaguá-Vezozzo DC, Carrilho FJ, Alves VA. 249 TP53 mutation has high prevalence and is correlated with larger and poorly differentiated HCC in Brazilian patients. BMC Cancer. 2009;9:204. [PMID: 19558663 DOI: 10.1186/1471-2407-9-204] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 1.9] [Reference Citation Analysis]
349 Schröder PC, Segura V, Riezu JI, Sangro B, Mato JM, Prieto J, Santamaría E, Corrales FJ. A signature of six genes highlights defects on cell growth and specific metabolic pathways in murine and human hepatocellular carcinoma. Funct Integr Genomics 2011;11:419-29. [PMID: 21562899 DOI: 10.1007/s10142-011-0230-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
350 Kotewall CN, Cheung TT, She WH, Ma KW, Tsang SHY, Dai JWC, Chan ACY, Chok KSH, Lo CM. The role of radiofrequency ablation to liver transection surface in patients with close tumor margin of HCC during hepatectomy-a case matched study. Transl Gastroenterol Hepatol 2017;2:33. [PMID: 28529987 DOI: 10.21037/tgh.2017.03.19] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
351 Han KH, Ahn SH. How to predict HCC development in patients with chronic B viral liver disease? Intervirology. 2005;48:23-28. [PMID: 15785086 DOI: 10.1159/000082091] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 2.1] [Reference Citation Analysis]
352 Jolly PE, Jiang Y, Ellis WO, Awuah RT, Appawu J, Nnedu O, Stiles JK, Wang J, Adjei O, Jolly CM, Williams JH. Association between aflatoxin exposure and health characteristics, liver function, hepatitis and malaria infections in Ghanaians. Journal of Nutritional & Environmental Medicine 2009;16:242-57. [DOI: 10.1080/13590840701703918] [Cited by in Crossref: 22] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
353 Di Maso V, Avellini C, Crocè LS, Rosso N, Quadrifoglio F, Cesaratto L, Codarin E, Bedogni G, Beltrami CA, Tell G. Subcellular localization of APE1/Ref-1 in human hepatocellular carcinoma: possible prognostic significance. Mol Med. 2007;13:89-96. [PMID: 17515960 DOI: 10.2119/2006-00084.di] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
354 Kim YJ, Lee H. Single Nucleotide Polymorphisms Associated with Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Virus Infection. Intervirology 2005;48:10-5. [DOI: 10.1159/000082089] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 2.0] [Reference Citation Analysis]
355 Cai Y, Chang Q, Xiao E, Shang QL, Chen Z. Transcatheter arterial chemoembolization (TACE) combined with γ-knife compared to TACE or γ-knife alone for hepatocellular carcinoma. Medicine (Baltimore) 2018;97:e10890. [PMID: 29851811 DOI: 10.1097/MD.0000000000010890] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
356 Lam VW, Ng KK, Chok KS, Cheung TT, Yuen J, Tung H, Tso WK, Fan ST, Poon RT. Risk factors and prognostic factors of local recurrence after radiofrequency ablation of hepatocellular carcinoma. J Am Coll Surg. 2008;207:20-29. [PMID: 18589357 DOI: 10.1016/j.jamcollsurg.2008.01.020] [Cited by in Crossref: 121] [Cited by in F6Publishing: 116] [Article Influence: 8.6] [Reference Citation Analysis]
357 Gómez Senent S, Gómez Raposo C, Segura Cabral JM. Guía para el diagnóstico, estadificación y tratamiento del hepatocarcinoma. Medicina Clínica 2007;128:741-8. [DOI: 10.1157/13106134] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
358 Koehler BC, Urbanik T, Vick B, Boger RJ, Heeger S, Galle PR, Schuchmann M, Schulze-Bergkamen H. TRAIL-induced apoptosis of hepatocellular carcinoma cells is augmented by targeted therapies. World J Gastroenterol 2009; 15(47): 5924-5935 [PMID: 20014456 DOI: 10.3748/wjg.15.5924] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 26] [Article Influence: 2.0] [Reference Citation Analysis]
359 Kaseb AO, Hanbali A, Cotant M, Hassan MM, Wollner I, Philip PA. Vascular endothelial growth factor in the management of hepatocellular carcinoma: a review of literature. Cancer. 2009;115:4895-4906. [PMID: 19637355 DOI: 10.1002/cncr.24537] [Cited by in Crossref: 65] [Cited by in F6Publishing: 66] [Article Influence: 5.0] [Reference Citation Analysis]
360 Lu M, Ma J, Xue W, Cheng C, Wang Y, Zhao Y, Ke Q, Liu H, Liu Y, Li P, Cui X, He S, Shen A. The expression and prognosis of FOXO3a and Skp2 in human hepatocellular carcinoma. Pathol Oncol Res 2009;15:679-87. [PMID: 19404778 DOI: 10.1007/s12253-009-9171-z] [Cited by in Crossref: 41] [Cited by in F6Publishing: 42] [Article Influence: 3.2] [Reference Citation Analysis]
361 Li C, Zhang W, Zhang R, Zhang L, Wu P, Zhang F. Therapeutic effects and prognostic factors in high-intensity focused ultrasound combined with chemoembolisation for larger hepatocellular carcinoma. Eur J Cancer. 2010;46:2513-2521. [PMID: 20663659 DOI: 10.1016/j.ejca.2010.06.015] [Cited by in Crossref: 22] [Cited by in F6Publishing: 28] [Article Influence: 1.8] [Reference Citation Analysis]
362 Wang Q, Luan W, Villanueva GA, Rahbari NN, Yee HT, Manizate F, Hiotis SP. Clinical prognostic variables in young patients (under 40 years) with hepatitis B virus-associated hepatocellular carcinoma. J Dig Dis 2012;13:214-8. [PMID: 22435506 DOI: 10.1111/j.1751-2980.2012.00577.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
363 Shiomi H, Naka S, Sato K, Demura K, Murakami K, Shimizu T, Morikawa S, Kurumi Y, Tani T. Thoracoscopy-assisted magnetic resonance guided microwave coagulation therapy for hepatic tumors. The American Journal of Surgery 2008;195:854-60. [DOI: 10.1016/j.amjsurg.2007.08.056] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 1.6] [Reference Citation Analysis]
364 Poon RT, Yu WC, Fan ST, Wong J. Long-term oral branched chain amino acids in patients undergoing chemoembolization for hepatocellular carcinoma: a randomized trial. Aliment Pharmacol Ther. 2004;19:779-788. [PMID: 15043519 DOI: 10.1111/j.1365-2036.2004.01920.x] [Cited by in Crossref: 84] [Cited by in F6Publishing: 71] [Article Influence: 4.7] [Reference Citation Analysis]
365 Ye X, Lu D, Chen X, Li S, Chen Y, Deng L. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Shuangbai San for Treating Primary Liver Cancer Patients With Cancer Pain. J Pain Symptom Manage 2016;51:979-86. [PMID: 26921496 DOI: 10.1016/j.jpainsymman.2015.12.330] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
366 Lin Y, Feng J, Yang D, Shen Y, Yan X. Suppression of human hepatoma growth in vivo by a monoclonal antibody against a Mr 45,000 protein. Cancer Invest 2006;24:734-9. [PMID: 17162555 DOI: 10.1080/07357900601062347] [Reference Citation Analysis]
367 Poon RT, Wong J. Long-Term Disease-Free Survival After Resection of Hepatocellular Carcinoma: Both Tumor Behavior and Surgeon’s Performance Are Important Determinants. Ann Surg Oncol 2003;10:834-6. [DOI: 10.1245/aso.2003.08.908] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
368 Neumann O, Kesselmeier M, Geffers R, Pellegrino R, Radlwimmer B, Hoffmann K, Ehemann V, Schemmer P, Schirmacher P, Lorenzo Bermejo J. Methylome analysis and integrative profiling of human HCCs identify novel protumorigenic factors. Hepatology. 2012;56:1817-1827. [PMID: 22689435 DOI: 10.1002/hep.25870] [Cited by in Crossref: 101] [Cited by in F6Publishing: 101] [Article Influence: 10.1] [Reference Citation Analysis]
369 Fang F, Yang L, Tao Y, Qin W. FBI-1 promotes cell proliferation and enhances resistance to chemotherapy of hepatocellular carcinoma in vitro and in vivo. Cancer 2012;118:134-46. [PMID: 21713761 DOI: 10.1002/cncr.26251] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 2.4] [Reference Citation Analysis]
370 Okuda K. Hepatocellular carcinoma. J Hepatol. 2000;32:225-237. [PMID: 10728807 DOI: 10.1016/s0168-8278(00)80428-6] [Cited by in Crossref: 380] [Cited by in F6Publishing: 125] [Article Influence: 17.3] [Reference Citation Analysis]
371 Boyault S, Rickman DS, de Reyniès A, Balabaud C, Rebouissou S, Jeannot E, Hérault A, Saric J, Belghiti J, Franco D, Bioulac-sage P, Laurent-puig P, Zucman-rossi J. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology 2007;45:42-52. [DOI: 10.1002/hep.21467] [Cited by in Crossref: 693] [Cited by in F6Publishing: 653] [Article Influence: 46.2] [Reference Citation Analysis]
372 Kawamura Y, Arase Y, Ikeda K, Seko Y, Imai N, Hosaka T, Kobayashi M, Saitoh S, Sezaki H, Akuta N, Suzuki F, Suzuki Y, Ohmoto Y, Amakawa K, Tsuji H, Kumada H. Large-scale long-term follow-up study of Japanese patients with non-alcoholic Fatty liver disease for the onset of hepatocellular carcinoma. Am J Gastroenterol. 2012;107:253-261. [PMID: 22008893 DOI: 10.1038/ajg.2011.327] [Cited by in Crossref: 148] [Cited by in F6Publishing: 154] [Article Influence: 13.5] [Reference Citation Analysis]
373 Oh SH, Lee BH. A ginseng saponin metabolite-induced apoptosis in HepG2 cells involves a mitochondria-mediated pathway and its downstream caspase-8 activation and Bid cleavage. Toxicol Appl Pharmacol. 2004;194:221-229. [PMID: 14761678 DOI: 10.1016/j.taap.2003.09.011] [Cited by in Crossref: 55] [Cited by in F6Publishing: 54] [Article Influence: 3.1] [Reference Citation Analysis]
374 Lee HY, Rhim H, Lee MW, Kim YS, Choi D, Park MJ, Kim YK, Kim SH, Lim HK. Early diffuse recurrence of hepatocellular carcinoma after percutaneous radiofrequency ablation: analysis of risk factors. Eur Radiol. 2013;23:190-197. [PMID: 23085860 DOI: 10.1007/s00330-012-2561-8] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 3.2] [Reference Citation Analysis]
375 Csepregi A, Ebert MP, Röcken C, Schneider-Stock R, Hoffmann J, Schulz HU, Roessner A, Malfertheiner P. Promoter methylation of CDKN2A and lack of p16 expression characterize patients with hepatocellular carcinoma. BMC Cancer 2010;10:317. [PMID: 20569442 DOI: 10.1186/1471-2407-10-317] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 2.3] [Reference Citation Analysis]
376 Kim HY, Cho HK, Hong SP, Cheong J. Hepatitis B virus X protein stimulates the Hedgehog-Gli activation through protein stabilization and nuclear localization of Gli1 in liver cancer cells. Cancer Lett. 2011;309:176-184. [PMID: 21726936 DOI: 10.1016/j.canlet.2011.05.033] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 2.1] [Reference Citation Analysis]
377 Cheng X, Li M, Rao X, Zhang W, Li X, Wang L, Huang G. KIAA1429 regulates the migration and invasion of hepatocellular carcinoma by altering m6A modification of ID2 mRNA. Onco Targets Ther 2019;12:3421-8. [PMID: 31118692 DOI: 10.2147/OTT.S180954] [Cited by in Crossref: 52] [Cited by in F6Publishing: 57] [Article Influence: 17.3] [Reference Citation Analysis]
378 Wang F, Wang R, Li Q, Qu X, Hao Y, Yang J, Zhao H, Wang Q, Li G, Zhang F, Zhang H, Zhou X, Peng X, Bian Y, Xiao W. A transcriptome profile in hepatocellular carcinomas based on integrated analysis of microarray studies. Diagn Pathol 2017;12:4. [PMID: 28086821 DOI: 10.1186/s13000-016-0596-x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
379 Kan Z, Kobayashi S, Phongkitkarun S, Charnsangavej C. Functional CT quantification of tumor perfusion after transhepatic arterial embolization in a rat model. Radiology. 2005;237:144-150. [PMID: 16183930 DOI: 10.1148/radiol.2371040526] [Cited by in Crossref: 51] [Cited by in F6Publishing: 46] [Article Influence: 3.0] [Reference Citation Analysis]
380 Akoad ME, Pomfret EA. Surgical Resection and Liver Transplantation for Hepatocellular Carcinoma. Clinics in Liver Disease 2015;19:381-99. [DOI: 10.1016/j.cld.2015.01.007] [Cited by in Crossref: 38] [Cited by in F6Publishing: 46] [Article Influence: 5.4] [Reference Citation Analysis]
381 Marı́n-hargreaves G, Azoulay D, Bismuth H. Hepatocellular carcinoma: surgical indications and results. Critical Reviews in Oncology/Hematology 2003;47:13-27. [DOI: 10.1016/s1040-8428(02)00213-5] [Cited by in Crossref: 55] [Cited by in F6Publishing: 32] [Article Influence: 2.9] [Reference Citation Analysis]
382 Jeng K, Jeng C, Jeng W, Sheen I, Chang C, Hsiau H, Hung Z, Yu M, Chang F. Sonic hedgehog pathway inhibitor mitigates mouse hepatocellular carcinoma. The American Journal of Surgery 2015;210:554-60. [DOI: 10.1016/j.amjsurg.2015.03.001] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
383 Choi SH, Chung JW, Kim HC, Baek JH, Park CM, Jun S, Kim MU, Lee ES, Cho HR, Jae HJ. The role of perfusion CT as a follow-up modality after transcatheter arterial chemoembolization: an experimental study in a rabbit model. Invest Radiol. 2010;45:427-436. [PMID: 20440211 DOI: 10.1097/rli.0b013e3181e07516] [Cited by in Crossref: 47] [Cited by in F6Publishing: 20] [Article Influence: 3.9] [Reference Citation Analysis]
384 Dawson SP. Hepatocellular carcinoma and the ubiquitin-proteasome system. Biochim Biophys Acta 2008;1782:775-84. [PMID: 18778769 DOI: 10.1016/j.bbadis.2008.08.003] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 2.2] [Reference Citation Analysis]
385 Imamoto R, Okano JI, Sawada S, Fujise Y, Abe R, Murawaki Y. Null anticarcinogenic effect of silymarin on diethylnitrosamine-induced hepatocarcinogenesis in rats. Exp Ther Med 2014;7:31-8. [PMID: 24348760 DOI: 10.3892/etm.2013.1391] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
386 Llovet JM, Ruff P, Tassopoulos N, Castells L, Bruix J, El-Hariry I, Peachey M. A phase II trial of oral eniluracil/5-fluorouracil in patients with inoperable hepatocellular carcinoma. Eur J Cancer 2001;37:1352-8. [PMID: 11435064 DOI: 10.1016/s0959-8049(01)00100-9] [Cited by in Crossref: 17] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
387 Marrero CR, Marrero JA. Viral Hepatitis and Hepatocellular Carcinoma. Archives of Medical Research 2007;38:612-20. [DOI: 10.1016/j.arcmed.2006.09.004] [Cited by in Crossref: 42] [Cited by in F6Publishing: 34] [Article Influence: 2.8] [Reference Citation Analysis]
388 Pang R, Tse E, Poon RT. Molecular pathways in hepatocellular carcinoma. Cancer Lett. 2006;240:157-169. [PMID: 16239065 DOI: 10.1016/j.canlet.2005.08.031] [Cited by in Crossref: 62] [Cited by in F6Publishing: 63] [Article Influence: 3.6] [Reference Citation Analysis]
389 Ren FY, Piao XX, Jin AL. Efficacy of ultrasonography and alpha-fetoprotein on early detection of hepatocellular carcinoma. World J Gastroenterol 2006; 12(29): 4656-4659 [PMID: 16937435 DOI: 10.3748/wjg.v12.i29.4656] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 17] [Article Influence: 1.3] [Reference Citation Analysis]
390 Seitz HK, Stickel F. Risk factors and mechanisms of hepatocarcinogenesis with special emphasis on alcohol and oxidative stress. Biol Chem. 2006;387:349-360. [PMID: 16606331 DOI: 10.1515/bc.2006.047] [Cited by in Crossref: 183] [Cited by in F6Publishing: 85] [Article Influence: 11.4] [Reference Citation Analysis]
391 Mándli T, Fazakas J, Ther G, Arkosy M, Füle B, Németh E, Fazakas J, Hidvégi M, Tóth S. [Evaluation of liver function before living donor liver transplantation and liver resection]. Orv Hetil 2008;149:779-86. [PMID: 18426759 DOI: 10.1556/OH.2008.28316] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
392 Zyoud SH. Global scientific trends on aflatoxin research during 1998-2017: a bibliometric and visualized study. J Occup Med Toxicol. 2019;14:27. [PMID: 31832075 DOI: 10.1186/s12995-019-0248-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
393 Wong GL, Wong VW, Tan GM, Ip KI, Lai WK, Li YW, Mak MS, Lai PB, Sung JJ, Chan HL. Surveillance programme for hepatocellular carcinoma improves the survival of patients with chronic viral hepatitis. Liver Int. 2008;28:79-87. [PMID: 17900247 DOI: 10.1111/j.1478-3231.2007.01576.x] [Cited by in Crossref: 90] [Cited by in F6Publishing: 84] [Article Influence: 6.0] [Reference Citation Analysis]
394 Kaibori M, Shikata N, Sakaguchi T, Ishizaki M, Matsui K, Iida H, Tanaka Y, Miki H, Nakatake R, Okumura T. Influence of Rictor and Raptor Expression of mTOR Signaling on Long-Term Outcomes of Patients with Hepatocellular Carcinoma. Dig Dis Sci. 2015;60:919-928. [PMID: 25371154 DOI: 10.1007/s10620-014-3417-7] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
395 Kaibori M, Matsui K, Ishizaki M, Iida H, Yoshii K, Asano H, Kon M. Effects of implementing an "enhanced recovery after surgery" program on patients undergoing resection of hepatocellular carcinoma. Surg Today 2017;47:42-51. [PMID: 27165267 DOI: 10.1007/s00595-016-1344-2] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 3.5] [Reference Citation Analysis]
396 Bremner KE, Bayoumi AM, Sherman M, Krahn MD. Management of solitary 1 cm to 2 cm liver nodules in patients with compensated cirrhosis: a decision analysis. Can J Gastroenterol 2007;21:491-500. [PMID: 17703248 DOI: 10.1155/2007/182383] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
397 Huang YH, Wu JC, Chen CH, Chang TT, Lee PC, Chau GY, Lui WY, Chang FY, Lee SD. Comparison of recurrence after hepatic resection in patients with hepatitis B vs. hepatitis C-related small hepatocellular carcinoma in hepatitis B virus endemic area. Liver Int. 2005;25:236-241. [PMID: 15780044 DOI: 10.1111/j.1478-3231.2005.01081.x] [Cited by in Crossref: 56] [Cited by in F6Publishing: 56] [Article Influence: 3.3] [Reference Citation Analysis]
398 Zang JJ, Xie F, Xu JF, Qin YY, Shen RX, Yang JM, He J. P16 gene hypermethylation and hepatocellular carcinoma: A systematic review and meta-analysis. World J Gastroenterol 2011; 17(25): 3043-3048 [PMID: 21799651 DOI: 10.3748/wjg.v17.i25.3043] [Cited by in CrossRef: 35] [Cited by in F6Publishing: 31] [Article Influence: 3.2] [Reference Citation Analysis]
399 Kraus S, Kleines M, Albers J, Blohm L, Piechotta G, Püttmann C, Barth S, Nähring J, Nebling E. Quantitative measurement of human anti-HCV Core immunoglobulins on an electrical biochip platform. Biosensors and Bioelectronics 2011;26:1895-901. [DOI: 10.1016/j.bios.2010.03.026] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
400 Bosch FX, Ribes J, Cléries R, Díaz M. Epidemiology of Hepatocellular Carcinoma. Clinics in Liver Disease 2005;9:191-211. [DOI: 10.1016/j.cld.2004.12.009] [Cited by in Crossref: 601] [Cited by in F6Publishing: 553] [Article Influence: 35.4] [Reference Citation Analysis]
401 Suk FM, Lien GS, Huang WJ, Chen CN, Lu SY, Yang YC, Yan MD, Liang YC. A Taiwanese Propolis Derivative Induces Apoptosis through Inducing Endoplasmic Reticular Stress and Activating Transcription Factor-3 in Human Hepatoma Cells. Evid Based Complement Alternat Med 2013;2013:658370. [PMID: 24222778 DOI: 10.1155/2013/658370] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
402 Iannaccone R, Piacentini F, Murakami T, Paradis V, Belghiti J, Hori M, Kim T, Durand F, Wakasa K, Monden M. Hepatocellular carcinoma in patients with nonalcoholic fatty liver disease: helical CT and MR imaging findings with clinical-pathologic comparison. Radiology. 2007;243:422-430. [PMID: 17356175 DOI: 10.1148/radiol.2432051244] [Cited by in Crossref: 54] [Cited by in F6Publishing: 44] [Article Influence: 3.6] [Reference Citation Analysis]
403 Llovet JM, Bruix J. Early diagnosis and treatment of hepatocellular carcinoma. Baillieres Best Pract Res Clin Gastroenterol 2000;14:991-1008. [PMID: 11139351 DOI: 10.1053/bega.2000.0143] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 1.6] [Reference Citation Analysis]
404 França AV, Elias Junior J, Lima BL, Martinelli AL, Carrilho FJ. Diagnosis, staging and treatment of hepatocellular carcinoma. Braz J Med Biol Res. 2004;37:1689-1705. [PMID: 15517086 DOI: 10.1590/s0100-879x2004001100015] [Cited by in Crossref: 53] [Cited by in F6Publishing: 20] [Article Influence: 2.9] [Reference Citation Analysis]
405 Lee NY, Choi HK, Shim JH, Kang KW, Dong Z, Choi HS. The prolyl isomerase Pin1 interacts with a ribosomal protein S6 kinase to enhance insulin-induced AP-1 activity and cellular transformation. Carcinogenesis. 2009;30:671-681. [PMID: 19168580 DOI: 10.1093/carcin/bgp027] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 2.7] [Reference Citation Analysis]
406 Tian Z, Si J, Chang Q, Zhou L, Chen S, Xiao P, Wu E. Antitumor activity and mechanisms of action of total glycosides from aerial part of Cimicifuga dahurica targeted against hepatoma. BMC Cancer 2007;7:237. [PMID: 18166137 DOI: 10.1186/1471-2407-7-237] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 1.7] [Reference Citation Analysis]
407 Uribe LA, Nguyen N, Kim L, Trinh HN, Wong C, Wong C, Nguyen LH, Nguyen MH. Rates of Treatment Eligibility in Follow-Up of Patients with Chronic Hepatitis B (CHB) Across Various Clinical Settings Who Were Initially Ineligible at Presentation. Dig Dis Sci 2016;61:618-25. [PMID: 26660679 DOI: 10.1007/s10620-015-3982-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
408 Yuan H, Cao P, Li HL, Hu HT, Guo CY, Zhao Y, Yao QJ, Geng X. Transarterial chemoembolization with radiofrequency ablation versus hepatectomy in hepatocellular carcinoma beyond the Milan criteria: a retrospective study. Cancer Manag Res 2018;10:5545-52. [PMID: 30519102 DOI: 10.2147/CMAR.S182914] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
409 Colagrande S, La Villa G, Bartolucci M, Lanini F, Barletta G, Villari N. Spiral computed tomography versus ultrasound in the follow-up of cirrhotic patients previously treated for hepatocellular carcinoma: a prospective study. J Hepatol 2003;39:93-8. [PMID: 12821049 DOI: 10.1016/s0168-8278(03)00159-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
410 Guo TK, Hao XY, Ma B, Yang KH, Li YP, Li HL, Gu YH, Cai H, Liu YL, Li Y, Zhan WP. Octreotide for advanced hepatocellular carcinoma: a meta-analysis of randomized controlled trials. J Cancer Res Clin Oncol 2009;135:1685-92. [PMID: 19536563 DOI: 10.1007/s00432-009-0615-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
411 Wong BW, Luk JM, Ng IO, Hu MY, Liu KD, Fan ST. Identification of liver-intestine cadherin in hepatocellular carcinoma--a potential disease marker. Biochem Biophys Res Commun 2003;311:618-24. [PMID: 14623315 DOI: 10.1016/j.bbrc.2003.10.032] [Cited by in Crossref: 63] [Cited by in F6Publishing: 57] [Article Influence: 3.5] [Reference Citation Analysis]
412 Becker G, Allgaier HP, Olschewski M, Zähringer A, Blum HE. Long-acting octreotide versus placebo for treatment of advanced HCC: a randomized controlled double-blind study. Hepatology. 2007;45:9-15. [PMID: 17187405 DOI: 10.1002/hep.21468] [Cited by in Crossref: 75] [Cited by in F6Publishing: 70] [Article Influence: 5.0] [Reference Citation Analysis]
413 Anzola M, Cuevas N, López‐martínez M, Martínez de Pancorbo M, Burgos JJ. Patterns of methylation profiles as diagnostic markers for multiple hepatocellular carcinomas. Scandinavian Journal of Gastroenterology 2009;39:246-51. [DOI: 10.1080/00365520310008124] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
414 Chen ZM, Crone KG, Watson MA, Pfeifer JD, Wang HL. Identification of a unique gene expression signature that differentiates hepatocellular adenoma from well-differentiated hepatocellular carcinoma. Am J Surg Pathol 2005;29:1600-8. [PMID: 16327432 DOI: 10.1097/01.pas.0000176426.21876.a5] [Cited by in Crossref: 24] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
415 Zheng L, Liang P, Zhou J, Huang X, Wen Y, Wang Z, Li J. BC047440 antisense eukaryotic expression vectors inhibited HepG2 cell proliferation and suppressed xenograft tumorigenicity. Braz J Med Biol Res 2012;45:97-103. [PMID: 22230953 DOI: 10.1590/s0100-879x2012007500001] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
416 Shinkawa H, Uenishi T, Takemura S, Ohba K, Ogawa M, Ichikawa T, Kodai S, Yamamoto T, Tanaka H, Kubo S. Risk factors for postoperative recurrence of non-B non-C hepatocellular carcinoma. Journal of Hepato-Biliary-Pancreatic Sciences 2010;17:291-5. [DOI: 10.1007/s00534-009-0186-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
417 Kamel MM, Saad MF, Mahmoud AA, Edries AA, Abdel-moneim AS. Evaluation of serum PIVKA-II and MIF as diagnostic markers for HCV/HBV induced hepatocellular carcinoma. Microbial Pathogenesis 2014;77:31-5. [DOI: 10.1016/j.micpath.2014.10.009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
418 Lee KT, Lu YW, Wang SN, Chen HY, Chuang SC, Chang WT, Shi HY, Ker CG, Chiu HC. The effect of preoperative transarterial chemoembolization of resectable hepatocellular carcinoma on clinical and economic outcomes. J Surg Oncol 2009;99:343-50. [PMID: 19226530 DOI: 10.1002/jso.21248] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 2.1] [Reference Citation Analysis]
419 Sasaki A, Kai S, Iwashita Y, Hirano S, Ohta M, Kitano S. Microsatellite distribution and indication for locoregional therapy in small hepatocellular carcinoma. Cancer 2005;103:299-306. [DOI: 10.1002/cncr.20798] [Cited by in Crossref: 106] [Cited by in F6Publishing: 103] [Article Influence: 6.2] [Reference Citation Analysis]
420 Devulapally R, Foygel K, Sekar TV, Willmann JK, Paulmurugan R. Gemcitabine and Antisense-microRNA Co-encapsulated PLGA-PEG Polymer Nanoparticles for Hepatocellular Carcinoma Therapy. ACS Appl Mater Interfaces 2016;8:33412-22. [PMID: 27960411 DOI: 10.1021/acsami.6b08153] [Cited by in Crossref: 39] [Cited by in F6Publishing: 43] [Article Influence: 6.5] [Reference Citation Analysis]
421 Piguet AC, Medová M, Keogh A, Glück AA, Aebersold DM, Dufour JF, Zimmer Y. Impact of MET targeting on tumor-associated angiogenesis and growth of MET mutations-driven models of liver cancer. Genes Cancer 2015;6:317-27. [PMID: 26413215 DOI: 10.18632/genesandcancer.74] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
422 Mashitani T, Yoshiji H, Yamazaki M, Ikenaka Y, Noguchi R, Ishikawa M, Kawaratani H, Matsuo N, Uemura M, Yamao J, Fujimoto M, Mitoro A, Toyohara M, Yoshida M, Sawai M, Morioka C, Tsujimoto T, Kitade M, Kaji K, Aihara Y, Fukui H. Development of hepatocellular carcinoma in a patient 13 years after sustained virological response to interferon against chronic hepatitis C: a case report. Cases J 2009;2:18. [PMID: 19128460 DOI: 10.1186/1757-1626-2-18] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
423 Liu W, Wang J, Wang L, Qian C, Qian Y, Xuan H, Zhuo W, Li X, Yu J, Si J. Ras-association domain family 10 acts as a novel tumor suppressor through modulating MMP2 in hepatocarcinoma. Oncogenesis 2016;5:e237. [PMID: 27348267 DOI: 10.1038/oncsis.2016.24] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
424 Wong C, Chan SK, Chan HL, Tsui SK. The Molecular Diagnosis of Hepatitis B Virus-Associated Hepatocellular Carcinoma. Critical Reviews in Clinical Laboratory Sciences 2008;43:69-101. [DOI: 10.1080/10408360500410407] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
425 Satoi S, Matsui Y, Kitade H, Yanagimoto H, Toyokawa H, Yamamoto H, Hirooka S, Kwon AH, Kamiyama Y. Long-term outcome of hepatocellular carcinoma patients who underwent liver resection using microwave tissue coagulation. HPB (Oxford) 2008;10:289-95. [PMID: 18773108 DOI: 10.1080/13651820802168068] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
426 Garin E, Rakotonirina H, Lejeune F, Denizot B, Roux J, Noiret N, Mesbah H, Herry J, Bourguet P, Lejeune J. Effect of a 188Re-SSS lipiodol/131I-lipiodol mixture, 188Re-SSS lipiodol alone or 131I-lipiodol alone on the survival of rats with hepatocellular carcinoma: . Nuclear Medicine Communications 2006;27:363-9. [DOI: 10.1097/00006231-200604000-00008] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
427 Kleek EJV, Schwartz JM, Rayhill SC, Rosen HR, Cotler SJ. Liver Transplantation for Hepatocellular Carcinoma: A Survey of Practices. Journal of Clinical Gastroenterology 2006;40:643-7. [DOI: 10.1097/00004836-200608000-00018] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
428 Ntagirabiri R, Munezero B, Kaze H, Ndirahisha E, Manirakiza S. [Incidence of hepatocellular carcinoma in chronic infection with hepatitis B]. Pan Afr Med J 2015;20:167. [PMID: 26113910 DOI: 10.11604/pamj.2015.20.167.6227] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
429 Barbare JC, Bouché O, Bonnetain F, Dahan L, Lombard-Bohas C, Faroux R, Raoul JL, Cattan S, Lemoine A, Blanc JF. Treatment of advanced hepatocellular carcinoma with long-acting octreotide: a phase III multicentre, randomised, double blind placebo-controlled study. Eur J Cancer. 2009;45:1788-1797. [PMID: 19303768 DOI: 10.1016/j.ejca.2009.02.018] [Cited by in Crossref: 42] [Cited by in F6Publishing: 43] [Article Influence: 3.2] [Reference Citation Analysis]
430 Ammerpohl O, Pratschke J, Schafmayer C, Haake A, Faber W, von Kampen O, Brosch M, Sipos B, von Schönfels W, Balschun K. Distinct DNA methylation patterns in cirrhotic liver and hepatocellular carcinoma. Int J Cancer. 2012;130:1319-1328. [PMID: 21500188 DOI: 10.1002/ijc.26136] [Cited by in Crossref: 64] [Cited by in F6Publishing: 66] [Article Influence: 5.8] [Reference Citation Analysis]
431 Takeshita S, Ichikawa T, Nakao K, Miyaaki H, Shibata H, Matsuzaki T, Muraoka T, Honda T, Otani M, Akiyama M, Miuma S, Ozawa E, Fujimito M, Eguchi K. A snack enriched with oral branched-chain amino acids prevents a fall in albumin in patients with liver cirrhosis undergoing chemoembolization for hepatocellular carcinoma. Nutr Res. 2009;29:89-93. [PMID: 19285598 DOI: 10.1016/j.nutres.2008.12.005] [Cited by in Crossref: 32] [Cited by in F6Publishing: 36] [Article Influence: 2.5] [Reference Citation Analysis]
432 Nguyen NH, Vutien P, Trinh HN, Garcia RT, Nguyen LH, Nguyen HA, Nguyen KK, Nguyen MH. Risk factors, genotype 6 prevalence, and clinical characteristics of chronic hepatitis C in Southeast Asian Americans. Hepatol Int. 2010;4:523-529. [PMID: 20827411 DOI: 10.1007/s12072-010-9181-7] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 2.6] [Reference Citation Analysis]
433 Park YK, Kim KM, Lee YJ, Kim KH, Lee SG, Lee D, Shim JH, Lim YS, Lee HC, Chung YH, Lee YS, Suh DJ. Could HBx protein expression affect signal pathway inhibition by gefitinib or selumetinib, a MEK inhibitor, in hepatocellular carcinoma cell lines? J Korean Med Sci 2011;26:214-21. [PMID: 21286012 DOI: 10.3346/jkms.2011.26.2.214] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
434 Huang XB, Wang XW, Li J, Zheng L, Zhao HZ, Liang P, Dai JG. Are autologous bone marrow stem cell transplantation and transcatheter arterial embolization the best choices for patients with hepatocellular carcinoma and hepatic dysfunction? Report of a case. Surg Today 2012;42:1225-8. [PMID: 22179797 DOI: 10.1007/s00595-011-0107-3] [Reference Citation Analysis]
435 Kubota N, Nomoto M, Hwang GW, Watanabe T, Kohara M, Wakita T, Naganuma A, Kuge S. Hepatitis C virus inhibitor synergism suggests multistep interactions between heat-shock protein 90 and hepatitis C virus replication. World J Hepatol 2016; 8(5): 282-290 [PMID: 26925202 DOI: 10.4254/wjh.v8.i5.282] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
436 Wei L, Lee D, Law CT, Zhang MS, Shen J, Chin DW, Zhang A, Tsang FH, Wong CL, Ng IO, Wong CC, Wong CM. Genome-wide CRISPR/Cas9 library screening identified PHGDH as a critical driver for Sorafenib resistance in HCC. Nat Commun 2019;10:4681. [PMID: 31615983 DOI: 10.1038/s41467-019-12606-7] [Cited by in Crossref: 48] [Cited by in F6Publishing: 59] [Article Influence: 16.0] [Reference Citation Analysis]
437 Michielsen PP, Francque SM, van Dongen JL. Viral hepatitis and hepatocellular carcinoma. World J Surg Oncol. 2005;3:27. [PMID: 15907199 DOI: 10.1186/1477-7819-3-27] [Cited by in Crossref: 85] [Cited by in F6Publishing: 82] [Article Influence: 5.0] [Reference Citation Analysis]
438 Jian J, Yang H, Zhao X, Xuan R, Zhang Y, Li D, Hu C. Visualization of microvasculature and thrombi by X-ray phase-contrast computed tomography in hepatocellular carcinoma. J Synchrotron Radiat 2016;23:600-5. [PMID: 26917149 DOI: 10.1107/S1600577516001016] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
439 Chen J, Huang K, Wu J, Zhu H, Shi Y, Wang Y, Zhao G. Survival after anatomic resection versus nonanatomic resection for hepatocellular carcinoma: a meta-analysis. Dig Dis Sci. 2011;56:1626-1633. [PMID: 21082347 DOI: 10.1007/s10620-010-1482-0.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
440 Ayers JW, Juon HS, Lee S, Park E. Hepatitis B vaccination prevalence and its predictors among Asian, Pacific Islander, Native American, and multiracial adults in the National Health and Nutrition Examination Survey. J Immigr Minor Health 2010;12:847-52. [PMID: 19967403 DOI: 10.1007/s10903-009-9309-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
441 Kew M. Epidemiology of HBV infection and HBV-related hepatocellular carcinoma in Africa: natural history and clinical outcome. ISBT Science Series 2006;1:84-8. [DOI: 10.1111/j.1751-2824.2006.00018.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
442 Zhang LJ, Wu S, Wang M, Lu L, Chen B, Jin L, Wang J, Larson AC, Lu GM. Quantitative dual energy CT measurements in rabbit VX2 liver tumors: Comparison to perfusion CT measurements and histopathological findings. Eur J Radiol. 2012;81:1766-1775. [PMID: 21835570 DOI: 10.1016/j.ejrad.2011.06.057] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 1.9] [Reference Citation Analysis]
443 Wang CS, Lin CL, Lee HC, Chen KY, Chiang MF, Chen HS, Lin TJ, Liao LY. Usefulness of serum des-γ-carboxy prothrombin in detection of hepatocellular carcinoma. World J Gastroenterol 2005; 11(39): 6115-6119 [PMID: 16273636 DOI: 10.3748/wjg.v11.i39.6115] [Cited by in CrossRef: 63] [Cited by in F6Publishing: 60] [Article Influence: 3.7] [Reference Citation Analysis]
444 Zimmermann E, Berentzen TL, Gamborg M, Sørensen TIA, Baker JL. Sex-specific associations between birth weight and adult primary liver cancer in a large cohort of Danish children: Birth weight and adult liver cancer. Int J Cancer 2016;138:1410-5. [DOI: 10.1002/ijc.29900] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
445 Eltawil KM, Berry R, Abdolell M, Molinari M. Analysis of survival predictors in a prospective cohort of patients undergoing transarterial chemoembolization for hepatocellular carcinoma in a single Canadian centre. HPB (Oxford) 2012;14:162-70. [PMID: 22321034 DOI: 10.1111/j.1477-2574.2011.00420.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
446 Sala M, Varela M, Forner A, Bruix J. [Early diagnosis of liver cancer]. Gastroenterol Hepatol 2005;28:292-7. [PMID: 15871814 DOI: 10.1157/13074066] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
447 Van Thiel DH, Yong S, Li SD, Kennedy M, Brems J. The development of de novo hepatocellular carcinoma in patients on a liver transplant list: frequency, size, and assessment of current screening methods. Liver Transpl 2004;10:631-7. [PMID: 15108254 DOI: 10.1002/lt.20120] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 1.6] [Reference Citation Analysis]
448 Chen YJ, Wu H, Shen XZ. The ubiquitin-proteasome system and its potential application in hepatocellular carcinoma therapy. Cancer Lett 2016;379:245-52. [PMID: 26193663 DOI: 10.1016/j.canlet.2015.06.023] [Cited by in Crossref: 30] [Cited by in F6Publishing: 34] [Article Influence: 4.3] [Reference Citation Analysis]
449 Hao XS, Wang PP, Chen KX, Li Q, He M, Yu SB, Guo ZY, Perruccio A, Rohan T. Twenty-year trends of primary liver cancer incidence rates in an urban Chinese population. Eur J Cancer Prev. 2003;12:273-279. [PMID: 12883379 DOI: 10.1097/00008469-200308000-00006] [Cited by in Crossref: 25] [Cited by in F6Publishing: 29] [Article Influence: 1.4] [Reference Citation Analysis]
450 Qu L, Kuai X, Liu T, Chen T, Ni Z, Shen X. Pre-S deletion and complex mutations of hepatitis B virus related to young age hepatocellular carcinoma in Qidong, China. PLoS One 2013;8:e59583. [PMID: 23555717 DOI: 10.1371/journal.pone.0059583] [Cited by in Crossref: 17] [Cited by in F6Publishing: 24] [Article Influence: 1.9] [Reference Citation Analysis]
451 Fan J, Li R, Zhang R, Liu HL, Zhang N, Zhang FQ, Dou KF. Effect of Bcl-2 and Bax on survival of side population cells from hepatocellular carcinoma cells. World J Gastroenterol 2007; 13(45): 6053-6059 [DOI: 10.3748/wjg.v13.i45.6053] [Reference Citation Analysis]
452 Kumar M, Zhao X, Wang XW. Molecular carcinogenesis of hepatocellular carcinoma and intrahepatic cholangiocarcinoma: one step closer to personalized medicine? Cell Biosci. 2011;1:5. [PMID: 21711594 DOI: 10.1186/2045-3701-1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
453 Drakaki A, Hatziapostolou M, Polytarchou C, Vorvis C, Poultsides GA, Souglakos J, Georgoulias V, Iliopoulos D. Functional microRNA high throughput screening reveals miR-9 as a central regulator of liver oncogenesis by affecting the PPARA-CDH1 pathway. BMC Cancer 2015;15:542. [PMID: 26206264 DOI: 10.1186/s12885-015-1562-9] [Cited by in Crossref: 44] [Cited by in F6Publishing: 44] [Article Influence: 6.3] [Reference Citation Analysis]
454 Huang C, Lu Y, Jen C. Investigation on supraphysiological thermal injury in two well-differentiated human hepatoma cell lines, HepG2 and Hep3B. Journal of Thermal Biology 2010;35:411-6. [DOI: 10.1016/j.jtherbio.2010.09.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
455 Iñarrairaegui M, Sangro B. Results in Hepatocellular Carcinoma. In: Bilbao JI, Reiser MF, editors. Liver Radioembolization with 90Y Microspheres. Berlin: Springer Berlin Heidelberg; 2008. pp. 107-15. [DOI: 10.1007/978-3-540-35423-9_10] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
456 Lodato F, Mazzella G, Festi D, Azzaroli F, Colecchia A, Roda E. Hepatocellular carcinoma prevention: A worldwide emergence between the opulence of developed countries and the economic constraints of developing nations. World J Gastroenterol 2006; 12(45): 7239-7249 [PMID: 17143937 DOI: 10.3748/wjg.v12.i45.7239] [Cited by in CrossRef: 59] [Cited by in F6Publishing: 53] [Article Influence: 3.7] [Reference Citation Analysis]
457 Liu HT, Huang YC, Cheng SB, Huang YT, Lin PT. Effects of coenzyme Q10 supplementation on antioxidant capacity and inflammation in hepatocellular carcinoma patients after surgery: a randomized, placebo-controlled trial. Nutr J 2016;15:85. [PMID: 27716246 DOI: 10.1186/s12937-016-0205-6] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 5.3] [Reference Citation Analysis]
458 Kaibori M, Matsui K, Yoshii K, Ishizaki M, Iwasaka J, Miyauchi T, Kimura Y. Perioperative exercise capacity in chronic liver injury patients with hepatocellular carcinoma undergoing hepatectomy. PLoS One 2019;14:e0221079. [PMID: 31412075 DOI: 10.1371/journal.pone.0221079] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
459 Nawawi O, Hazman M, Abdullah B, Vijayananthan A, Manikam J, Mahadeva S, Goh K. Transarterial embolisation of hepatocellular carcinoma with doxorubicin-eluting beads: single centre early experience. Biomed Imaging Interv J 2010;6:e7. [PMID: 21611067 DOI: 10.2349/biij.6.1.e7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
460 Basu A, Meyer K, Lai KK, Saito K, Di Bisceglie AM, Grosso LE, Ray RB, Ray R. Microarray analyses and molecular profiling of Stat3 signaling pathway induced by hepatitis C virus core protein in human hepatocytes. Virology. 2006;349:347-358. [PMID: 16545852 DOI: 10.1016/j.virol.2006.02.023] [Cited by in Crossref: 53] [Cited by in F6Publishing: 55] [Article Influence: 3.3] [Reference Citation Analysis]
461 Yasui K, Okamoto H, Arii S, Inazawa J. Association of over-expressed TFDP1 with progression of hepatocellular carcinomas. J Hum Genet 2003;48:609-13. [PMID: 14618416 DOI: 10.1007/s10038-003-0086-3] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 1.7] [Reference Citation Analysis]
462 Shih YL, Shyu RY, Hsieh CB, Lai HC, Liu KY, Chu TY, Lin YW. Promoter methylation of the secreted frizzled-related protein 1 gene SFRP1 is frequent in hepatocellular carcinoma. Cancer. 2006;107:579-590. [PMID: 16795071 DOI: 10.1002/cncr.22023] [Cited by in Crossref: 77] [Cited by in F6Publishing: 69] [Article Influence: 4.8] [Reference Citation Analysis]
463 Zeeneldin AA, Eid SM, Darweesh AD, Moneer MM, Saadeldin M. Tamoxifen compared to best supportive care in advanced hepatocelluar carcinoma: A retrospective matched-cohort study. J Egypt Natl Canc Inst 2014;26:1-7. [PMID: 24565676 DOI: 10.1016/j.jnci.2013.03.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
464 Marcassa JC, Ferreira J, Zucoloto S, Castro e Silva O, Marcassa LG, Bagnato VS. Detection of hepatocarcinoma in rats by integration of the fluorescence spectrum: Experimental model. Laser Phys 2006;16:827-32. [DOI: 10.1134/s1054660x06050136] [Cited by in Crossref: 4] [Article Influence: 0.3] [Reference Citation Analysis]
465 Zha Y, Gan P, Liu Q, Tan J. Relationship between polymorphism of angiotensin-converting enzyme gene insertion/deletion and risk of hepatocellular carcinoma in a Chinese Dai population. J Renin Angiotensin Aldosterone Syst 2015;16:695-9. [DOI: 10.1177/1470320314539829] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
466 Zhou Y, Fukuda T, Hang Q, Hou S, Isaji T, Kameyama A, Gu J. Inhibition of fucosylation by 2-fluorofucose suppresses human liver cancer HepG2 cell proliferation and migration as well as tumor formation. Sci Rep 2017;7:11563. [PMID: 28912543 DOI: 10.1038/s41598-017-11911-9] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 5.4] [Reference Citation Analysis]
467 Cadoret A, Ovejero C, Terris B, Souil E, Lévy L, Lamers WH, Kitajewski J, Kahn A, Perret C. New targets of beta-catenin signaling in the liver are involved in the glutamine metabolism. Oncogene. 2002;21:8293-8301. [PMID: 12447692 DOI: 10.1038/sj.onc.1206118] [Cited by in Crossref: 267] [Cited by in F6Publishing: 259] [Article Influence: 13.4] [Reference Citation Analysis]
468 Castronuovo CC, Cuestas ML, Oubiña JR, Mathet VL. Effect of several PEO-PPO amphiphiles on bax , bcl-2 , and hTERT mRNAs: An insight into apoptosis and cell immortalization induced in hepatoma cells by these polymeric excipients: Effect of PEO-PPO Copolymers on bax and hTERT. Biotechnology and Applied Biochemistry 2016;63:273-80. [DOI: 10.1002/bab.1352] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
469 Arguedas MR. Screening for hepatocellular carcinoma: Why, when, how? Curr Gastroenterol Rep 2003;5:57-62. [DOI: 10.1007/s11894-003-0010-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
470 Wong PY, Xia V, Imagawa DK, Hoefs J, Hu KQ. Clinical presentation of hepatocellular carcinoma (HCC) in Asian-Americans versus non-Asian-Americans. J Immigr Minor Health 2011;13:842-8. [PMID: 20890660 DOI: 10.1007/s10903-010-9395-8] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
471 Lang H, Sotiropoulos GC, Brokalaki EI, Schmitz KJ, Bertona C, Meyer G, Frilling A, Paul A, Malagó M, Broelsch CE. Survival and recurrence rates after resection for hepatocellular carcinoma in noncirrhotic livers. J Am Coll Surg. 2007;205:27-36. [PMID: 17617329 DOI: 10.1016/j.jamcollsurg.2007.03.002] [Cited by in Crossref: 86] [Cited by in F6Publishing: 78] [Article Influence: 5.7] [Reference Citation Analysis]
472 Choi M, Philip PA. Liver-directed therapies for hepatocellular cancer. Community Oncology 2007;4:571-5. [DOI: 10.1016/s1548-5315(11)70037-7] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
473 Tan TL, Chen WN. A proteomics analysis of cellular proteins associated with HBV genotype-specific HBX: potential in identification of early diagnostic markers for HCC. J Clin Virol 2005;33:293-8. [PMID: 16036179 DOI: 10.1016/j.jcv.2004.12.015] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 1.4] [Reference Citation Analysis]
474 Wang G, Dong L, Zhang Y, Ji Y, Xiang W, Zhao M. Polysaccharides from Phellinus linteus inhibit cell growth and invasion and induce apoptosis in HepG2 human hepatocellular carcinoma cells. Biologia 2012;67:247-54. [DOI: 10.2478/s11756-011-0160-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
475 Zhu J, Liu S, Ye F, Shen Y, Tie Y, Zhu J, Jin Y, Zheng X, Wu Y, Fu H. The long noncoding RNA expression profile of hepatocellular carcinoma identified by microarray analysis. PLoS One. 2014;9:e101707. [PMID: 25025236 DOI: 10.1371/journal.pone.0101707] [Cited by in Crossref: 48] [Cited by in F6Publishing: 49] [Article Influence: 6.0] [Reference Citation Analysis]
476 Shen J, Chen M, Lee D, Law C, Wei L, Tsang FH, Chin DW, Cheng CL, Lee JM, Ng IO, Wong CC, Wong C. Histone chaperone FACT complex mediates oxidative stress response to promote liver cancer progression. Gut 2020;69:329-42. [DOI: 10.1136/gutjnl-2019-318668] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
477 Bruix J, Llovet JM. Hepatitis B virus and hepatocellular carcinoma. J Hepatol 2003;39 Suppl 1:S59-63. [PMID: 14708679 DOI: 10.1016/s0168-8278(03)00140-5] [Cited by in Crossref: 70] [Cited by in F6Publishing: 24] [Article Influence: 3.9] [Reference Citation Analysis]
478 Pang RW, Lee TK, Man K, Poon RT, Fan ST, Kwong YL, Tse E. PIN1 expression contributes to hepatic carcinogenesis. J Pathol. 2006;210:19-25. [PMID: 16841372 DOI: 10.1002/path.2024] [Cited by in Crossref: 44] [Cited by in F6Publishing: 42] [Article Influence: 2.8] [Reference Citation Analysis]
479 Raut CP, Izzo F, Marra P, Ellis LM, Vauthey JN, Cremona F, Vallone P, Mastro A, Fornage BD, Curley SA. Significant long-term survival after radiofrequency ablation of unresectable hepatocellular carcinoma in patients with cirrhosis. Ann Surg Oncol. 2005;12:616-628. [PMID: 15965731 DOI: 10.1245/aso.2005.06.011] [Cited by in Crossref: 121] [Cited by in F6Publishing: 34] [Article Influence: 7.1] [Reference Citation Analysis]
480 Wu Q, Zhang H, Chen M, Zhang Y, Huang J, Xu Z, Wang W. Preparation of carbon-coated iron nanofluid and its application in radiofrequency ablation: Application of Fe@C Nanofluids in Radiofrequency Ablation. J Biomed Mater Res 2015;103:908-14. [DOI: 10.1002/jbm.b.33275] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
481 Becker D, Sfakianakis I, Krupp M, Staib F, Gerhold-Ay A, Victor A, Binder H, Blettner M, Maass T, Thorgeirsson S, Galle PR, Teufel A. Genetic signatures shared in embryonic liver development and liver cancer define prognostically relevant subgroups in HCC. Mol Cancer 2012;11:55. [PMID: 22891627 DOI: 10.1186/1476-4598-11-55] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 2.8] [Reference Citation Analysis]
482 Yang JC, Teng CF, Wu HC, Tsai HW, Chuang HC, Tsai TF, Hsu YH, Huang W, Wu LW, Su IJ. Enhanced expression of vascular endothelial growth factor-A in ground glass hepatocytes and its implication in hepatitis B virus hepatocarcinogenesis. Hepatology. 2009;49:1962-1971. [PMID: 19475690 DOI: 10.1002/hep.22889] [Cited by in Crossref: 79] [Cited by in F6Publishing: 84] [Article Influence: 6.1] [Reference Citation Analysis]
483 Hong SN, Lee SY, Choi MS, Lee JH, Koh KC, Paik SW, Yoo BC, Rhee JC, Choi D, Lim HK, Lee KW, Joh JW. Comparing the outcomes of radiofrequency ablation and surgery in patients with a single small hepatocellular carcinoma and well-preserved hepatic function. J Clin Gastroenterol. 2005;39:247-252. [PMID: 15718869 DOI: 10.1097/01.mcg.0000152746.72149.31] [Cited by in Crossref: 181] [Cited by in F6Publishing: 162] [Article Influence: 10.6] [Reference Citation Analysis]
484 Chouhan A, Maiwand S, Ngo M, Putalapattu V, Rychtář J, Taylor D. Game-Theoretical Model of Retroactive Hepatitis B Vaccination in China. Bull Math Biol 2020;82:80. [PMID: 32542575 DOI: 10.1007/s11538-020-00748-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
485 Zhang F, Wu L, Zhou L, Chen Q, Xie H, Feng X, Zheng S. Predictive Value of Expression and Promoter Hypermethylation of XAF1 in Hepatitis B Virus-Associated Hepatocellular Carcinoma Treated with Transplantation. Ann Surg Oncol 2008;15:3494-502. [DOI: 10.1245/s10434-008-0146-1] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.2] [Reference Citation Analysis]
486 Sharp GB, Mizuno T, Cologne JB, Fukuhara T, Fujiwara S, Tokuoka S, Mabuchi K. Hepatocellular carcinoma among atomic bomb survivors: Significant interaction of radiation with hepatitis C virus infections. Int J Cancer 2003;103:531-7. [DOI: 10.1002/ijc.10862] [Cited by in Crossref: 27] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
487 Grasso A, Watkinson AF, Tibballs JM, Burroughs AK. Radiofrequency ablation in the treatment of hepatocellular carcinoma--a clinical viewpoint. J Hepatol. 2000;33:667-672. [PMID: 11059876 DOI: 10.1016/s0168-8278(00)80023-9] [Cited by in Crossref: 23] [Cited by in F6Publishing: 2] [Article Influence: 1.1] [Reference Citation Analysis]
488 Kew MC. Prevention of hepatocellular carcinoma. HPB (Oxford) 2005;7:16-25. [PMID: 18333157 DOI: 10.1080/13651820410024030] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
489 Habib SL, Said B, Awad AT, Mostafa MH, Shank RC. Novel adenine adducts, N7-guanine-AFB1 adducts, and p53 mutations in patients with schistosomiasis and aflatoxin exposure. Cancer Detection and Prevention 2006;30:491-8. [DOI: 10.1016/j.cdp.2006.10.006] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.2] [Reference Citation Analysis]
490 Dilou N, Patouillard B, Audigier JC. [Staging systems in hepatocellular carcinoma]. Gastroenterol Clin Biol 2004;28:359-66. [PMID: 15146151 DOI: 10.1016/s0399-8320(04)94936-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
491 Couto OFM, Dvorchik I, Carr BI. Causes of Death in Patients with Unresectable Hepatocellular Carcinoma. Dig Dis Sci 2007;52:3285-9. [DOI: 10.1007/s10620-007-9750-3] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 2.3] [Reference Citation Analysis]
492 Parody JP, Alvarez MDL, Quiroga A, Ronco MT, Francés D, Carnovale C, Carrillo MC. Hepatocytes isolated from preneoplastic rat livers are resistant to ethacrynic acid cytotoxicity. Arch Toxicol 2007;81:565-73. [DOI: 10.1007/s00204-007-0183-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
493 Molinari M, Helton S. Hepatic resection versus radiofrequency ablation for hepatocellular carcinoma in cirrhotic individuals not candidates for liver transplantation: a Markov model decision analysis. Am J Surg. 2009;198:396-406. [PMID: 19520354 DOI: 10.1016/j.amjsurg.2009.01.016] [Cited by in Crossref: 54] [Cited by in F6Publishing: 51] [Article Influence: 4.2] [Reference Citation Analysis]
494 Becker G, Schmitt-Graeff A, Ertelt V, Blum HE, Allgaier HP. CD117 (c-kit) expression in human hepatocellular carcinoma. Clin Oncol (R Coll Radiol). 2007;19:204-208. [PMID: 17359908 DOI: 10.1016/j.clon.2006.12.009] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 1.9] [Reference Citation Analysis]
495 Soni S, Pareek P, Narayan S, Rakesh A, Abhilasha A. Hepatocellular Carcinoma (HCC) in North-Western India: A Retrospective Study Focusing on Epidemiology, Risk Factors, and Survival. J Gastrointest Cancer 2021. [PMID: 34550547 DOI: 10.1007/s12029-021-00712-z] [Reference Citation Analysis]
496 Ogino R, Hosono M, Ishii K, Tatsumi D, Tsutsumi S, Miki Y, Masuoka Y, Shimatani Y, Miki Y. A dose-volume intercomparison of volumetric-modulated arc therapy, 3D static conformal, and rotational conformal techniques for portal vein tumor thrombus in hepatocellular carcinoma. J Radiat Res 2013;54:697-705. [PMID: 23418389 DOI: 10.1093/jrr/rrs139] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
497 Valls C, Cos M, Figueras J, Andía E, Ramos E, Sánchez A, Serrano T, Torras J. Pretransplantation diagnosis and staging of hepatocellular carcinoma in patients with cirrhosis: value of dual-phase helical CT. AJR Am J Roentgenol. 2004;182:1011-1017. [PMID: 15039179 DOI: 10.2214/ajr.182.4.1821011] [Cited by in Crossref: 73] [Cited by in F6Publishing: 65] [Article Influence: 4.1] [Reference Citation Analysis]
498 Qiu DM, Wang GL, Chen L, Xu YY, He S, Cao XL, Qin J, Zhou JM, Zhang YX, E Q. The expression of beclin-1, an autophagic gene, in hepatocellular carcinoma associated with clinical pathological and prognostic significance. BMC Cancer. 2014;14:327. [PMID: 24885292 DOI: 10.1186/1471-2407-14-327] [Cited by in Crossref: 66] [Cited by in F6Publishing: 69] [Article Influence: 8.3] [Reference Citation Analysis]
499 Smukler AJ, Ratner L. Hepatitis viruses and hepatocellular carcinoma in HIV-infected patients: . Current Opinion in Oncology 2002;14:538-42. [DOI: 10.1097/00001622-200209000-00011] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.0] [Reference Citation Analysis]
500 Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. The Lancet 2003;362:1907-17. [DOI: 10.1016/s0140-6736(03)14964-1] [Cited by in Crossref: 3076] [Cited by in F6Publishing: 1294] [Article Influence: 161.9] [Reference Citation Analysis]
501 Liu H, Wang Y, Chen B, Shen X, Li W. Effects of Lidocaine-Mediated CPEB3 Upregulation in Human Hepatocellular Carcinoma Cell Proliferation In Vitro. Biomed Res Int 2018;2018:8403157. [PMID: 29850575 DOI: 10.1155/2018/8403157] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
502 Kew MC. Hepatocellular carcinoma: epidemiology and risk factors. J Hepatocellular Carcinoma. 2014;1:115-125. [PMID: 27508181 DOI: 10.2147/jhc.s44381] [Cited by in Crossref: 48] [Cited by in F6Publishing: 31] [Article Influence: 6.0] [Reference Citation Analysis]
503 Sevastianos VA, Deutsch M, Dourakis SP. Case 3. Grey-Turner's sign as the first indication of a ruptured hepatocellular carcinoma. J Clin Oncol 2004;22:1156-7. [PMID: 15020619 DOI: 10.1200/JCO.2004.05.146] [Cited by in Crossref: 3] [Article Influence: 0.2] [Reference Citation Analysis]
504 Chen ZK, Cai MX, Yang J, Lin LW, Xue ES, Huang J, Wei HF, Zhang XJ, Ke LM. Chemotherapy with PLGA microspheres containing docetaxel decreases angiogenesis in human hepatoma xenograft. Med Oncol 2012;29:62-9. [PMID: 21136211 DOI: 10.1007/s12032-010-9762-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
505 Kitzing B, Kitzing YX. Imaging of hepatocellular carcinoma recurrence post liver resection: a pictorial essay. J Med Imaging Radiat Oncol 2013;57:337-44. [PMID: 23721143 DOI: 10.1111/j.1754-9485.2012.02468.x] [Reference Citation Analysis]
506 Poon RT. Prognostic Impact of Diabetes Mellitus on Patients with Hepatocellular Carcinoma. Am J Gastroenterology 2004;99:1488-9. [DOI: 10.1111/j.1572-0241.2004.40545.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
507 Tsou AP, Yang CW, Huang CY, Yu RC, Lee YC, Chang CW, Chen BR, Chung YF, Fann MJ, Chi CW. Identification of a novel cell cycle regulated gene, HURP, overexpressed in human hepatocellular carcinoma. Oncogene. 2003;22:298-307. [PMID: 12527899 DOI: 10.1038/sj.onc.1206129] [Cited by in Crossref: 91] [Cited by in F6Publishing: 92] [Article Influence: 4.8] [Reference Citation Analysis]
508 Sasaki K, Matsuda M, Ohkura Y, Kawamura Y, Hashimoto M, Ikeda K, Kumada H, Watanabe G. Minimum resection margin should be based on tumor size in hepatectomy for hepatocellular carcinoma in hepatoviral infection patients: Base resection margin on tumor size. Hepatol Res 2013;43:1295-303. [DOI: 10.1111/hepr.12079] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 2.8] [Reference Citation Analysis]
509 Strebel BM, Dufour JF. Combined approach to hepatocellular carcinoma: a new treatment concept for nonresectable disease. Expert Rev Anticancer Ther. 2008;8:1743-1749. [PMID: 18983234 DOI: 10.1586/14737140.8.11.1743] [Cited by in Crossref: 55] [Cited by in F6Publishing: 58] [Article Influence: 4.2] [Reference Citation Analysis]
510 Pollicino T, Squadrito G, Cerenzia G, Cacciola I, Raffa G, Craxi A, Farinati F, Missale G, Smedile A, Tiribelli C, Villa E, Raimondo G. Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection. Gastroenterology. 2004;126:102-110. [PMID: 14699492 DOI: 10.1053/j.gastro.2003.10.048] [Cited by in Crossref: 300] [Cited by in F6Publishing: 292] [Article Influence: 16.7] [Reference Citation Analysis]
511 Lin YW, Shih YL, Lien GS, Suk FM, Hsieh CB, Yan MD. Promoter methylation of SFRP3 is frequent in hepatocellular carcinoma. Dis Markers 2014;2014:351863. [PMID: 24591760 DOI: 10.1155/2014/351863] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
512 Taoka M, Morofuji N, Yamauchi Y, Ojima H, Kubota D, Terukina G, Nobe Y, Nakayama H, Takahashi N, Kosuge T. Global PROTOMAP profiling to search for biomarkers of early-recurrent hepatocellular carcinoma. J Proteome Res. 2014;13:4847-4858. [PMID: 24967658 DOI: 10.1021/pr500262p] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
513 Schimanski CC, Bahre R, Gockel I, Müller A, Frerichs K, Hörner V, Teufel A, Simiantonaki N, Biesterfeld S, Wehler T. Dissemination of hepatocellular carcinoma is mediated via chemokine receptor CXCR4. Br J Cancer. 2006;95:210-217. [PMID: 16819541 DOI: 10.1038/sj.bjc.6603251] [Cited by in Crossref: 125] [Cited by in F6Publishing: 116] [Article Influence: 7.8] [Reference Citation Analysis]
514 Igetei R, Otegbayo JA, Ndububa DA, Lesi OA, Anumudu CI, Hainaut P, Gormally E. Detection of p53 codon 249 mutation in Nigerian patients with hepatocellular carcinoma using a novel evaluation of cell-free DNA. Annals of Hepatology 2008;7:339-44. [DOI: 10.1016/s1665-2681(19)31834-4] [Cited by in Crossref: 16] [Article Influence: 1.1] [Reference Citation Analysis]
515 Kawamura Y, Ikeda K, Hirakawa M, Yatsuji H, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Saitoh S, Suzuki F. New classification of dynamic computed tomography images predictive of malignant characteristics of hepatocellular carcinoma. Hepatol Res. 2010;40:1006-1014. [PMID: 20887336 DOI: 10.1111/j.1872-034x.2010.00703.x] [Cited by in Crossref: 37] [Cited by in F6Publishing: 17] [Article Influence: 3.4] [Reference Citation Analysis]
516 Shiratori Y, Yoshida H, Omata M. Management of hepatocellular carcinoma: advances in diagnosis, treatment and prevention. Expert Rev Anticancer Ther. 2001;1:277-290. [PMID: 12113033 DOI: 10.1586/14737140.1.2.277] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
517 González-uriarte J, Valdivieso A, Gastaca M, Errasti G, Campo M, Hernandez M, Montejo M, Bustamante J, Suarez M, Testillano M, Fernandez J, Ortiz de Urbina J. Liver transplantation for hepatocellular carcinoma in cirrhotic patients. Transplantation Proceedings 2003;35:1827-9. [DOI: 10.1016/s0041-1345(03)00582-7] [Cited by in Crossref: 20] [Cited by in F6Publishing: 1] [Article Influence: 1.1] [Reference Citation Analysis]
518 Marrero JA. Hepatocellular carcinoma: . Current Opinion in Gastroenterology 2003;19:243-9. [DOI: 10.1097/00001574-200305000-00007] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
519 Kaibori M, Matsui K, Shimada M, Kubo S, Hasegawa K. Update on perioperative management of patients undergoing surgery for liver cancer. Annals of Gastroent Surgery. [DOI: 10.1002/ags3.12529] [Reference Citation Analysis]
520 Huang R, Wu T, Xu L, Liu A, Ji Y, Hu G. Upstream binding factor up-regulated in hepatocellular carcinoma is related to the survival and cisplatin-sensitivity of cancer cells. FASEB J 2002;16:293-301. [PMID: 11874979 DOI: 10.1096/fj.01-0687com] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 1.3] [Reference Citation Analysis]
521 Xie X, Zhu H, Yang H, Huang W, Wu Y, Wang Y, Luo Y, Wang D, Shao G. Solamargine triggers hepatoma cell death through apoptosis. Oncol Lett 2015;10:168-74. [PMID: 26170994 DOI: 10.3892/ol.2015.3194] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
522 Hassoun Z, Gores GJ. Treatment of hepatocellular carcinoma. Clinical Gastroenterology and Hepatology 2003;1:10-8. [DOI: 10.1053/jcgh.2003.50003] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 1.4] [Reference Citation Analysis]
523 Kim YJ, Lee HS. [Genetic epidemiological study on single nucleotide polymorphisms associated with hepatocellular carcinoma in patients with chronic HBV infection]. Korean J Hepatol. 2009;15:7-14. [PMID: 19346781 DOI: 10.3350/kjhep.2009.15.1.7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
524 Mergental H, Adam R, Ericzon B, Kalicinski P, Mühlbacher F, Höckerstedt K, Klempnauer JL, Friman S, Broelsch CE, Mantion G, Fernandez-sellez C, van Hoek B, Fangmann J, Pirenne J, Muiesan P, Königsrainer A, Mirza DF, Lerut J, Detry O, Le Treut Y, Mazzaferro V, Löhe F, Berenguer M, Clavien P, Rogiers X, Belghiti J, Kóbori L, Burra P, Wolf P, Schareck W, Pisarski P, Foss A, Filipponi F, Krawczyk M, Wolff M, Langrehr JM, Rolles K, Jamieson N, Hop WC, Porte RJ. Liver transplantation for unresectable hepatocellular carcinoma in normal livers. Journal of Hepatology 2012;57:297-305. [DOI: 10.1016/j.jhep.2012.03.022] [Cited by in Crossref: 38] [Cited by in F6Publishing: 26] [Article Influence: 3.8] [Reference Citation Analysis]
525 Hao K, Lamb J, Zhang C, Xie T, Wang K, Zhang B, Chudin E, Lee NP, Mao M, Zhong H, Greenawalt D, Ferguson MD, Ng IO, Sham PC, Poon RT, Molony C, Schadt EE, Dai H, Luk JM. Clinicopathologic and gene expression parameters predict liver cancer prognosis. BMC Cancer 2011;11:481. [PMID: 22070665 DOI: 10.1186/1471-2407-11-481] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
526 Sarin SK, Kumar M, Garg S, Hissar S, Pandey C, Sharma BC. High dose vitamin K3 infusion in advanced hepatocellular carcinoma. J Gastroenterol Hepatol 2006;21:1478-82. [PMID: 16911696 DOI: 10.1111/j.1440-1746.2006.04383.x] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
527 Peng ZW, Zhang YJ, Chen MS, Liang HH, Li JQ, Zhang YQ, Lau WY. Risk factors of survival after percutaneous radiofrequency ablation of hepatocellular carcinoma. Surg Oncol. 2008;17:23-31. [PMID: 17869095 DOI: 10.1016/j.suronc.2007.08.002] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 1.9] [Reference Citation Analysis]
528 Raidl M, Berger W, Schulte-hermann R, Kandioler-eckersberger D, Kappel S, Wrba F, Micksche M, Grasl-kraupp B. Expression of the lung resistance-related protein in human and rat hepatocarcinogenesis. American Journal of Physiology-Gastrointestinal and Liver Physiology 2002;283:G1117-24. [DOI: 10.1152/ajpgi.00195.2002] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
529 Ribes J, Cl??ries R, Borr??s J, Galceran J, Bosch FX. Time trends in incidence and mortality for chronic liver disease and liver cancer in the interval 1980???1997 in Catalonia, Spain: . European Journal of Gastroenterology & Hepatology 2004;16:865-72. [DOI: 10.1097/00042737-200409000-00009] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
530 Van Damme P, Ward J, Shouval D, Wiersma S, Zanetti A. Hepatitis B vaccines. Vaccines. Elsevier; 2013. pp. 205-34. [DOI: 10.1016/b978-1-4557-0090-5.00025-2] [Cited by in Crossref: 14] [Article Influence: 1.6] [Reference Citation Analysis]
531 Raptis I, Koskinas J, Emmanouil T, Hadziyannis S. Changing relative roles of hepatitis B and C viruses in the aetiology of hepatocellular carcinoma in Greece. Epidemiological and clinical observations. J Viral Hepat 2003;10:450-4. [PMID: 14633179 DOI: 10.1046/j.1365-2893.2003.00442.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
532 Xie N, Chen X, Zhang T, Liu B, Huang C. Using proteomics to identify the HBx interactome in hepatitis B virus: how can this inform the clinic? Expert Rev Proteomics. 2014;11:59-74. [PMID: 24308553 DOI: 10.1586/14789450.2014.861745] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
533 Tulin PE, Dolgushin MB, Odzharova AA, Mikhaylov AI, Medvedeva BM, Shiryaev SV, Dolgushin BI. Perfusion CT and PET with 18F-FDG and 18F-FCh in the complex diagnosis of hepatocellular carcinoma. Eur J Hybrid Imaging 2017;1:13. [PMID: 29782602 DOI: 10.1186/s41824-017-0018-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
534 Lu JW, Chang JG, Yeh KT, Chen RM, Tsai JJ, Hu RM. Decreased expression of p39 is associated with a poor prognosis in human hepatocellular carcinoma. Med Oncol 2011;28 Suppl 1:S239-45. [PMID: 20936377 DOI: 10.1007/s12032-010-9707-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
535 Couvert P, Carrié A, Pariès J, Vaysse J, Miroglio A, Kerjean A, Nahon P, Chelly J, Trinchet JC, Beaugrand M, Ganne-Carrié N. Liver insulin-like growth factor 2 methylation in hepatitis C virus cirrhosis and further occurrence of hepatocellular carcinoma. World J Gastroenterol 2008; 14(35): 5419-5427 [PMID: 18803353 DOI: 10.3748/wjg.14.5419] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
536 Hou J, Liu Z, Gu F. Epidemiology and Prevention of Hepatitis B Virus Infection. Int J Med Sci 2005;2:50-7. [PMID: 15968340 DOI: 10.7150/ijms.2.50] [Cited by in Crossref: 164] [Cited by in F6Publishing: 170] [Article Influence: 9.6] [Reference Citation Analysis]
537 Wu Y, Han B, Sheng H, Lin M, Moore PA, Zhang J, Wu J. Clinical significance of detecting elevated serum DcR3/TR6/M68 in malignant tumor patients. Int J Cancer. 2003;105:724-732. [PMID: 12740925 DOI: 10.1002/ijc.11138] [Cited by in Crossref: 75] [Cited by in F6Publishing: 74] [Article Influence: 3.9] [Reference Citation Analysis]
538 Choi JW, Park JY, Ahn SH, Yoon KT, Ko HK, Lee DY, Lee JT, Kim KS, Choi JS, Han KH. Efficacy and safety of transarterial chemoembolization in recurrent hepatocellular carcinoma after curative surgical resection. Am J Clin Oncol. 2009;32:564-569. [PMID: 19564783 DOI: 10.1097/COC.0b013e3181967da0] [Cited by in Crossref: 25] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
539 Wang Y, He H, Chang J, He C, Liu S, Li M, Zeng N, Wu J, Ma H. Mueller matrix microscope: a quantitative tool to facilitate detections and fibrosis scorings of liver cirrhosis and cancer tissues. J Biomed Opt 2016;21:071112. [DOI: 10.1117/1.jbo.21.7.071112] [Cited by in Crossref: 62] [Cited by in F6Publishing: 12] [Article Influence: 10.3] [Reference Citation Analysis]
540 Wang H, Wang H, Yu Z, Liu H. Alternative treatment strategies to sorafenib in patients with advanced hepatocellular carcinoma: a meta-analysis of randomized Phase III trials. Onco Targets Ther 2018;11:5195-201. [PMID: 30214225 DOI: 10.2147/OTT.S171918] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
541 Lei J, Wang W, Yan L. Surgical resection versus open-approach radiofrequency ablation for small hepatocellular carcinomas within Milan criteria after successful transcatheter arterial chemoembolization. J Gastrointest Surg 2013;17:1752-9. [PMID: 23959694 DOI: 10.1007/s11605-013-2311-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
542 Kaibori M, Ishizaki M, Matsui K, Nakatake R, Sakaguchi T, Habu D, Yoshiuchi S, Kimura Y, Kon AH. Assessment of preoperative exercise capacity in hepatocellular carcinoma patients with chronic liver injury undergoing hepatectomy. BMC Gastroenterol 2013;13:119. [PMID: 23875788 DOI: 10.1186/1471-230X-13-119] [Cited by in Crossref: 17] [Cited by in F6Publishing: 4] [Article Influence: 1.9] [Reference Citation Analysis]
543 Lazarevich NL, Cheremnova OA, Varga EV, Ovchinnikov DA, Kudrjavtseva EI, Morozova OV, Fleishman DI, Engelhardt NV, Duncan SA. Progression of HCC in mice is associated with a downregulation in the expression of hepatocyte nuclear factors. Hepatology. 2004;39:1038-1047. [PMID: 15057908 DOI: 10.1002/hep.20155] [Cited by in Crossref: 147] [Cited by in F6Publishing: 155] [Article Influence: 8.2] [Reference Citation Analysis]
544 Orimo T, Ojima H, Hiraoka N, Saito S, Kosuge T, Kakisaka T, Yokoo H, Nakanishi K, Kamiyama T, Todo S. Proteomic profiling reveals the prognostic value of adenomatous polyposis coli-end-binding protein 1 in hepatocellular carcinoma. Hepatology. 2008;48:1851-1863. [PMID: 18937283 DOI: 10.1002/hep.22552] [Cited by in Crossref: 67] [Cited by in F6Publishing: 70] [Article Influence: 5.2] [Reference Citation Analysis]
545 Chang PE, Ong WC, Lui HF, Tan CK. Is the prognosis of young patients with hepatocellular carcinoma poorer than the prognosis of older patients? A comparative analysis of clinical characteristics, prognostic features, and survival outcome. J Gastroenterol. 2008;43:881-888. [PMID: 19012042 DOI: 10.1007/s00535-008-2238-x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 2.5] [Reference Citation Analysis]
546 Tam KY, Leung KC, Wang YX. Chemoembolization agents for cancer treatment. Eur J Pharm Sci 2011;44:1-10. [PMID: 21726636 DOI: 10.1016/j.ejps.2011.06.013] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 3.7] [Reference Citation Analysis]
547 Bannangkoon K, Hongsakul K, Tubtawee T, McNeil E, Sriplung H, Chongsuvivatwong V. Rate and Predictive Factors for Sustained Complete Response after Selective Transarterial Chemoembolization (TACE) in Patients with Hepatocellular Carcinoma. Asian Pac J Cancer Prev 2018;19:3545-50. [PMID: 30583681 DOI: 10.31557/APJCP.2018.19.12.3545] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
548 Zhou JY, Wong DW, Ding F, Venkatesh SK, Tian Q, Qi YY, Xiong W, Liu JJ, Leow WK. Liver tumour segmentation using contrast-enhanced multi-detector CT data: performance benchmarking of three semiautomated methods. Eur Radiol. 2010;20:1738-1748. [PMID: 20157817 DOI: 10.1007/s00330-010-1712-z] [Cited by in Crossref: 31] [Cited by in F6Publishing: 23] [Article Influence: 2.6] [Reference Citation Analysis]
549 Jiang J, Gusev Y, Aderca I, Mettler TA, Nagorney DM, Brackett DJ, Roberts LR, Schmittgen TD. Association of MicroRNA expression in hepatocellular carcinomas with hepatitis infection, cirrhosis, and patient survival. Clin Cancer Res. 2008;14:419-427. [PMID: 18223217 DOI: 10.1158/1087-0432.CCR-07-0523] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
550 Zhu Z, Cong W, Liu S, Xian Z, Wu W, Wu M, Gao B, Hou L, Zhu G. A p53 polymorphism modifies the risk of hepatocellular carcinoma among non-carriers but not carriers of chronic hepatitis B virus infection. Cancer Letters 2005;229:77-83. [DOI: 10.1016/j.canlet.2005.04.014] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 1.6] [Reference Citation Analysis]
551 Ding WZ, Ni QF, Lu YT, Kong LL, Yu JJ, Tan LW, Kong LB. MicroRNA-497 regulates cell proliferation in hepatocellular carcinoma. Oncol Lett 2016;11:1081-8. [PMID: 26893696 DOI: 10.3892/ol.2015.3981] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
552 Sakaguchi H, Seki S, Tsuji K, Teramoto K, Suzuki M, Kioka K, Isoda N, Ido K. Endoscopic thermal ablation therapies for hepatocellular carcinoma: a multi-center study. Hepatol Res. 2009;39:47-52. [PMID: 18761680 DOI: 10.1111/j.1872-034x.2008.00410.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
553 Csepregi A, Röcken C, Hoffmann J, Gu P, Saliger S, Müller O, Schneider-Stock R, Kutzner N, Roessner A, Malfertheiner P. APC promoter methylation and protein expression in hepatocellular carcinoma. J Cancer Res Clin Oncol. 2008;134:579-589. [PMID: 17973119 DOI: 10.1111/j.1582-4934.2010.01124.x] [Cited by in Crossref: 42] [Cited by in F6Publishing: 40] [Article Influence: 2.8] [Reference Citation Analysis]
554 Kaibori M, Ishizaki M, Matsui K, Kitade H, Matsui Y, Kwon AH. Evaluation of metabolic factors on the prognosis of patients undergoing resection of hepatocellular carcinoma. J Gastroenterol Hepatol. 2011;26:536-543. [PMID: 21332549 DOI: 10.1111/j.1440-1746.2010.06439.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
555 Schlaeger C, Longerich T, Schiller C, Bewerunge P, Mehrabi A, Toedt G, Kleeff J, Ehemann V, Eils R, Lichter P, Schirmacher P, Radlwimmer B. Etiology-dependent molecular mechanisms in human hepatocarcinogenesis. Hepatology 2008;47:511-20. [DOI: 10.1002/hep.22033] [Cited by in Crossref: 128] [Cited by in F6Publishing: 125] [Article Influence: 8.5] [Reference Citation Analysis]
556 Paul SB, Shalimar, Sreenivas V, Gamanagatti SR, Sharma H, Dhamija E, Acharya SK. Incidence and risk factors of hepatocellular carcinoma in patients with hepatic venous outflow tract obstruction. Aliment Pharmacol Ther. 2015;41:961-971. [PMID: 25809735 DOI: 10.1111/apt.13173] [Cited by in Crossref: 26] [Cited by in F6Publishing: 13] [Article Influence: 3.7] [Reference Citation Analysis]
557 Che Y, Zhang DY, Ye F, Wu B, Jiang B. Combination of flavopiridol and embelin effectively inhibit cell growth in hepatocellular carcinoma depending on regulatory relationship between CDK6 and XIAP. Med Chem Res 2012;21:3369-75. [DOI: 10.1007/s00044-011-9867-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
558 Zhang SH, Cong WM, Xian ZH, Wu MC. Clinicopathological significance of loss of heterozygosity and microsatellite instability in hepatocellular carcinoma in China. World J Gastroenterol 2005; 11(20): 3034-3039 [PMID: 15918185 DOI: 10.3748/wjg.v11.i20.3034] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 28] [Article Influence: 1.5] [Reference Citation Analysis]
559 Tsai HW, Lin YJ, Lin PW, Wu HC, Hsu KH, Yen CJ, Chan SH, Huang W, Su IJ. A clustered ground-glass hepatocyte pattern represents a new prognostic marker for the recurrence of hepatocellular carcinoma after surgery. Cancer. 2011;117:2951-2960. [PMID: 21692054 DOI: 10.1002/cncr.25837] [Cited by in Crossref: 42] [Cited by in F6Publishing: 44] [Article Influence: 3.8] [Reference Citation Analysis]
560 Peng C, Zhou RL, Shao GZ, Rui JA, Wang SB, Lin M, Zhang S, Gao ZF. Expression of lysosome-associated protein transmembrane 4B-35 in cancer and its correlation with the differentiation status of hepatocellular carcinoma. World J Gastroenterol 2005; 11(18): 2704-2708 [PMID: 15884107 DOI: 10.3748/wjg.v11.i18.2704] [Cited by in CrossRef: 32] [Cited by in F6Publishing: 34] [Article Influence: 1.9] [Reference Citation Analysis]
561 Helmberger T, Dogan S, Straub G, Schrader A, Jüngst C, Reiser M, Waggershauser T, Jakobs T, Hoffmann R, Löhe F, Graeb C, Rau H, Schauer R, Jauch K, Caselmann WH, Göke B, Jüngst D. Liver Resection or Combined Chemoembolization and Radiofrequency Ablation Improve Survival in Patients with Hepatocellular Carcinoma. Digestion 2007;75:104-12. [DOI: 10.1159/000104730] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 2.1] [Reference Citation Analysis]
562 Bonilla Guerrero R, Roberts LR. The role of hepatitis B virus integrations in the pathogenesis of human hepatocellular carcinoma. J Hepatol. 2005;42:760-777. [PMID: 15826727 DOI: 10.1016/j.jhep.2005.02.005] [Cited by in Crossref: 127] [Cited by in F6Publishing: 122] [Article Influence: 7.5] [Reference Citation Analysis]
563 Poon RT, Fan ST. Evaluation of the new AJCC/UICC staging system for hepatocellular carcinoma after hepatic resection in Chinese patients. Surg Oncol Clin N Am. 2003;12:35-50, viii. [PMID: 12735128 DOI: 10.1016/s1055-3207(02)00086-8] [Cited by in Crossref: 74] [Cited by in F6Publishing: 26] [Article Influence: 3.9] [Reference Citation Analysis]
564 Garin E, Laffont S, Rolland Y, Olivie D, Lecloirec J, Herry JY, Boucher E, Raoul JL, Bourguet P. Safe radiation exposure of medical personnel by using simple methods of radioprotection while administering 131I-lipiodol therapy for hepatocellular carcinoma. Nucl Med Commun 2003;24:671-8. [PMID: 12766603 DOI: 10.1097/00006231-200306000-00009] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
565 Saleem S, Shaharyar MA, Khusroo MJ, Ahmad P, Rahman RU, Ahmad K, Alam MJ, Al-Harbi NO, Iqbal M, Imam F. Anticancer potential of rhamnocitrin 4'-β-D-galactopyranoside against N-diethylnitrosamine-induced hepatocellular carcinoma in rats. Mol Cell Biochem 2013;384:147-53. [PMID: 24026428 DOI: 10.1007/s11010-013-1792-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
566 Koo JS, Kim H, Park BK, Ahn SH, Han KH, Chon CY, Park C, Park YN. Predictive value of liver cell dysplasia for development of hepatocellular carcinoma in patients with chronic hepatitis B. J Clin Gastroenterol. 2008;42:738-743. [PMID: 18277883 DOI: 10.1097/mcg.0b013e318038159d] [Cited by in Crossref: 24] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
567 Anthony PP. Hepatocellular carcinoma: an overview. Histopathology. 2001;39:109-118. [PMID: 11493326 DOI: 10.1046/j.1365-2559.2001.01188.x] [Cited by in Crossref: 91] [Cited by in F6Publishing: 80] [Article Influence: 4.3] [Reference Citation Analysis]
568 Tsai C, Huang K, Chen H, Zhan B, Lai Y, Lee F, Lin C, Ho Y, Chao Y, Su Y, Jane S, Chen Y, Hsu C, Li P, Hsu H, Suzuki Y, Sugano S, Lin J. Gene expression analysis of human hepatocellular carcinoma by using full-length cDNA library. J Biomed Sci 2006;13:241-9. [DOI: 10.1007/s11373-005-9062-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
569 Morimoto M, Numata K, Sugimori K, Shirato K, Kokawa A, Oka H, Hirasawa K, Koh R, Nihommatsu H, Tanaka K. Successful initial ablation therapy contributes to survival in patients with hepatocellular carcinoma. World J Gastroenterol 2007; 13(7): 1003-1009 [PMID: 17373733 DOI: 10.3748/wjg.v13.i7.1003] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.2] [Reference Citation Analysis]
570 Marra M, Sordelli IM, Lombardi A, Lamberti M, Tarantino L, Giudice A, Stiuso P, Abbruzzese A, Sperlongano R, Accardo M. Molecular targets and oxidative stress biomarkers in hepatocellular carcinoma: an overview. J Transl Med. 2011;9:171. [PMID: 21985599 DOI: 10.1186/1479-5876-9-171] [Cited by in Crossref: 143] [Cited by in F6Publishing: 134] [Article Influence: 13.0] [Reference Citation Analysis]
571 Henry SH, Bosch FX, Bowers JC. Aflatoxin, hepatitis and worldwide liver cancer risks. Adv Exp Med Biol. 2002;504:229-233. [PMID: 11922091 DOI: 10.1007/978-1-4615-0629-4_24] [Cited by in Crossref: 66] [Cited by in F6Publishing: 51] [Article Influence: 3.3] [Reference Citation Analysis]
572 Geller DA, Tsung A, Marsh JW, Dvorchik I, Gamblin TC, Carr BI. Outcome of 1000 liver cancer patients evaluated at the UPMC Liver Cancer Center. J Gastrointest Surg. 2006;10:63-68. [PMID: 16368492 DOI: 10.1016/j.gassur.2005.06.032] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
573 van Pelt JF, Severi T, Crabbé T, Eetveldt AV, Verslype C, Roskams T, Fevery J. Expression of hepatitis C virus core protein impairs DNA repair in human hepatoma cells. Cancer Lett. 2004;209:197-205. [PMID: 15159022 DOI: 10.1016/j.canlet.2003.11.035] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 1.2] [Reference Citation Analysis]
574 Schwartz JM, Ham JM. Treatment of Hepatocellular Carcinoma. Curr Treat Options Gastroenterol 2003;6:465-72. [PMID: 14585235 DOI: 10.1007/s11938-003-0048-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.5] [Reference Citation Analysis]
575 Tanaka H, Iijima H, Nouso K, Aoki N, Iwai T, Takashima T, Sakai Y, Aizawa N, Iwata K, Ikeda N, Iwata Y, Enomoto H, Saito M, Imanishi H, Nishiguchi S. Cost-effectiveness analysis on the surveillance for hepatocellular carcinoma in liver cirrhosis patients using contrast-enhanced ultrasonography: Cost-effectiveness of CEUS surveillance for HCC. Hepatology Research 2012;42:376-84. [DOI: 10.1111/j.1872-034x.2011.00936.x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 13] [Article Influence: 3.4] [Reference Citation Analysis]
576 Patel D, Terrault NA, Yao FY, Bass NM, Ladabaum U. Cost-effectiveness of hepatocellular carcinoma surveillance in patients with hepatitis C virus-related cirrhosis. Clin Gastroenterol Hepatol 2005;3:75-84. [PMID: 15645408 DOI: 10.1016/s1542-3565(04)00443-4] [Cited by in Crossref: 65] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
577 Bose PP, Mandal G, Kumar D, Duseja A, Chatterjee BP. Visual detection of serum asialohaptoglobin by plasmonic sandwich ELLSA--a new platform for cirrhosis diagnosis. Analyst 2016;141:76-84. [PMID: 26568048 DOI: 10.1039/c5an02000j] [Cited by in Crossref: 10] [Cited by in F6Publishing: 2] [Article Influence: 1.4] [Reference Citation Analysis]
578 Jiang J, Gusev Y, Aderca I, Mettler TA, Nagorney DM, Brackett DJ, Roberts LR, Schmittgen TD. Association of MicroRNA expression in hepatocellular carcinomas with hepatitis infection, cirrhosis, and patient survival. Clin Cancer Res. 2008;14:419-427. [PMID: 18223217 DOI: 10.1158/1078-0432.ccr-07-0523] [Cited by in Crossref: 368] [Cited by in F6Publishing: 222] [Article Influence: 26.3] [Reference Citation Analysis]
579 Shu X, McCulloch M, Xiao H, Broffman M, Gao J. Chinese herbal medicine and chemotherapy in the treatment of hepatocellular carcinoma: a meta-analysis of randomized controlled trials. Integr Cancer Ther. 2005;4:219-229. [PMID: 16113029 DOI: 10.1177/1534735405279927] [Cited by in Crossref: 48] [Cited by in F6Publishing: 39] [Article Influence: 3.0] [Reference Citation Analysis]
580 Alexander DD, Kelsh MA, Mink PJ, Mandel JH, Basu R, Weingart M. A meta-analysis of occupational trichloroethylene exposure and liver cancer. Int Arch Occup Environ Health. 2007;81:127-143. [PMID: 17492303 DOI: 10.1007/s00420-007-0201-4] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 1.5] [Reference Citation Analysis]
581 Nazeer SS, Sandhyamani S, Jayasree RS. Optical diagnosis of the progression and reversal of CCl 4 -induced liver injury in rodent model using minimally invasive autofluorescence spectroscopy. Analyst 2015;140:3773-80. [DOI: 10.1039/c4an01507j] [Cited by in Crossref: 14] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
582 Kawamura Y, Ikeda K, Seko Y, Hosaka T, Kobayashi M, Saitoh S, Kumada H. Heterogeneous Type 4 Enhancement of Hepatocellular Carcinoma on Dynamic CT Is Associated With Tumor Recurrence After Radiofrequency Ablation. American Journal of Roentgenology 2011;197:W665-73. [DOI: 10.2214/ajr.11.6843] [Cited by in Crossref: 32] [Cited by in F6Publishing: 16] [Article Influence: 2.9] [Reference Citation Analysis]
583 Sangro B, Bilbao JI, Boan J, Martinez-Cuesta A, Benito A, Rodriguez J, Panizo A, Gil B, Inarrairaegui M, Herrero I. Radioembolization using 90Y-resin microspheres for patients with advanced hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2006;66:792-800. [PMID: 16904840 DOI: 10.1016/j.ijrobp.2006.05.065] [Cited by in Crossref: 147] [Cited by in F6Publishing: 136] [Article Influence: 9.2] [Reference Citation Analysis]
584 Chen Z, Lei Y, Chen X. Immunoassay for serum alpha-fetoprotein using silver nanoparticles and detection via resonance light scattering. Microchim Acta 2012;179:241-8. [DOI: 10.1007/s00604-012-0888-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
585 El-Zayadi AR, Badran HM, Barakat EM, Attia MED, Shawky S, Mohamed MK, Selim O, Saeid A. Hepatocellular carcinoma in Egypt: A single center study over a decade. World J Gastroenterol 2005; 11(33): 5193-5198 [PMID: 16127751 DOI: 10.3748/wjg.v11.i33.5193] [Cited by in F6Publishing: 42] [Reference Citation Analysis]
586 Manzione L, Grimaldi AM, Romano R, Ferrara D, Dinota A. Hepatocarcinoma: from pathogenic mechanisms to target therapy. Oncol Rev 2008;2:214-22. [DOI: 10.1007/s12156-008-0077-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
587 Mehta A, Herrera H, Block T. Glycosylation and liver cancer. Adv Cancer Res. 2015;126:257-279. [PMID: 25727150 DOI: 10.1016/bs.acr.2014.11.005] [Cited by in Crossref: 63] [Cited by in F6Publishing: 62] [Article Influence: 9.0] [Reference Citation Analysis]
588 Chen W, Hou J, Yin Y, Jang J, Zheng Z, Fan H, Zou G. alpha-Bisabolol induces dose- and time-dependent apoptosis in HepG2 cells via a Fas- and mitochondrial-related pathway, involves p53 and NFkappaB. Biochem Pharmacol 2010;80:247-54. [PMID: 20346922 DOI: 10.1016/j.bcp.2010.03.021] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 3.3] [Reference Citation Analysis]
589 Wang Y, Wu MC, Sham JS, Tai LS, Fang Y, Wu WQ, Xie D, Guan XY. Different expression of hepatitis B surface antigen between hepatocellular carcinoma and its surrounding liver tissue, studied using a tissue microarray. J Pathol. 2002;197:610-616. [PMID: 12210080 DOI: 10.1002/path.1150] [Cited by in Crossref: 35] [Cited by in F6Publishing: 29] [Article Influence: 1.8] [Reference Citation Analysis]
590 Kaibori M, Ishizaki M, Iida H, Matsui K, Sakaguchi T, Inoue K, Mizuta T, Ide Y, Iwasaka J, Kimura Y, Hayashi F, Habu D, Kon M. Effect of Intramuscular Adipose Tissue Content on Prognosis in Patients Undergoing Hepatocellular Carcinoma Resection. J Gastrointest Surg 2015;19:1315-23. [DOI: 10.1007/s11605-015-2838-8] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
591 Okano JI, Fujise Y, Abe R, Imamoto R, Murawaki Y. Chemoprevention against hepatocellular carcinoma. Clin J Gastroenterol 2011;4:185-97. [PMID: 26189518 DOI: 10.1007/s12328-011-0227-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
592 Xian ZH, Zhang SH, Cong WM, Yan HX, Wang K, Wu MC. Expression of aspartyl beta-hydroxylase and its clinicopathological significance in hepatocellular carcinoma. Mod Pathol 2006;19:280-6. [PMID: 16341145 DOI: 10.1038/modpathol.3800530] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 1.1] [Reference Citation Analysis]
593 Lam VW, Ng KK, Chok KS, Cheung TT, Yuen J, Tung H, Tso WK, Fan ST, Poon RT. Incomplete ablation after radiofrequency ablation of hepatocellular carcinoma: analysis of risk factors and prognostic factors. Ann Surg Oncol. 2008;15:782-790. [PMID: 18095030 DOI: 10.1245/s10434-007-9733-9] [Cited by in Crossref: 54] [Cited by in F6Publishing: 52] [Article Influence: 3.6] [Reference Citation Analysis]
594 Chen YW, Paliwal S, Draheim K, Grossman SR, Lewis BC. p19Arf inhibits the invasion of hepatocellular carcinoma cells by binding to C-terminal binding protein. Cancer Res 2008;68:476-82. [PMID: 18199542 DOI: 10.1158/0008-5472.CAN-07-1960] [Cited by in Crossref: 45] [Cited by in F6Publishing: 36] [Article Influence: 3.2] [Reference Citation Analysis]
595 Huo TI, Lui WY, Huang YH, Chau GY, Wu JC, Lee PC, Chang FY, Lee SD. Diabetes mellitus is a risk factor for hepatic decompensation in patients with hepatocellular carcinoma undergoing resection: a longitudinal study. Am J Gastroenterol. 2003;98:2293-2298. [PMID: 14572582 DOI: 10.1111/j.1572-0241.2003.07688.x] [Cited by in Crossref: 50] [Cited by in F6Publishing: 45] [Article Influence: 2.6] [Reference Citation Analysis]
596 Levi F, Lucchini F, Negri E, Boyle P, La Vecchia C. Cancer mortality in Europe, 1995-1999, and an overview of trends since 1960. Int J Cancer 2004;110:155-69. [PMID: 15069676 DOI: 10.1002/ijc.20097] [Cited by in Crossref: 126] [Cited by in F6Publishing: 116] [Article Influence: 7.0] [Reference Citation Analysis]
597 Kaibori M, Ha-Kawa SK, Maehara M, Ishizaki M, Matsui K, Sawada S, Kwon AH. Usefulness of Tc-99m-GSA scintigraphy for liver surgery. Ann Nucl Med. 2011;25:593-602. [PMID: 21800021 DOI: 10.1007/s12149-011-0520-0] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 2.0] [Reference Citation Analysis]
598 Batmunkh E, Tátrai P, Szabó E, Lódi C, Holczbauer Á, Páska C, Kupcsulik P, Kiss A, Schaff Z, Kovalszky I. Comparison of the expression of agrin, a basement membrane heparan sulfate proteoglycan, in cholangiocarcinoma and hepatocellular carcinoma. Human Pathology 2007;38:1508-15. [DOI: 10.1016/j.humpath.2007.02.017] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 2.1] [Reference Citation Analysis]
599 Zhang L, Guo Y, Li B, Qu J, Zang C, Li F, Wang Y, Pang H, Li S, Liu Q. Identification of biomarkers for hepatocellular carcinoma using network-based bioinformatics methods. Eur J Med Res 2013;18:35. [PMID: 24083576 DOI: 10.1186/2047-783X-18-35] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
600 Nazeer SS, Saraswathy A, Shenoy SJ, Jayasree RS. Fluorescence spectroscopy as an efficient tool for staging the degree of liver fibrosis: an in vivo comparison with MRI. Sci Rep 2018;8:10967. [PMID: 30030510 DOI: 10.1038/s41598-018-29370-1] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
601 Huo TI, Lui WY, Wu JC, Huang YH, King KL, Loong CC, Lee PC, Chang FY, Lee SD. Deterioration of hepatic functional reserve in patients with hepatocellular carcinoma after resection: incidence, risk factors, and association with intrahepatic tumor recurrence. World J Surg. 2004;28:258-262. [PMID: 14961198 DOI: 10.1007/s00268-003-7182-6] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 1.3] [Reference Citation Analysis]
602 Borzio M. Clinical relevance of hepatocyte proliferative activity. Dig Liver Dis 2002;34:174-6. [PMID: 11990388 DOI: 10.1016/s1590-8658(02)80189-x] [Reference Citation Analysis]
603 Pérez Saborido B, Meneu JC, Moreno E, García I, Moreno A, Fundora Y. Is transarterial chemoembolization necessary before liver transplantation for hepatocellular carcinoma? Am J Surg. 2005;190:383-387. [PMID: 16105523 DOI: 10.1016/j.amjsurg.2005.06.001] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 2.1] [Reference Citation Analysis]
604 Langeswaran K, Jagadeesan A, Revathy R, Balasubramanian M. Chemotherapeutic efficacy of limonin against Aflatoxin B1 induced primary hepatocarcinogenesis in Wistar albino rats. Biomedicine & Aging Pathology 2012;2:206-11. [DOI: 10.1016/j.biomag.2012.08.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
605 Liu M, Chen L, Chan TH, Wang J, Li Y, Li Y, Zeng TT, Yuan YF, Guan XY. Serum and glucocorticoid kinase 3 at 8q13.1 promotes cell proliferation and survival in hepatocellular carcinoma. Hepatology 2012;55:1754-65. [PMID: 22262416 DOI: 10.1002/hep.25584] [Cited by in Crossref: 27] [Cited by in F6Publishing: 31] [Article Influence: 2.7] [Reference Citation Analysis]
606 Li X, Zhou X, Guan Y, Wang YX, Scutt D, Gong QY. N-nitrosodiethylamine-induced pig liver hepatocellular carcinoma model: radiological and histopathological studies. Cardiovasc Intervent Radiol 2006;29:420-8. [PMID: 16502159 DOI: 10.1007/s00270-005-0099-8] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 1.9] [Reference Citation Analysis]
607 Iguchi T, Aishima S, Sanefuji K, Fujita N, Sugimachi K, Gion T, Taketomi A, Shirabe K, Maehara Y, Tsuneyoshi M. Both fibrous capsule formation and extracapsular penetration are powerful predictors of poor survival in human hepatocellular carcinoma: a histological assessment of 365 patients in Japan. Ann Surg Oncol. 2009;16:2539-2546. [PMID: 19533247 DOI: 10.1245/s10434-009-0453-1] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 2.7] [Reference Citation Analysis]
608 Chen M, Wei L, Law C, Tsang FH, Shen J, Cheng CL, Tsang L, Ho DW, Chiu DK, Lee JM, Wong CC, Ng IO, Wong C. RNA N6-methyladenosine methyltransferase-like 3 promotes liver cancer progression through YTHDF2-dependent posttranscriptional silencing of SOCS2. Hepatology 2018;67:2254-70. [DOI: 10.1002/hep.29683] [Cited by in Crossref: 404] [Cited by in F6Publishing: 444] [Article Influence: 101.0] [Reference Citation Analysis]
609 Yuen MF, Hou JL, Chutaputti A;  Asia Pacific Working Party on Prevention of Hepatocellular Carcinoma. Hepatocellular carcinoma in the Asia pacific region. J Gastroenterol Hepatol. 2009;24:346-353. [PMID: 19220670 DOI: 10.1111/j.1440-1746.2009.05784.x] [Cited by in Crossref: 322] [Cited by in F6Publishing: 305] [Article Influence: 24.8] [Reference Citation Analysis]
610 Liu W, Liu Q, Zhang B, Lin Z, Li X, Yang X, Pu M, Zou R, He Z, Wang F, Dou K. The mRNA of TCTP functions as a sponge to maintain homeostasis of TCTP protein levels in hepatocellular carcinoma. Cell Death Dis 2020;11:974. [PMID: 33184257 DOI: 10.1038/s41419-020-03149-7] [Reference Citation Analysis]
611 Zhang Q, Chen H, Li Q, Zang Y, Chen X, Zou W, Wang L, Shen ZY. Combination adjuvant chemotherapy with oxaliplatin, 5-fluorouracil and leucovorin after liver transplantation for hepatocellular carcinoma: a preliminary open-label study. Invest New Drugs 2011;29:1360-9. [PMID: 21809025 DOI: 10.1007/s10637-011-9726-1] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
612 Garin E, Denizot B, Noiret N, Lepareur N, Roux J, Moreau M, Herry J, Bourguet P, Benoit J, Lejeune J. 188Re-SSS lipiodol: radiolabelling and biodistribution following injection into the hepatic artery of rats bearing hepatoma: . Nuclear Medicine Communications 2004;25:1007-13. [DOI: 10.1097/00006231-200410000-00004] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 1.6] [Reference Citation Analysis]
613 Liu XE, Desmyter L, Gao CF, Laroy W, Dewaele S, Vanhooren V, Wang L, Zhuang H, Callewaert N, Libert C, Contreras R, Chen C. N-glycomic changes in hepatocellular carcinoma patients with liver cirrhosis induced by hepatitis B virus. Hepatology. 2007;46:1426-1435. [PMID: 17683101 DOI: 10.1002/hep.21855] [Cited by in Crossref: 120] [Cited by in F6Publishing: 123] [Article Influence: 8.0] [Reference Citation Analysis]
614 Zhu ZZ, Cong WM, Liu SF, Dong H, Zhu GS, Wu MC. Homozygosity for Pro of p53 Arg72Pro as a potential risk factor for hepatocellular carcinoma in Chinese population. World J Gastroenterol 2005; 11(2): 289-292 [PMID: 15633234 DOI: 10.3748/wjg.v11.i2.289] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 28] [Article Influence: 1.7] [Reference Citation Analysis]
615 Ikai I, Takayasu K, Omata M, Okita K, Nakanuma Y, Matsuyama Y, Makuuchi M, Kojiro M, Ichida T, Arii S. A modified Japan Integrated Stage score for prognostic assessment in patients with hepatocellular carcinoma. J Gastroenterol. 2006;41:884-892. [PMID: 17048053 DOI: 10.1007/s00535-006-1878-y] [Cited by in Crossref: 57] [Cited by in F6Publishing: 52] [Article Influence: 3.8] [Reference Citation Analysis]
616 Pang R, Lee TK, Poon RT, Fan ST, Wong KB, Kwong YL, Tse E. Pin1 interacts with a specific serine-proline motif of hepatitis B virus X-protein to enhance hepatocarcinogenesis. Gastroenterology. 2007;132:1088-1103. [PMID: 17383430 DOI: 10.1053/j.gastro.2006.12.030] [Cited by in Crossref: 89] [Cited by in F6Publishing: 85] [Article Influence: 5.6] [Reference Citation Analysis]
617 Guan XX, Chen LB, Ding GX, De W, Zhang AH. Transfection of p27kip1 enhances radiosensitivity induced by 60Co γ-irradiation in hepatocellular carcinoma HepG2 cell line. World J Gastroenterol 2004; 10(21): 3103-3106 [PMID: 15457552 DOI: 10.3748/wjg.v10.i21.3103] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
618 Befeler A, Di Bisceglie AM. Treatment of hepatocellular carcinoma. Viruses and Liver Cancer. Elsevier; 2002. pp. 161-72. [DOI: 10.1016/s0168-7069(02)06074-3] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
619 Cui J, Kang X, Dai Z, Huang C, Zhou H, Guo K, Li Y, Zhang Y, Sun R, Chen J, Li Y, Tang Z, Uemura T, Liu Y. Prediction of chronic hepatitis B, liver cirrhosis and hepatocellular carcinoma by SELDI-based serum decision tree classification. J Cancer Res Clin Oncol 2007;133:825-34. [PMID: 17516088 DOI: 10.1007/s00432-007-0224-y] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 1.7] [Reference Citation Analysis]
620 Fujikawa T, Shiraha H, Nakanishi Y, Takaoka N, Ueda N, Suzuki M, Shiratori Y. Cimetidine inhibits epidermal growth factor-induced cell signaling. J Gastroenterol Hepatol 2007;22:436-43. [PMID: 17295779 DOI: 10.1111/j.1440-1746.2006.04541.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
621 Li L, Huang T, Lan C, Jia A, Mao Y. The growth inhibitory effects of garlic polysaccharide combined with cis-dichlorodiamine platinum on human HepG2 cells. Biologia 2017;72:1377-84. [DOI: 10.1515/biolog-2017-0155] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
622 Zeeneldin AA, Salem SE, Tabashy RH, Ibrahim AA, Alieldin NH. Transarterial chemoembolization for the treatment of hepatocellular carcinoma: a single center experience including 221 patients. J Egypt Natl Canc Inst 2013;25:143-50. [PMID: 23932751 DOI: 10.1016/j.jnci.2013.05.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
623 Yasuda E, Kumada T, Takai S, Ishisaki A, Noda T, Matsushima-Nishiwaki R, Yoshimi N, Kato K, Toyoda H, Kaneoka Y. Attenuated phosphorylation of heat shock protein 27 correlates with tumor progression in patients with hepatocellular carcinoma. Biochem Biophys Res Commun. 2005;337:337-342. [PMID: 16199221 DOI: 10.1016/j.bbrc.2005.08.273] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 2.0] [Reference Citation Analysis]
624 Muros-ortega M, Díaz-carrasco MS, Capel A, Calleja MÁ, Martínez F. Effectiveness and safety of doxorubicin loaded beads in hepatocellular carcinoma. Int J Clin Pharm 2013;35:1105-12. [DOI: 10.1007/s11096-013-9831-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
625 Uzunalimoğlu O, Yurdaydin C, Cetinkaya H, Bozkaya H, Sahin T, Colakoğlu S, Tankurt E, Sarioğlu M, Ozenirler S, Akkiz H, Tözün N, Değertekin H, Okten A. Risk factors for hepatocellular carcinoma in Turkey. Dig Dis Sci 2001;46:1022-8. [PMID: 11341644 DOI: 10.1023/a:1010705910858] [Cited by in Crossref: 31] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
626 Ercolani G, Grazi GL, Ravaioli M, Del Gaudio M, Gardini A, Cescon M, Varotti G, Cetta F, Cavallari A. Liver resection for hepatocellular carcinoma on cirrhosis: univariate and multivariate analysis of risk factors for intrahepatic recurrence. Ann Surg. 2003;237:536-543. [PMID: 12677151 DOI: 10.1097/01.sla.0000059988.22416.f2] [Cited by in Crossref: 159] [Cited by in F6Publishing: 112] [Article Influence: 8.4] [Reference Citation Analysis]
627 Morihara D, Iwata K, Hanano T, Kunimoto H, Kuno S, Fukunaga A, Yotsumoto K, Takata K, Tanaka T, Sakurai K, Iwashita H, Ueda S, Hirano G, Yokoyama K, Nakane H, Nishizawa S, Yoshikane M, Anan A, Takeyama Y, Kakumitsu S, Kitamura Y, Sakamoto M, Irie M, Shakado S, Sohda T, Watanabe H, Sakisaka S. Late-evening snack with branched-chain amino acids improves liver function after radiofrequency ablation for hepatocellular carcinoma: LES with BCAA improves liver function. Hepatology Research 2012;42:658-67. [DOI: 10.1111/j.1872-034x.2012.00969.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
628 Hiwatashi K, Ueno S, Sakoda M, Iino S, Minami K, Yamasaki Y, Okubo K, Noda M, Kurahara H, Mataki Y, Maemura K, Shinchi H, Natsugoe S. Problems of Long Survival Following Surgery in Patients with NonBNonC-HCC: Comparison with HBV and HCV Related-HCC. J Cancer 2015;6:438-47. [PMID: 25874007 DOI: 10.7150/jca.10398] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]